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Abstract 
 
This research describes the development of immunoassays for the detection of 
residues of three anti-protozoan drugs (coccidiostats), namely, halofuginone, 
toltrazuril and diclazuril, used in the treatment of Eimeria spp. infections in cattle, 
pigs, chickens and turkeys.  
 
An avian-derived halofuginone-specific scFv library was constructed, from which 
the best scFv isolated did not possess the required analytical sensitivity. To 
circumvent this, genetic engineering via light-chain shuffling of the optimal light: 
heavy chain pairings of the scFv library were investigated. Use of this light-chain 
shuffled library and rigorous screening, led to the isolation of a scFv with a 185-
fold greater sensitivity than the original. This scFv was incorporated into both 
enzyme-linked immunosorbent assay (ELISA) and Biacore assay formats that 
were applied successfully for the detection of halofuginone in ‘spiked’ egg 
samples. 
 
Immune phage display libraries were constructed and screened for diclazuril using 
a number of diclazuril-conjugates. A functional diclazuril-specific scFv could not 
be isolated, due to complications which arose during library amplification. 
Subsequently, an anti-diclazuril polyclonal antibody was sourced externally, 
characterised and used in the development of a high sensitivity lateral-flow 
immunoassay for diclazuril detection in eggs. 
 
Rabbit polyclonal antibodies to the primary metabolite of toltrazuril, ‘ponazuril’, 
were produced, characterised and were subsequently used to generate ELISA, 
lateral-flow and Biacore-based assays. The performance of each of these assay 
formats for the detection of toltrazuril in ‘spiked’ egg samples was directly 
compared. 
 
Finally, multi-coccidiostat detection in a lateral-flow dipstick format, for the 
simultaneous determination of halofuginone, diclazuril and toltrazuril in eggs, 
using antibody-coated coloured latex particles as the detection element, was 
successfully optimised. 
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1.1 Coccidiosis: prevalence and life-cycle of Eimeria species 
Protozoa are unicellular eukaryotes which feed heterotrophically. They constitute 
their own "kingdom" according to taxonomic classification. Coccidian parasites are 
protozoa in the subphylum Apicomplexa (Figure 1.0). Coccidiosis is a disease caused 
by intracellular parasites of species in the genera, Eimeria, Isospora, Caryospora, 
Cryptosporidium, Atoxoplasma, Sarcocystis and Toxoplasma (Douglas et al., 1995). 
Figure 1.0 illustrates the taxonomic positions of the genera of the seven coccidian 
species mentioned above. Coccidian species are generally small micro-organisms 
ranging from 2 μm to 1 mm in diameter, primarily present in livestock (Douglas et 
al., 1995). They cause diseases in several species of animals, which in turn has severe 
economic implications.  
 
 
Figure 1.0 Taxonomic positions of the genera of Eimeria spp. Class Coccidia are the 
largest group of Apicomplexan protozoa. The Order Eimeriidia comprises numerous 
genera in which there are many protozoa of medical and veterinary importance 
(Barta, 1989). 
 
 
 
 
 
 
 
Phylum Apicomplexa (Sporozoa) 
Class Coccidia 
Order Eimeriida 
Genera ; Cryptosporidium, Cyclospora, Eimeria, Isospora, Sarcocystis, Atoxoplasma, 
Toxoplasma 
 
 
3 
In the phylum Apicomplexa, most protist possess a unique organelle called an 
apicoplast and an ‘apical complex’ structure, which is involved in the entry of the 
host cell. The invasion of host cells and parasite multiplication generally relies on this 
‘apical complex’ set of structures (Barta, 1989). Figure 1.1 illustrates the structure of 
an Apicomplexan parasite. The apical complex labelled in Figure 1.1 is made up of 
the conoid which is a hollow structure of hundreds of fibres arranged in a spiral, a 
band of microtubules called polar rings, and subpellicular microtubules, which are 
involved in the stabilising cell boundary complex or pellicle (Scholtyseck et al., 
1970). 
 
 
 
Figure 1.1 Diagram of an Apicomplexan parasite showing the apical complex. The 
central part of the apical complex is the conoid (B), which is made of hundreds of 
fibres arranged in a spiral. The apical complex also consists of polar rings (C) and 
subpellicular microtubules (A). This structure acts like a drill bit during host cell 
invasion.  The apical complex can retract and extend, and also secrete enzymes that 
aid in attachment and penetration of the host cell. Illustration adapted from Hu et al. 
(2006). 
 
In previous studies it was suggested that if all animals were examined, 45,000 species 
of Eimeria would be identified (Douglas et al., 1995). The life-cycles of Eimeria 
species occur both exogeneously and endogenously and generally include three 
different phases, namely; sporogony, merogony and gametony. The exogenous stage 
(gametony), retaining the oocysts, is where infection occurs (Figure 1.2). These 
oocysts are encased in a thick-walled shell, making them impervious to even the 
harshest environmental conditions. Coccidia are generally transmitted via ingestion of 
contaminated food or water, primarily from faeces of infected animals. Parasitised 
Apical Complex 
A    B     C 
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animals shed environmentally resistant oocysts in their faeces which undergo 
sporogony exogenously (Jeurissen et al., 1996). Sporulation produces four sporocysts 
with two sporozoites each. Only oocysts containing fully formed sporozoites can 
infect animals. After ingestion, the oocysts encyst in the small intestine releasing 
infective sporozoites. The sporozoites subsequently infect epithelial cells and undergo 
asexual proliferation (formation of schizonts). After two to five schizont generations, 
the sexual proliferation stage, or the formation of male and female gametes, occurs. 
Following this, fertilisation occurs, producing zygotes and then finally oocysts. This 
entire cycle takes about 4-6 days depending on the species of animal (Jeurissen et al., 
1996).  
 
Life-cycle of Eimeria tenella 
 
Figure 1.2 The life-cycle of Eimeria tenella, typical of the genus Eimeria, adapted 
from Jeurissen et al. (1996). Eimeria have a complex life-cycle that begins with 
oocysts in the faeces being ingested. Sporozoites that are released search out 
particular regions of the gut and invade the epithelial cells lining the intestine. The 
sporozoites are then replicated, which leads to another stage of the cycle, called 
merozoites (Day 5). These develop into micro- and macrogametes which fuse to form 
a zygote. The zygote develops into an oocyst and at this stage is released in the 
faeces. 
 
Animals which are bred in intensive environments, usually for commercial purposes, 
are most susceptible to coccidiosis. All Eimeria species parasitise the epithelial cells 
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of the intestinal lining, causing varying degrees of physiological harm to the host. 
This can range from effects such as weight loss, dehydration, inflammation, bloody 
diarrhoea and endothelial lesions. Eimeria can also affect the host systemically 
causing effects such as blood loss, shock syndrome and even death (Vermeulen et al., 
2001). The pathological effects of infection vary with each species. E. tenella can 
develop deep in the intestinal mucosa and cause gross lesions and major damage, 
whereas E. praecox is known to reduce weight gain and feed conversion efficiency 
without any cases of morbidity being reported (Morris and Gasser, 2006). Diagnosis 
of intestinal Eimeria is traditionally made using faecal flotation and a direct smear of 
freshly excreted material. Detecting or enumerating oocysts excreted, and 
measurement of oocyst/sporocyst dimensions, will determine the extent of infection 
in the intestines of animals (Morris and Gasser, 2006). Immunity is species-specific, 
since even after exposure to one type of Eimeria, the animal is still susceptible to 
infection from other species of Eimeria. Seven different species of Eimeria (E. 
acervulina, E. brunette, E. maxima, E. mitis, E. necartrix, E. praecox and E. tenella) 
are known to infect chickens (Vermeulen et al., 2001)  and fifteen different species 
are known to infect cattle (Cox, 1998), each of which has its own pathogenicity 
related characteristics. 
 Coccidiosis has a major economic impact on the poultry industry worldwide, with an 
estimated cost of approximately US $3.0 billion per year in financial losses (Dalloul 
and Lillehoj, 2006). This is as a result of reduced production efficiency caused by 
retarded growth rates, a drop in egg production, mortality, and the costs of veterinary 
treatment and prophylactic chemotherapeutic methods. 
The control of coccidiosis has relied mainly on vaccines and preventative methods, 
such as the use of anti-coccidial drugs (coccidiostats). However, the use of anti-
coccidial drugs has also led to the development of drug-resistant strains. To limit the 
selection of drug-resistant strains, rotation programs are employed in which different 
coccidiostats are alternately used either within a single flock, or in a series of 
consecutive flocks (Vermeulen et al., 2001). It was estimated in 2006 that over 
25,500 tonnes of coccidiostats were used in broiler production alone in the EU 
(Advisory Committee on Novel Foods and Processes, 2007). 
Coccidiostats are currently regulated as feed additives under Annex 1 in EC 
Regulation 1831/2003, and, at present, 11 different coccidiostats have been granted 
28 different authorisations for use in different livestock species (European 
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Parliament-COD, 2002). In general, they are used as prophylactic drugs and are not 
necessarily used to treat coccidiosis. In 2008, a decision was required from the EU 
member states on the proposed ‘phasing out’ of coccidiostats for use in animals by 
January 1st, 2012. However, it was concluded that the use of coccidiostats for the 
prevention of coccidiosis is essential, as alternative feed additives, such as vaccines or 
herbal remedies, do not offer the same advantages as coccidiostats (European 
Parliament- COD, 2002). The authorization and safety evaluation of coccidiostats 
approved for use in animals in the European Union is set and monitored by several 
agencies including the European Agency for the Evaluation of Medicinal Products 
(EMEA), the European Food Safety Authority (EFSA) and also by the Joint Food and 
Agriculture Organisation/ World Health organisation (FAO/WHO) Expert Committee 
on Food Additives. Human health risks associated with anti-protozoan drug residues 
are primarily confined to sensitive individuals such as pregnant females, infants and 
the elderly. Teratogenic and embryotoxic effects were observed in rats treated with 
toltrazuril (EMEA, 2000). Gastrointestinal inflammation and necrotic lesions were 
observed (at recommended dosages) in calves treated with halofuginone, and at 
higher dosages, deaths were observed. Toxicity effects were also observed in dogs, 
mice and rats when treated with high concentrations of diclazuril (EMEA, 1996). To 
ensure that no threat is posed by the incorporation of coccidiostats in animal feed, 
maximum residue limits (MRLs) have been set for all feed additives by the EU.  
However, a study carried out in 2005 demonstrated that 36 % of 320 egg samples 
tested positive for the presence of coccidiostat residues (Mortier et al., 2005b).  This 
indicates that the current methods for the monitoring of these residues are not 
sufficient to ensure food safety. 
 
Analytical detection methods are characterised by parameters, such as selectivity, 
specificity, accuracy, precision, repeatability, analytical range, and detection 
sensitivities described by the limits of detection (LOD) and quantification (LOQ) 
(Blanchflower et al., 1994). Alternatively, two new parameters have recently been 
introduced by the EU for residue detection, namely the decision limit (CCα) and the 
detection capability (CCβ). These are analytical parameters that must be defined to 
provide a better characterization of the LOD and LOQ for a validated analytical 
method intended for regulatory use within the EU. The decision limit is defined as the 
limit at and above which it can be concluded with an error probability (1 %) that a 
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sample is noncompliant, while the detection capability is the smallest content of the 
substance that may be detected, identified, and/or quantified in a sample with an error 
probability of β (5 %). Validated residue detection assays are required to provide 
results for these parameters (Blanchflower et al., 1994). The lack of rapid and 
inexpensive validated methods for the detection of anti-protozoan residues has made 
national screening programs somewhat difficult.  
This research describes the development of several specific antibodies to the 
coccidiostats halofuginone, diclazuril and toltrazuril, and their subsequent 
incorporation into immunoassays to allow the rapid and cost effective detection of 
these residues in a variety of foodstuffs. 
 
1.2 Target drugs 
1.2.1 Halofuginone 
Halofuginone (HFG) is a halogenated analogue of the naturally occurring 
quinazolinone alkaloid, febrifugine. HFG is licensed for use in broilers and turkeys 
and is marketed by Intervet either in the hydrobromide form as Stenerol ® (Intervet, 
Mechelen, Belgium) or the lactate salt form as Halocur ® (Intervet, Mechelen, 
Belgium). The molecular weight of HFG is 414.68 Da. The mode of action of HFG is 
unknown. The chemical structure of HFG is shown in Figure 1.3. HFG ingestion was 
recognised as having adverse effects in the cardiovascular and central nervous 
systems in rat and mice models (EC No. 124/2009). Hence, the European Medicines 
Agency (EMEA) established HFG as the marker residue and has set a maximum 
residue limit (MRL) of 10 and 30 μg/kg for bovine muscle and liver, respectively. 
According to a pharmacokinetics study of halofuginone by Stecklair et al., in 2001, 
halofuginone was the main substance detected in tissue and plasma, in several 
animals administered with the drug, where no halofuginone metabolites were 
detected.  The EU has specific legislation in place under Commission Regulation 
(EC) No. 2430/1999 which permits HFG for use in laying hens but no residues may 
be found in eggs. In February 2009, under EU legislation, a commission decision 
regarding “unavoidable contaminating residues’’ of coccidiostats was amended 
(2009/8/EC). This introduced MRLs for HFG in certain foodstuffs that were not 
previously required (Dubois et al., 2004). The MRLs for HFG for food of animal 
origin from animal species other than chickens for fattening, turkeys and bovine 
(except dairy cattle) were set, as outlined in Table 1.0;  
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Table 1.0 Maximum residue limits set by the EU for halofuginone for animal species 
Tissue Maximum Residue Limit (μg/kg) 
Liver 30 
Kidney 30 
Milk 1 
Eggs 6 
 
To ensure that food is free from any HFG residues and safe for human consumption, 
monitoring schemes usually adopt a two-tier testing system consisting of screening 
and confirmatory tests (Hagren et al., 2005). Screening tests can be typically 
perceived as rapid, low-cost and high throughput tests, which classify a substantial 
number of samples as compliant or potentially non-compliant, whereas, confirmatory 
methods, tend to be specific but are also slow, high-cost and of low volume, and are 
utilised to re-analyse the potentially non-compliant samples (Hagren et al., 2005).  
Currently, there are several detection systems available for the monitoring of HFG 
residues in foodstuffs. These are primarily based around methods such as 
chromatography (Mortier et al., 2003; Dubois et al., 2004) mass spectrophotometry 
(Yakkundi et al., 2002) and immunosassay technology (Hagren et al., 2005; Huet et 
al., 2005). 
 
 
 
Figure 1.3 Chemical structure of halofuginone (trans-7-bromo-6-chloro-3-(3-
hydroxy-2-piperidyl)-acetonyl)-4-(3H)-quinazolinone).  
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1.2.2 Diclazuril 
Diclazuril (DIC) (4-chlorophenyl [2, 6-dichloro-4-(4, 5-dihydro-3H-3, 5-dioxo-1, 2, 
4-triazin-2-yl) phenyl] acetonitrile) is a benzeneacetonitrile anti-coccidial drug 
primarily used for broiler chickens. The molecular weight of DIC is 407.64 Da. It is 
marketed commercially as ‘Clinacox™’, a 0.5% (w/v) premix by Janssen® 
(Germany), and is recommended for use in poultry feed at a concentration of 1 mg/kg 
with a withdrawal period of 5 days prior to slaughter. The chemical structure of DIC 
is shown in Figure 1.4.  
 
 
Figure 1.4 Chemical structure of diclazuril (4-chlorophenyl) [2, 6-dichloro-4-(4, 5-
dihydro-3H-3, 5-dioxo-1, 2, 4-triazin-2-yl) phenyl] acetonitrile).  
 
DIC has been shown to be effective against intestinal Eimeria spp. in avian 
coccidiosis, intestinal and hepatic coccidiosis in rabbits, toxoplasmosis in mice 
(Mortier et al., 2005a) and Eimeria spp. in turkeys (Vanparijs et al., 1991). The 
activity of DIC is directed only against specific endogen stages of Eimeria species. 
Thus, DIC is active against second generation schizonts of E. acervulina, E. 
mitis and E. necatrix, against gamonts and late schizonts of E. brunetti, zygotes of E. 
maxima, and first and second generation schizonts and sexual stages of E. tenella. 
While sporulation is delayed by DIC (Maes et al., 1988), the actual mode of action of 
DIC is still unknown. 
DIC is licensed by the Joint FAO/WHO Expert Committee on Food Additives, the 
EMEA and the EFSA (Olejnik et al., 2009). The MRLs set by these agencies are 
shown in Table 1.1. 
 
 
 
 
 
10 
 
Table 1.1 Maximum residue limits set by the EU for diclazuril for both turkeys and 
chickens for fattening, and for chickens reared for laying. 
Tissue Maximum Residue Limit (μg/kg) 
Liver 1.5 
Kidney 1.0 
Muscle 0.5 
Skin/Fat 0.5 
 
The EU has also recently put in place MRLs for DIC in non-target feeds caused by 
unavoidable cross contamination. These are listed in Table 1.2. 
 
Table 1.2 Maximum residue limits for diclazuril in non-target feedstuffs under Annex 
1 to directive 2002/32/EC (amended in February 2009 under Commission Directive 
2009/8/EC). 
Non-target food Maximum residue limit (μg/kg) 
Laying birds 10 
Rabbits for fattening or during 
withdrawal feeding. 
10 
Other species excluding laying chickens 
(<16wks old) or chickens/turkeys for 
fattening (<12wks old) 
30 
 
Current methods for the detection of DIC include liquid chromatography-mass 
spectrophotometry/MS with detection limits (CCβ) of 0.6 μg/kg in poultry meat 
(Mortier et al., 2005a) and 1 ng/mL in animal plasma (Croubels et al., 2002), liquid 
chromatography with UV detection, with detection limits down to 0.1 mg/kg, and gas 
chromatography-MS with a detection limit of 20 μg/kg (Blanchflower et al., 1994). It 
appears that no methods are published in current relevant literature reporting 
immunoassay screening of diclazuril residues. 
 
1.2.3 Toltrazuril 
Toltrazuril (TLZ) (1-methyl-3-[3-methyl-4-[4-(trifluoromethylsulfanyl) phenoxy] 
phenyl]-1, 3, 5-triazinane-2, 4, 6-trione) is a triazinetrione derivative widely used in 
 
 
11 
chickens, turkeys, pigs and cattle for the prevention of coccidiosis. The molecular 
weight of TLZ is 425.38 Da. The chemical structure of TLZ is shown in Figure 1.5. 
 
 
Figure 1.5 Chemical structure of toltrazuril (1-methyl-3-[3-methyl-4-[4-
(trifluoromethylsulfanyl) phenoxy] phenyl]-1, 3, 5-triazinane-2, 4, 6-trione).  
 
TLZ administration affects all intracellular developmental stages of Eimeria spp., 
including those of schizogony and gametogony (Steinfelder et al., 2005). It was 
reported that chickens treated with TLZ and infected with E. tenella showed a level of 
immunity to re-infection in comparison with control models. This was observed when 
the titre of antibodies, specific to E. tenella, was higher in TLZ-treated chickens than 
in those treated with a polyether ionophore (Greif, 2000). This is thought to be due to 
the destruction of intracellular stages that stay in the host cells and act as antigens. 
TLZ is marketed commercially as Baycox® by Bayer Healthcare. Following oral 
administration, it is oxidised to toltrazuril sulfone and toltrazuril sulfoxide. Toltrazuril 
sulfone (Ponazuril - Figure 1.6), the major metabolite, is listed as the marker residue 
for TLZ detection by the EMEA. The molecular weight of ponazuril is 489.5 Da. The 
EMEA observed that ponazuril represented almost 100% of residues remaining in 
edible tissues after a 16-day withdrawal period in chickens (EMEA, 1998). 
 
 
Figure 1.6 Chemical structure of ponazuril (1, 3, 5-Triazine-2, 4, 6(1H, 3H, 5H)-
trione, 1-methyl-3-[3-methyl-4-[4-[(trifluoromethyl) sulfonyl] phenoxy] phenyl]-(9C).  
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Previous methods for the detection of ponazuril include the use of a high-performance 
liquid chromatography diode array method for residues in plasma, which has a 
detection capability of 10 ng/mL (Dirikolu et al., 2009a). Using GC/MS, a capability 
of also detecting down to 10 ng/mL was reported (Tobin et al., 1997). The lowest 
detection capability was observed at 2 μg/kg in kidney using a HPLC method based 
on fluorescence detection (EMEA, 2005). It is understood that only one antibody has 
previously been reported for the detection of ponazuril. This was a polyclonal 
antibody which exhibited an IC50 of 18 μg/kg, in a competitive ELISA format 
(Connolly et al., 2002). 
The current MRLs for ponazuril, as set by the EMEA, are outlined in Table 1.3. TLZ 
was not included in the amended Annex 1 to directive 2002/32/EC under Commission 
Directive 2009/8/EC for cross-contamination of unintended foodstuffs. 
 
Table 1.3 Maximum residue limits for toltrazuril sulfone (ponazuril) in foodstuff, as 
set by the EMEA. 
Foodstuff Maximum residue limit (μg/kg) 
Chicken/Turkey – Muscle 100 
                             - Skin/Fat 200 
                             - Liver 600 
                             - Kidney 400 
Porcine                - Skin 150 
Bovine/Porcine   - Muscle 100 
                             - Skin 150 
                             - Liver 500 
                             - Kidney 250 
 
It is understood there is currently no immunoassay available for the detection of TLZ 
or ponazuril in foodstuff. In order to develop immunoassays to detect these residues 
below the current EU MRLs, recombinant antibody technology can be employed to 
developed antibodies with tailored affinities and specificities. 
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1.3 Introduction to Antibodies 
Antibodies are a group of glycoproteins generated by the immune system in response 
to any foreign particles (antigens) that enter the body. The body’s defence system 
generates antibodies upon exposure to potentially hazardous pathogens which 
eliminate and destroy them. The molecules are also referred to as immunoglobulins 
(Ig) because of their globular structure. All Ig consist of a basic four-polypeptide 
chain structure of two identical heavy chains (each approximately 440 amino acids 
long) and two identical light chains (each approximately 220 amino acids long), 
which are held together by disulphide bonds. The heavy and light chains also contain 
intrachain disulphide bonds, which stabilise their folding into 110-amino acid 
domains. Sequence analysis has revealed that antibodies have one of two types of 
light chain, kappa (κ) or lambda (λ), and their ratio varies with species (mouse 95% κ, 
humans 60% κ) (Benjamini et al., 2000). There are five distinct classes of antibody 
designated by their heavy chain, IgA, IgM, IgD, IgE and IgG. The structure of an 
antibody varies depending on its isotype. However, antibody structure is generally 
represented by the immunoglobulin G (IgG) molecule. Recombinant antibody 
technology can be used to develop different antibody formats such as scFv, Fab, 
scAb, and dimeric antibodies. Their structural formats are shown in Figure 1.7. An 
IgG is composed of four polypeptide chains, consisting of two identical heavy (H) 
and two identical light (L) chains, held together by interchain disulphide bonds. 
Heavy chains have a molecular weight of approximately 50 kDa and consist of one 
variable region and three constant domains. These constant domains determine the 
antibody class. Light chains consist of one variable region and one constant domain 
and have a molecular weight of approximately 25 kDa. 
While specificity is derived from variable regions, the constant regions are involved 
in effector functions of the Ig (e.g. binding to phagocytes, activation of complement). 
It is both this specificity and biological activity that makes their role crucial for the 
immune system. The variable regions, which are located at the N-terminal portions of 
both the heavy and light chains, form the antigen-binding fragment (Fab). 
Comparison of these variable (VL and VH) gene sequences showed the greatest 
amount of variability in regions referred to as the hypervariable regions (Kabat et al., 
1971). These regions, which participate in antigen binding, are also referred to as 
complementarity-determining regions (CDRs), as they form regions complementary 
in structure to antigen epitopes. It is the variation in the amino acid sequence of the 
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CDRs that allows for the generation of a repertoire of antibodies that exhibit great 
diversity, each specific to a particular antigen. The CDRH3, which displays the 
greatest variation in terms of length and sequence, is considered (in conjunction with 
the CDRL3) to make the most significant contributions to affinity and specificity 
(Barbas et al., 2004). The remainder of the variable heavy and light domains, referred 
to as framework regions (FRs), exhibit far less variation, and fold into relatively rigid 
beta strands that maintain the overall Ig structure. 
 
 
Figure 1.7 Diagrammatic representation of different antibody ‘formats’ IgG, F(ab’)2, 
Fab, scFv, dimeric scFv and the dimeric bifunctional scFv. The amino terminal end 
of the antibody is characterised by variability (V) of the sequences in both the heavy 
(H) and light (L) chains, which are known as the VH and VL regions, respectively. 
The CDR regions confer the specificity of the antibody to a particular antigen and 
this is known as the antigen binding site. 
 
The ability of antibodies to detect and distinguish between infinite numbers of 
antigens has focused increased attention on immunoassay technology as an alternative 
to ‘standard’ analytical techniques. While immunoassays have been proven in their 
sensitivity, specificity, reproducibility and robustness (Fitzpatrick et al., 2000), the 
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quality of the assay is entirely dependent upon the availability of high quality 
antibodies for detection. Previous assays for detecting anti-protozoan drug residues 
have predominantly used mass spectrophotometry or liquid chromatography for 
analysis (Ding et al., 2005; Mortier et al., 2005a; Qi et al., 2007 and Dirikolu et al., 
2009b). However, in many instances, for drug residue screening, an immunological 
procedure is preferred due to the low cost and simplicity associated with such 
methods. Antibody engineering has transformed the field of immunoassays, allowing 
the generation of an immortal repertoire of antibody fragments with a defined affinity 
and specificity towards target molecules. It also offers the possibility of altering the 
antibody’s affinity and specificity, if desired (Plückthun and Pack, 1997). 
  
Recombinant antibody technology allows the generation of antibody fragments from 
several species including human, rabbit, mouse, chicken and sheep in both 
prokaryotic and eukaryotic expression systems (Daly et al., 2000). Recombinant 
antibodies can be sensitive and specific for their target molecules, and can be 
produced relatively easily and cheaply. They can be generated by directly cloning the 
heavy and light chain variable domains from a monoclonal antibody-producing 
hybridoma cell or by amplifying the variable genes from the cDNA from the 
lymphocytes of an immunised source. The challenge in producing recombinant 
antibodies arises in the selection procedure, where specific antibody fragments are 
isolated and enriched from a large repertoire of non-functional and non-specific 
antibody fragments. In the immune system, a diverse collection of antibody binding 
sites is created by the combinatorial assembly of germline-encoded segments. This 
produces a repertoire of naive B-cell lymphocytes which, when activated, express a 
unique antibody binding site on their surface (Hoogenboom, 2005). Exposure to 
antigen promotes somatic hypermutations in the variable genes, allowing subsequent 
selection of mutations that improve the affinity of the antibody for the antigen. 
Antibodies can also be isolated from recombinant antibody libraries in the laboratory, 
using methods for selection that ‘mimic’ this in vivo process. Many of these selection 
platforms share four key steps with the process for antibody generation in the immune 
system: first, the generation (or cloning) of genotypic diversity; second, the coupling 
of genotype to phenotype; third, the application of selective pressure; and fourth, 
amplification (Hoogenboom, 2005). Various display mechanisms, including phage, 
yeast and ribosomal display, have been developed for the isolation of specific 
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antibody fragments, which provide an efficient method to select antibodies based on 
the antigen-binding behaviour of individual clones. These systems enable coupling of 
genotype to phenotype, allowing simultaneous isolation of the desired antibody 
fragment and the genetic sequence encoding it. 
 
1.4 Phage Display Technology 
Phage display is currently the most widespread method used for the display and 
selection of large collections of antibodies, and for the engineering of selected 
antibodies (Hoogenboom, 2002). The principle of phage display was first introduced 
in 1985 by George Smith (Smith, 1985). Phage display is a molecular diversity 
technique that employs non-lytic filamentous bacteriophage fd/M13 to display 
ligands on the surface of their phage coat. E. coli containing the F conjugative 
plasmid are a natural host for replication of this phage family. Initially, complete 
phage vectors or bacteriophage, which carried all the genetic information required for 
the phage life-cycle, were used as the display vector. Now, small plasmid vector or 
phagemids, which contain the appropriate packaging signal and cloning sites, have 
become a more popular type of vector for display. Phagemids have high 
transformation efficiencies, making them ideal for generating large antibody 
repertoires. When using phage to display antibody fragments, phagemids usually 
consist of the DNA encoding a scFv, fused to the gene encoding a phage coat protein 
(pIII or pVIII) (See Figure 1.8). 
 
 
 
Figure 1.8 Filamentous phage structure, PIII, PVIII, PVII and PIX are phage coat 
proteins. Exogenous fragments are usually expressed or ‘displayed’ on PIII or PVIII. 
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 Other vector features include an antibiotic resistance marker, an origin of replication, 
a promoter region and an affinity tag to aid in purification. Helper phage, such as 
M13K07 or VCSM13 are also required to supply all necessary structural proteins for 
correct packaging of the phage particle. The lacZ promoter is the most common 
promoter used to control expression. Expression may be suppressed by the addition of 
the catabolic repressor, glucose, or induced by addition of isopropyl-β-D-1-
thiogalactopyranoside (IPTG). Upon induction, the scFv-coat fusion -isopropyl-
protein is incorporated into new phage particles that are assembled in the bacterium 
and displayed on their surface, while the genetic information encoding the scFv 
remains within the phage particle (Barbas et al., 2004) (Figure 1.8).  
Phage display has been successfully employed to isolate antibody fragments specific 
for small molecules (Sheedy et al., 2007). Small molecules alone do not have the 
molecular mass required to elicit an immune response and hence, must be conjugated 
to larger carrier proteins (Fodey et al., 2007a). Various carrier proteins, including 
bovine serum albumin (BSA), ovalbumin (OVA), keyhole limpet hemocyanin (KLH) 
and thyroglobulin (THY), are commonly used for this purpose. Regardless of the type 
of molecule, a carrier must be highly immunogenic, have the required solubility 
properties, be non-toxic in vivo and possess suitable functional groups for coupling to 
the hapten (Hermanson, 2005). Conjugation is a crucial step in antibody production, 
as the specificity of the resultant antibodies is dependent on the hapten used to 
produce them. The choice of method is governed by the functional groups available 
on both the hapten and the carrier and the orientation of the hapten desired, for 
presentation to the immune system. However, a major problem associated with the 
use of conjugates for antibody production is that antibodies will be produced against 
the hapten, the carrier and the linker molecule. To reduce the production of non-
specific antibodies and direct the production of antibodies to the hapten rather than 
the carrier, the number of haptens conjugated to each carrier molecule can be 
optimized. The use of conjugation procedures employing EDC (1-ethyl-3-(3-
dimethyl-aminopropyl) carbodiimide hydrochloride), does not introduce a bridging 
molecule between the hapten and carrier, thus, eliminating the potential for antibodies 
being generated against the coupling reagent (Hermanson, 2005). 
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1.5 Biopanning of phage display libraries 
Biopanning is an affinity selection technique which relies on subjecting a library of 
antibodies on filamentous phage to bind to a specific target (immobilized on a solid 
support or in solution). This process enriches analyte-specific clones, by incubation 
with the target molecule in consecutive rounds, with increasing stringency. Unbound 
phage are washed away and specific phage are eluted by changing the binding 
conditions, either by pH elution, enzymatic cleavage or incubation with excess 
antigen. Specific phage are then amplified in E. coli. This selection process is 
outlined in Figure 1.9. In practice, several rounds of selection (approximately 3-5) 
are necessary, as the binding of non-specific phage limits the enrichment that can be 
achieved in one single cycle (Azzazy and Highsmith, 2002). 
Using the pComb vector series, specific phage can then be solubly expressed by 
infection into a non-supressor E.coli strain such as Top10F, which allows the scFv to 
be secreted independently of the phage particle. Screening of the enriched library is 
then performed by analysing single colonies in a monoclonal ELISA to determine the 
specificity of each isolated clone. 
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Phage selection 
cycle
(i) Phage repertoire
(ii) Immunotube
selection
(iii) Removal of non-
specific phage
(iv) Elution of 
specific phage
(vii) Amplification of 
infected bacteria
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(vi) Re-infection of 
specific phage into 
bacteria
(viii) Production of  phage 
particles
 
 
Figure 1.9 Bio-panning of a phage display library. The library is subjected to several 
different steps; (i) the phage library is constructed (ii) binding of  phage to the target 
antigen (in this case antigen immobilized on a solid support in the form of an 
immunotube), (iii) washing to remove unbound  phage, (iv) dissociation to recover 
antigen-specific phage, (v) analysis of specific phage by ELISA, (vi) Re-infection of 
phage into bacteria, (vii) amplification of the antigen-specific phage by infection of E. 
coli and (viii) production of enriched phage repertoire for the specific target. 
 
Once a specific antibody is isolated, affinity maturation may be employed to enhance 
the affinity of a low sensitivity antibody. Several different antibody engineering 
techniques may be employed for this purpose. 
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1.6 Antibody Engineering and affinity maturation 
 
Antibody engineering for the purpose of affinity maturation is discussed in greater 
detail in Chapter 3. In brief, understanding the molecular mechanisms of antibody 
affinity and specifity towards a given antigen is a key goal in antibody engineering. In 
order to improve or alter antibody functionality, affinity and specificity may be 
manipulated in a multitude of ways. Mutations in antibody structure may affect the 
antibody affinity indirectly by influencing the positioning of side chains contacting 
the antigen. Taking this into account, antibody function may be directed by providing 
new contact residues (particularly when they are located in or near the centre of the 
antigen combining site) or by replacing ‘repulsive’ or low-affinity contact residues 
for contact residues with more favourable energetics (Hoogenboom, 1997). Error 
prone PCR (McCullum et al., 2010), site directed mutagenesis (Lou and Marks, 
2010), CDR walking mutagenesis (Yang et al., 1995), alanine scanning (Da Silva, et 
al., 2010), the use of  bacterial mutator cells (Low et al., 1996), DNA shuffling 
(Nakajima et al., 2002) and chain shuffling (Yoshinaga et al., 2008; Hur et al., 2010 
and Lou et al., 2010)  are some of the numerous methods used for the affinity 
maturation of antibodies. The method of chain shuffling was originally proposed in 
1989 by Huse and colleagues, and involves the re-cloning of the gene for one of the 
variable domains (e.g. VH) into a repertoire of genes for the other chain (e.g. VL). 
The resulting mutant library contains the VH domain gene of the parent antibody and 
random VL chain genes. It is a rapid approach for generating high affinity antibodies, 
and, since shuffling approaches mimic somatic hypermutation, they are believed to be 
more efficient than random or site-directed mutagenesis in producing functional 
antibodies (Sheedy et al., 2007). A 300-fold improvement in sensitivity has 
previously been observed for an anti-hapten scFv from a naïve scFv library (Marks et 
al., 1992). Other than affinity maturation, chain shuffling has also been reported to 
overcome improper prokaryotic expression of certain scFv (Rojas et al., 2004). 
Additionally, chain shuffling has been employed to improve the sensitivity of an scFv 
against another environmental toxin, domoic acid (Finlay et al., 2006). 
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1.7 Thesis Outline 
The main aim of this research was the development of rapid immunoassays for the 
detection of the food contaminants halofuginone, diclazuril and toltrazuril.  
Chapter 3 describes the use of antibody chain shuffling for the affinity improvement 
of an anti-halofuginone-specific scFv and subsequent incorporation into ELISA and 
Biacore detection assays. The repertoire of antigen-sensitised heavy chain regions 
was shuffled with the original wild-type light chain fragment repertoire, resulting in 
the production of a secondary heavy chain-biased library. This chain shuffling-
technique was employed for a bio-panned halofuginone-specific phage library. From 
this, an affinity matured scFv with 185-fold greater sensitivity than the wild-type was 
isolated.  This scFv was used in the generation of validated ELISA and Biacore 
assays, in spiked egg samples, for the detection of halofuginone. 
Chapter 4 focuses on the development of an immune library for diclazuril, and 
discusses the numerous problems encountered with this murine library. 
Chapter 5 describes the production of anti-toltrazuril polyclonal antibodies using an 
antigen mimic and a commercial conjugate as immunogens. The identification and 
purification of anti-toltrazuril antibodies is reported. The antibodies are incorporated 
into validated ELISA, Biacore, and lateral flow assays, and their performance of each 
assay is subsequently compared. This chapter also describes the development of a 
multi-analyte lateral flow assay for the simultaneous detection of halofuginone, 
diclazuril, and toltrazuril. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Materials and Methods 
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2. 1 Equipment 
Apparatus Supplier 
Balances (Chyo-Model JK-180 and Mettler 
Model-PJ300) 
 
Orion 3 star-pH meter 
Medical Supply Company Ltd., 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
Biacore 3000TM Instrument 
 
Biacore sensor CM5 chips 
Pharmacia Biosensor AB, Uppsala, 
Sweden. 
Biometra TGRADIENT Thermal Cycler 
 
Orbital Shaker 
 
Millipore Ultra Pure H2O Milli-Q 
Academic 
 
Sanyo Orbital Incubator 
ABG Scientific Ltd., Dublin Industrial 
Estate, Glasnevin, Dublin 9, Ireland. 
Bio-Rad Gene Pulser Xcell 
 
SDS Bio-Rad Min-Protean® 3 Cell  
 
Trans-Blot® SD Semi-Dry Transfer cell 
 
Bio-Rad PowerPac TM  Basic 
 
DNA Gel Apparatus Bio-Rad (Wide-Mini-
Sub® Cell GT) 
Alpha Technologies, The Leinster 
Technology Centre, Blessington Industrial 
Estate, Blessington, Co. Wicklow, Ireland. 
Blood Tube Rotator SB1 Stuart Scientific, Beacon Road, Stone, 
Staffordshire, ST15 0SA, UK. 
Gelaire BSB4 Laminar Flow Cabinet Gelman Ltd, 71 Broomhill Road, Tallaght 
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Industrial Estate, Tallaght, Dublin 24, 
Ireland. 
Hermle Z233M-2 Air-cooled version 
Microcentrifuge 
Hermle Labortechnik GmbH, 25 
Siemensstrasse, Wehingen, 78564, 
Germany. 
Homogeniser Ultra Turrax Janke & Kunkel IKA-Werk Ultra-Turrax, 
Staufen, 79129, Germany. 
Camag Linomat 5 Lateral Flow Instrument 
 
New Brunswick Scientific-Excella® 
Incubator Shaker Type E24 
 
ND-1000 Spectrophotometer (Nanodrop) 
 
Tomy Autoclave SX-700E High Pressure 
Steam Sterilizer 
 
Eppendorf 5810r Benchtop centrifuge 
 
Mason Technologies, Greenville Hall, 228 
South Circular Road, Dublin 8, Ireland. 
IKA ® MTS 2/4 Digital Microtitre Shaker 
Platform Shaker STR6 
Lennox, John F. Kennedy Drive, Naas 
Road, Dublin 12, Ireland. 
Tecan Safire2 Plate reader Tecan Austria GmbH, Untersbergstrasse, 
5082 Grödig, Austria. 
ThermostaticWater Bath Model Y6 Grant Instruments (Cambridge) Ltd, 29 
Station Road, Shepreth, Royston, Herts., 
SG8 6PZ, UK. 
Beckman Coulter Delsa Nano C (DLS) Beckman Coulter Diagnostics Limited 
Lismeehan, O'Callaghans Mills, Co. Clare 
Ireland. 
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Reagent Supplier 
Acetic acid 
 
Hydrochloric acid 
Riedel de-Haen AG, Wunstorfer, Strabe 40, D-
30926, Hannover, Germany. 
 
Superscript III cDNA synthesis kit 
 
Invitrogen, Biosciences Ltd., 3 Charlemont 
Terrace, Crofton Road, Dun Laoghaire, Ireland. 
Bacteriological Agar 
 
Tryptone Powder 
 
Yeast Extract 
Oxoid, Basingstoke, Hampshire, RG24 8PW, 
England. 
DNA ligase 
 
Boehringer-Mannheim Ltd., East Sussex, BN7 
1LG, England. 
Trizol 
 
Gibro BRL, Renfew Rd, Paisley, PA49RF, 
Scotland. 
Pre-stain  markers Fermentas/Fisher Scientific  Fermentas GmbH 
Opelstrasse 9, 68789 St. Leon-Rot, Germany 
PCR Primers MWG-Biotech Ltd, Milton Keynes, MK12 5RD, 
UK. 
Restriction enzymes 
 
New England Biolabs, Hitchin, Hertfordshire, SG4 
0TY, England. 
VCSM13/M13K07 Helper Phage 
 
Stratagene, North Torrey Pines Rd. La Jolla, USA. 
Wizard Plus Mini-prep kit 
 
PCR prep DNA purification kit 
 
Reverse-Transcription kit 
Promega Corporation, 2800 Wood Hollow Rd., 
 Madison, WI 53711-5399, USA. 
2.2 Reagents 
All reagents were of analytical grade and purchased from Sigma-Aldrich Ireland 
Ltd.   (Dublin, Ireland), unless otherwise stated.  
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2.2.1 Culture formulations and buffer compositions 
Media Formulation 
2 x Tryptone and Yeast Extract (TY) medium Tryptone                16  g/L 
Yeast Extract         10  g/L  
NaCl                        5  g/L 
Luria Bertani Broth (LB) medium Tryptone                10  g/L 
Yeast Extract           5  g/L 
NaCl                        5  g/L 
Super Broth (SB) medium MOPS         10  g/L 
Tryptone                30  g/L 
Yeast Extract        20  g/L 
Super Optimal Broth (SOB) medium Tryptone                20  g/L 
Yeast Extract           5  g/L 
NaCl                      0.5 g/L 
Diclazuril polyclonal Antibody 
(sheep IgG) 
Toltrazuril-BSA/BTG conjugate 
Randox Laboratories Ltd., 55 Diamond Road, 
Crumlin, Co. Antrim, BT29 4QY, Northern 
Ireland. 
 
Perfect Prep gel cleanup kit Unitech, Unitech House, Magna Drive, Magna 
Business Park, City West, Dublin 24, Ireland. 
Polybead® Carboxylate 
Microspheres 0.2 μm 
Polysciences Europe GmbH, Handelsstrasse 3, D-
69214 Eppelhein, Germany. 
HiFlow Plus HF135 nitrocellulose 
membrane 
G Scientific Ltd., Dublin Industrial Estate, 
Glasnevin, Dublin 9, Ireland. 
HRP-labeled Anti-HA, Anti-
Rabbit and Anti-Goat antibodies. 
HRP-labeled Anti-M13 antibody. 
Anti-HA, Anti Rabbit and Anti-
Goat antibodies. 
Sigma-Aldrich Ireland Limited, Vale Road, 
Arklow,Wicklow, Ireland. 
(All other reagents were sourced from Sigma if not 
previously stated) 
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KCl                       2.5  mM 
MgCl2                   20  mM 
Super Optimal Broth with Catabolite 
repression (SOC) medium 
Tryptone                20  g/L 
Yeast Extract          5   g/L 
NaCl                    0.5   g/L 
KCl                       2.5  mM 
MgCl2                   20   mM 
Glucose                 20   mM 
pH                              7.0 
Top Agar  
 
 
 
Tryptone                10   g/L 
Yeast Extract           5   g/L 
NaCl                      10   g/L 
Bacto agar               7   g/L              
 1 x 505 media supplement  0.5% (v/v) glycerol 
 0.05% (v/v) glucose 
Solid media was made by adding 15 g/L bacteriological agar to the media formulations 
above. 
 
2.2.2 Buffer compositions 
Buffer Composition 
Phosphate buffered saline (PBS) 0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
Reagents are dissolved in 800 mL ultra 
pure H2O, pH is adjusted to 7.4, by titration 
with appropriate acid or base and made up 
to 1 litre with ultra pure H2O.  
PBS-Tween 20 (0.05%) (PBST) 0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
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1.8 mM KH2PO4 
0.05% (v/v) Tween 20 
(Milk/BSA)PBST PBS formulation above 
Specified % (w/v)  BSA/Milk MarvelTM 
powder 
pH 7.4 
TBS  0.05 M Tris 
0.15 M NaCl 
pH 7.4 
Sonication Buffer  1X PBS 
0.5M NaCl 
20mM Imidazole 
Running Buffer 1X PBS 
0.5M NaCl 
20mM Imidazole  
1% (v/v) Tween 20 
10X Electrophoresis Buffer  50mM Tris, pH 8.3 
196mM Glycine    
0.1% (w/v) SDS 
Agarose Electrophoresis loading buffer 
(4x) 
25%  (w/v) Tris 0.5M, pH 6.8 
20%  (v/v) Glycerol  
14.4mM β- Mercaptoethanol   
5%    (w/v) SDS  
0.1% (w/v) Bromophenol blue  
SDS sample loading buffer 25%  (v/v) Glycerol 
2%    (w/v) SDS 
14.4 mM β-Mercaptoethanol 
0.1% (w/v) Bromophenol blue 
Transfer Buffer (Western Blot) 20%  (v/v) Methanol 
10%  (v/v) 10 x Electrophoresis Buffer 
70%  (v/v) De-ionised water 
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Sodium Citrate Buffer 150 mM NaCl,  
15 mM Sodium Citrate, 
Use 1M NaOH to adjust the pH to 7.0 
 
2.3 SDS PAGE and Western Blotting  
12.5% Separation Gel      1 gel/6mL  
1 M Tris-HCl, pH 8.8      1.5 mL 
30% (w/v) Acrylamide (Acrylagel)    2.5 mL 
2% (w/v) Methylamine Bisacrylamide (Bis-Acrylagel) 1.0 mL   
Water                   934 µL  
10% (w/v) Sodium Dodecyl Sulfate (SDS)       30 μL  
10% (w/v) Ammonium Persulfate (APS)     30 μL  
Tetramethylethylenediamine (TEMED)         6 μL   
 
4.5% Stacking gel      1 gel/2.5mL  
1 M Tris-HCl, pH 6.8      300 μL  
30% (w/v) Acrylamide (Acrylagel)    375 μL   
2% (w/v) Methylamine Bisacrylamide (Bis-Acrylagel) 150 μL   
Water                      1.625 mL   
10% (w/v) SDS        24 μL   
10% (w/v) APS        24 μL   
TEMED          2 μL   
 
2.3.1 Coomassie blue staining for SDS-PAGE  
Coomassie blue staining solution ((0.2%, w/v) Coomassie blue R250 in 30:10:60 (v/v/v) 
methanol: acetic acid: water), was prepared and gels were stained for 30 minutes. Gels 
were destained in 50 mL of destaining solution (30:10:60 (v/v/v) methanol: acetic acid: 
water) overnight at 4ºC. The destain solution was changed 2-3 times, until the protein bands 
were clearly visible. 
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2.4 Bacterial cells for cloning and expression 
E. coli TOP10 F strain: F{lacIq, Tn10(TetR)} mcrA (mrr-hsdRMS-mcrBC) 
80lacZ M15 lacX74 deoR recA1 araD139 (ara-leu)7697 galU galK rpsL (StrR) 
endA1 nupG λ- 
E. coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB 
lacIqZ∆M15 Tn10 (TetR)]. 
 
 2.4.1 Maintenance of bacterial stocks 
A working stock of bacteria was streaked on LB agar plates containing the appropriate 
antibiotic. Bacterial glycerol stocks were prepared by growing an overnight culture from a 
single bacterial colony. These were stored in 15% (v/v) glycerol and 1% (w/v) glucose at  
– 80ºC. 
 
2.5 General Lab techniques* 
*These methods are generic and any modification made will be cited in the corresponding 
sections. 
 
2.5.1 Agarose gel electrophoresis for DNA characterisation 
Agarose gel electrophoresis is a highly effective method for separating, identifying and 
purifying DNA fragments. Agarose gels are prepared containing a concentration of agarose 
appropriate for the size of DNA fragments to be resolved. The DNA is stained with the 
fluorescent dye, ethidium bromide, and can then be visualised under U.V light. 
DNA was analysed by resolution on agarose gels (containing 0.5 g/mL ethidium 
bromide), in a horizontal gel apparatus. Gels were prepared by dissolving agarose 
(typically 0.7-1.2% (v/v)) in 1 x Tris-Acetate-EDTA (TAE) buffer by heating.  Ethidium 
bromide was added to the cooled gel prior to setting. The gels were placed in the gel 
apparatus and 1 x TAE was used as the running buffer. A tracker dye was incorporated into 
the sample (1 l dye + 5 l sample) to facilitate loading of samples. Small gels were 
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frequently run at 100 Volts for 1 hour or until the dye reached the end of the gel while 
larger gels were frequently run at 40-80 Volts. Gels were then visualised on a UV 
transilluminator and photographed using a UV image analyser. 
 
2.5.2 SDS-PAGE 
The following stock solutions were prepared: 0.5 M Tris-HCl, pH 6.8, 0.4% (w/v) SDS, 
10% (w/v) APS and 1.5 M Tris-HCl, pH 8.8 (Tris base, rather than Tris-HCl, should be 
used for buffer preparation and pH adjustment should be made with HCl). Use of Tris-HCl 
would result in higher ionic strength, poor migration and diffuse protein bands. The 
composition of each gel formulation is outlined in Section 2.3. SDS denatures the protein 
and coats it with a negative charge. The amount of SDS bound is relative to the size of the 
protein, and, therefore, all proteins will have a similar mass-to-charge ratio. This separation 
method also employs β-mercaptoethanol, a reducing agent. Heat is applied to dissociate 
proteins into individual polypeptides before they are loaded onto the polyacrylamide gel. 
Glass plates are held together by using Bio-rad gel holder cassettes. Free radical-induced 
polymerisation of the resolving gel acrylamide was catalysed by addition of APS and the 
accelerator TEMED. Once the gel had polymerised, the stacking gel was added directly 
onto the resolving gel. A plastic comb was placed in this gel to create the wells for sample 
application. When the stacking gel had fully polymerised, the plates were then placed in an 
electrophoresis chamber, the comb was removed and the chamber and wells filled with 
electrophoresis buffer. The pore size of the gel, dependent on the amount of acrylamide and 
degree of crosslinking, facilitates protein separation on the basis of size. Excess sample 
buffer is essential to maintain reduction of protein sulfhydryls and to prevent 
intramolecular disulfide bond formation through oxidised cysteines. Therefore, samples 
were mixed 4:1 with SDS sample buffer and heated for 5 minutes at 95ºC. A Fermentas 
pre-stained colourburst marker (Product number: SM1811) was used with each gel. A 
sample volume of 20 μL was added to the respective wells on the gel. The gel was run at 30 
mA until the sample had reached the bottom of the gel. The separated protein was then 
visualized by staining with Coomassie blue for 1-2 hours followed by the addition of 
destain for 2-3 hours, or  the gels were used for subsequent Western blotting, as described 
in Section 2.5.3. 
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2.5.3 Western Blotting 
Proteins are eluted from a polyacrylamide gel onto a nitrocellulose membrane by 
electrophoretic transfer. This technique is used for the qualitative detection or 
characterisation of a specific protein. The transfer buffer used is essentially SDS running 
buffer with methanol included. The presence of methanol in the transfer buffer serves two 
main purposes. Firstly it promotes dissociation of SDS from the protein and secondly it 
dramatically improves adsorption of proteins onto membranes in the presence of SDS, 
although these effects may vary with proteins (Pettegrew et al., 2009). Following 
separation of the proteins by SDS-PAGE, as described in Section 2.5.2, the polyacrylamide 
gel, filter paper and nitrocellulose membrane were soaked in transfer buffer for 
approximately 15 minutes. The proteins were then transferred to the membrane by 
electrophoresis using a Trans-Blot SD semi-dry cell (Bio-Rad) at 15V for 20 minutes. The 
membrane was blocked with PBS containing 5% (w/v) Milk Marvel (Premier Foods Ltd., 
UK) overnight at 4ºC. The membrane was washed three times with PBST for 10 minutes 
each time. Ten mLs of the appropriate antibody, at the required dilution, was prepared in 
PBS containing 2% (w/v) Milk Marvel and added to the nitrocellulose for 1.5 hours, while 
shaking at room temperature. The membrane was then washed thoroughly as before and a 
secondary antibody (if required), prepared in PBS containing 2% (w/v) Milk Marvel, was 
added and incubated as before. Once the blot was washed, TMB peroxidase substrate is 
added which forms an insoluble blue precipitate when acted upon by the HRP-labelled 
antibody. This allows the protein bands to be clearly visualised. 
 
2.5.4 Quantification of proteins/nucleic acids on the Nanodrop 1000 (Thermo 
Scientific) 
The Nanodrop spectrophotometer is set to the correct parameters depending on the samples 
to be quantified. Proteins are measured at an absorbance of 280nm and DNA is measured at 
260nm. The Nanodrop is initialized by adding water, and blanked by addition of the sample 
buffer. The sample to be quantified (1.6 μL) is pipetted onto the measurement pedestal of 
the spectrophotometer and a measurement is then taken. This is repeated in duplicate to 
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ensure accuracy. The sample is then simply wiped clean from the pedestal and another 
sample can be measured. 
 
2.6 Generation of the chicken anti-halofuginone scFv library-immunisation schedule 
and antibody serum titre for the production of anti-halofuginone antibodies 
A Leghorn chicken was initially immunised sub-cutaneously with a mixture of equal parts 
of halofuginone-HSA (HFG-HSA) conjugate and Freund’s complete adjuvant. The final 
concentration of the initial immunisation was 200 µg/mL. The first boost (day 14) was then 
administered using 100 µg/mL of HFG-HSA in PBS, mixed in a 1:1 ratio with Freund’s 
incomplete adjuvant, in a final volume of 1 mL. The final 4 boosts that followed (days 36, 
52 and 66) all contained 100 µg/mL of HFG-HSA and were administered in the same 
manner as the first boost using incomplete adjuvant. Finally, the chicken was sacrificed 
(day 71), and the spleen and bone marrow removed. Nunc MaxisorbTM immunoplates were 
coated with 100 μL per well of the HFG-BTG at a concentration of 1 μg/mL and incubated 
overnight at 4ºC. Excess conjugate was discarded. The plates were then blocked with PBS 
containing 5% (w/v) Milk Marvel for 1 hour at 37ºC. Serial dilutions of each of the chicken 
anti-serum in PBS containing 1% (w/v) Milk Marvel were added to the wells and allowed 
to bind at 37ºC for 1 hour. The plates were washed 3 times with PBST and 3 times with 
PBS. This was followed by the addition of a 1 in 2,000 dilution of HRP-labelled rabbit 
anti-chicken antibody (Sigma) in PBS containing 1% (w/v) Marvel. The plate was 
incubated for 1 hour at 37°C, washed as before, and TMB substrate was added (100 
μL/well). Following incubation for 30 minutes at 37ºC, the reaction was stopped by the 
addition of 10% (v/v) HCl and the absorbance read at 450nm on a Tecan Safire2TM 
platereader. 
 
2.6.1 Extraction and isolation of total RNA from chicken spleen 
Prior to the extraction procedure, several preparatory steps are taken. Oakridge tubes are 
cleaned with Virkon® to ensure that no contamination is present. They are then washed 
with ‘Rnase-free’ water (Sigma), sprayed with Rnase zap® (Sigma) and left overnight to 
ensure no contaminating Rnases remain. The homogenizer to be used is incubated in 
PreceptTM, washed thoroughly with ‘Rnase-free’ water, autoclaved and then baked in an 
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oven at 60ºC overnight. Ethanol (75% (v/v) in ‘Rnase-free’ water) was prepared in ‘Rnase-
free’ tubes and stored at -20ºC. A laminar flow hood was de-contaminated by cleaning with 
70% (v/v Ethanol in ‘Rnase-free’ water) IMS and Rnase Zap. Materials and reagents to be 
used during the extraction procedure are also decontaminated. The chicken was sacrificed 
by cervical dislocation. The spleen was removed, placed in a ‘Rnase-free’ tube and 
homogenized in 30 mL of TriZol® reagent (Sigma) using a sterile homogenizer. The tubes 
were centrifuged in an Eppendorf 5810r centrifuge at 1575 g for 10 minutes at 4ºC. The 
supernatant was removed into 50 mL Oakridge tubes containing 6 mL of chloroform. This 
was mixed well by shaking and incubated at room temperature for 15 minutes. The samples 
were then centrifuged at 17,500 g for 20 minutes at 4ºC. After this centrifugation step, three 
visible layers are produced. The upper aqueous layer is carefully removed (ensuring that 
none of the organic layer of protein is transferred from the interphase) and added to a large 
Oakridge tube with 15 mL of isopropanol for precipitation of RNA. This is mixed and left 
at room temperature for 10 minutes. It is then centrifuged at 17,500 g for 20 minutes at 4ºC. 
The supernatant is carefully removed and discarded ensuring that the pellet is not disrupted. 
The RNA pellet is washed by adding 30 mL of 75% (v/v) ethanol. This is centrifuged again 
at 17,500 g for 10 minutes at 4ºC and the supernatant is again discarded. The pellet was air 
dried in the laminar flow cabinet and then gently resuspended in 500 μL of molecular grade 
water (Sigma). The RNA was subsequently quantified on the Nanodrop and cDNA 
synthesis is performed. 
 
2.6.2 cDNA synthesis 
Total RNA was transcribed to cDNA by reverse transcriptase PCR. The cDNA will 
subsequently serve as a template for the amplification of the variable heavy and variable 
light chain gene fragments. This reaction was performed using a Superscript III first strand 
cDNA synthesis kit (Invitrogen). This polymerase is superior to other superscripts due to 
its reduced Rnase H activity and full enzymatic activity at 50oC. The reaction components 
were as follows; 
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Mixture 1    Volume 
Total RNA (100ug)    22 μL 
Oligo dT   20 μL 
10mM dntp’s   20 μL 
Water             138 μL 
 
 
Mixture 1 was split into eight 25 μL aliquots and incubated at 65ºC for 5 minutes (Biometra 
TGradient PCR machine). This was then left on ice for 1 minute. An equal volume of mixture 
2 was added to each 25 μL sample of mixture 1 and incubated at 50ºC for 5 minutes. The 
reaction was continued at 85ºC for 5 minutes. Five µL of RnaseH was then added to the 
mixture and subsequently incubated at 37ºC for 20 minutes. Finally, the eight separate 
aliquots were combined and stored at -20ºC. The amount of cDNA present was then 
determined by quantification on the Nanodrop. 
 
2.6.3 PCR primers for amplification of chicken scFv (pComb3XSS vector) 
Vλ Primers 
CSCVK (sense) 
5´ GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG GTG TC 3´ 
CKJo-B (reverse) 
5´ GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT CAG G 3´ 
 
VH Primers 
CSCVHo-F (sense), Short Linker 
5´ GGT CAG TCC TCT AGA TCT TCC GCC GTG ACG TTG GAC GAG 3´ 
CSCVHo-FL (sense), Long Linker 
5´ GGT CAG TCC TCT AGA TCT TCC GGC GGT GGT GGC AGC TCC GGT GGT 
GGC GGT TCC GCC GTG ACG TTG GAC GAG 3  ´
CSCG-B (reverse)  
5´ CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC GAT GAC TTC GGT CC 3  ´
Mixture 2    Volume 
10x RT Buffer   40 μL 
25mM MgCl2   80μL 
0.1M DTT   40 μL 
Rnase out   20 μL 
Superscript III   20 μL 
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Overlap Extension Primers 
CSC-F (sense) 
5´ GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG ACT CAG 3´ 
CSC-B (reverse) 
5´ GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC CTG GCC ACT AGT GGA 
GG 3´ 
The primers listed above were obtained from Eurofins MWG and are compatible with the 
primers set described by Barbas for the pComb vector system (Barbas et al., 2004). 
 
2.6.4 Amplification of antibody variable domain genes using pComb series primers 
The standard PCR reaction components and conditions were as follows; 
  
 Component     Concentration in 50 μL reaction 
cDNA    0.5 μg 
dNTP’s    0.2 mM 
Forward primer    60 pm 
Reverse primer    60 pm  
MgCl2    4 mM 
5X buffer    1 X 
Go Taq Polymerase (5units/μL)  1 unit 
This mixture is made up to 50 μL with MgH2O 
Go Taq polymerase and its corresponding buffer were used. The PCR amplification of the 
variable regions from avian cDNA was performed in a Biometra TGradient PCR machine 
under the following conditions: 
Step 1 94ºC for 5 minutes 
Step 2 
30 cycles of: 94ºC for 15 seconds 
 56 ºC for 15 seconds 
 72 ºC for 90 seconds 
Step 3 72 ºC for 10 minutes 
After successfully optimizing the amplification of the variable regions the PCR products  
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(5 μL of each reaction) were analysed on a 2% (w/v) agarose gel, as described in Section 
2.2.5. The reaction was scaled up (5X), the PCR products were pooled and ethanol 
precipitated. The ethanol precipitated DNA was then purified from a 2% (w/v) agarose gel 
and DNA was quantified by measuring the absorbance at 260nm on the Nanodrop. 
 
2.6.5 Ethanol Precipitation of DNA 
One-tenth the volume of 3M sodium acetate, pH 5.2, was added to a solution of DNA. The 
solution was mixed and two volumes of absolute ethanol were added, mixed and incubated 
at –20ºC for 2 hours. Following incubation, DNA was pelleted by centrifugation at 20,000 
g for 15-30 minutes at 4ºC in a microcentrifuge. The supernatant was removed carefully 
without disrupting the pellet and the tube was centrifuged at 20,000 g for 1 minute at 4ºC to 
remove any residual liquid. The pellet was washed to remove excess contaminants 
(especially salts and chelators) in 1 mL of 70% (v/v) ethanol and centrifuged at 20,000 g 
for 2 minutes at 4°C. The supernatant was removed carefully and the tube re-centrifuged 
briefly to remove any remaining liquid. The pellet was air-dried and dissolved in the 
required amount of molecular grade water. 
 
2.6.5.1 Purification of the variable region gene fragments using the Qiagen clean up  
The variable gene fragments were purified by excising the corresponding sized band from 
the agarose gel (approx. 400bp for VH and approx. 350bp for VL chains). The excised gel 
slices were weighed and binding buffer was added at a ratio of 1 g gel slice: 3 mL of 
binding buffer. The gel slices were incubated at 50ºC until completely melted. An equal 
volume of isopropanol to the weight of the excised fragment was added and the resulting 
mixture was applied to the silica membrane of the Qiagen purification column. The column 
was centrifuged at 21,000 g for 1 minute in a microcentrifuge. The ‘flow-through’ was 
discarded and the column was washed with 750 μL of wash buffer. This was allowed to 
pass through the membrane by centrifugation at 21,000 g for 1 minute. The ‘flow-through’ 
was discarded and any residual buffer was removed by centrifuging again for a further 2 
minutes. The column was transferred into a sterile 1.5 mL eppendorf tube and the DNA 
was eluted from the column with the addition of 30 μL MgH2O at 60ºC and centrifugation 
for 1 minute at 21,000 g. The eluted DNA was then quantified using the Nanodrop. 
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2.6.6 Splice by overlap extension PCR 
In the SOE-PCR the appropriate purified variable heavy and variable light chain gene 
fragments are mixed in equal ratios to generate the overlap product. The VH and VL 
purified fragments were joined using an SOE-PCR via a glycine-serine linker (G4S)4 
incorporated in the primers, producing a fragment of approximately 800bp. 
 
SOE-PCR components for amplification of joined antibody light and heavy chain genes; 
  
 Component     Concentration in 50 μL reaction 
5 X buffer     1 X   
MgCl2      4 mM   
dNTP      0.2 mM    
VH      100 ng 
VL      100 ng 
Forward primer    60 pm 
Reverse primer    60 pm 
Phusion high fidelity polymerase  
(5 units/μL)      1 unit  
This mixture is made up to 50 μL with molecular grade H2O 
 
The polymerase used to generate the full length SOE product was Phusion high fidelity 
polymerase. In Phusion polymerase a unique dsDNA-binding domain is fused to 
a ‘Pyrococcus-like’ proofreading polymerase. This is designed to produce PCR products 
with high fidelity, accuracy and speed. The PCR amplification of the SOE product was 
performed in a Biometra TGradient PCR machine under the following conditions: 
Step 1 94ºC for 5 minutes 
Step 2 
25 cycles of;   94ºC for 15 seconds 
 56 ºC for 15 seconds 
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 72 ºC for  2 minutes 
Step 3 72 ºC for 10 minutes 
 
 
2.6.7 Restriction-digest of the purified overlap PCR product and vector DNA 
The restriction digest was performed using Sfi1 enzyme from NEB alongside the 
recommended NEB Buffer. 
 
Restriction digest of the purified overlap PCR product: 
Component concentration per reaction   (1X) 
Purified overlap PCR product     10 μg 
SfiI (36U per μg of DNA)     360 U 
NEB Buffer 2 (10X)       20 μL 
BSA (100X)          2 μL  
Molecular grade water was added to a final volume of 200 μL. 
 
Restriction-digest of the purified vector DNA: 
Component Concentration per reaction    (1X) 
Vector DNA (pComb3XSS)      20 μg 
SfiI (6U per μg of DNA)      120 U 
NEB Buffer 2 (10X)       20 μL 
BSA (100X)         2 μL  
Molecular grade water was added to a total volume of 200 μL. 
 
The digests were incubated for 5 hours at 50ºC. The digested PCR fragment, the 
pComb3XSS vector and pComb3XSS stuffer fragments were purified on a 1% (w/v) 
agarose gel and 0.6% (w/v) agarose gel, respectively, by electroelution. DNA was 
quantified by measuring the absorbance on the Nanodrop at 260nm.  
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2.6.8 Ligation of the digested overlap PCR product with vector DNA 
The gel-purified SfiI-restricted scFv insert fragment was cloned into the Sfi1-digested 
pComb3XSS which was facilitated by the use of T4 DNA ligase. The ligase works by 
catalyzing the formation of phosphodiester bonds between 5l phosphate and 3l hydroxyl 
groups in duplex DNA. 
 
 
Component Concentration per reaction    (20X) 
pComb3XSS (digested and purified)     1.4 μg 
Overlap PCR product (digested and purified)   700 ng 
T4 DNA ligase buffer      40 μL 
T4 DNA Ligase       10 μL 
Molecular grade water was added to a total volume of 400 μL 
 
Ligations were incubated at 16ºC overnight. The ligated vector and insert was then ethanol-
precipitated, as described in Section 2.6.6. The DNA pellet was resuspended in 20 μL of 
molecular grade water and transformed into E. coli XL1-Blue electrocompetent cells 
(Stratagene) by electroporation.      
 
2.6.8.1 Transformation of E.coli XL1-Blue electrocompetent cells with pComb3XSS 
vector containing light and heavy chain genes and measurement of transformation 
efficiencies 
The ligated DNA and electroporation cuvettes (0.2 cm, Bio-Rad) were incubated on ice for 
10 minutes. At the same time the electrocompetent E.coli XL1-Blue cells were thawed on 
ice. Each ligation was added to the cells (300 μL), mixed gently, transferred to a chilled 
cuvette and incubated on ice for 1 minute. The sample was then electroporated with 
settings of 25 µF, 1.25 kV and gene pulse controller at 200 Ω (Bio-Rad Gene Pulser 
XcellTM). The cuvette was immediately flushed with 1 mL SOC medium, followed by 2mL 
SOC (x2) at room temperature, and transferred to 50 mL polypropylene tube. The cells 
were incubated at 37ºC for one hour with shaking at 250 rpm. Following incubation 10 mL 
of pre-warmed (37ºC) SB media, containing 100 μg/mL carbenicillin, was added and the 
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culture was incubated for a further hour at 37ºC with shaking. Ten µL of the culture was 
taken to estimate the titre of transformed bacteria before incubation. PComb3XSS 
transformants were plated out on SB agar supplemented with 100 μg/mL carbenicillin. 
Control transformants were plated out on SB agar supplemented with 20 μg/mL of 
kanamycin.  Both sets of plates were allowed to grow overnight at 37ºC. PComb3XSS 
transformed colonies were scraped off the plates and used as library stocks. These stocks 
were suspended in 15% (v/v) glycerol and stored at –80ºC.  
 
2.7 Rescue and subsequent precipitation of scFv-displaying phage 
The transformed library stock was inoculated into 400 mL of SB media with 100 μg/mL 
carbenicillin. The culture was grown at 37ºC, while shaking at 250 rpm, until an O.D600 of 
0.4 - 0.5 was reached. The optimal cell density is in the mid-log phase of growth, O.D600 is 
used because the cellular components of bacteria absorb greater light at wavelengths lower 
than 600 nm. Helper phage M13K07 (200 μL) was added to the culture, which was then 
incubated at 37ºC stationary for 30 minutes. The culture was then incubated at 30ºC for one 
hour, while shaking at 250 rpm. Kanamycin was added to the culture to a final 
concentration of 60 μg/mL and the culture was incubated overnight shaking at 30ºC and 
250 rpm. 
An immunotube was then coated with 500 μL of 100 μg/mL halofuginone-BTG and left at 
4ºC stationary overnight.  An overnight culture of XL1-Blue was also prepared. This was 
sub-cultured the next day by adding 500 μL of the overnight culture to 50 mL of fresh 
2xTY and left growing until an O.D 600 of 0.4- 0.5 was reached. Agar plates were prepared 
with 100 μg/mL of carbenicillin. The overnight phage culture was then removed from the 
30ºC incubator, transferred to sterilin tubes and centrifuged for 10 minutes at 3220 g in an 
Eppendorf 5810r centrifuge. The phage supernatant was transferred to sterile sorval tubes 
and centrifuged at 15,300 g for 20 minutes. The supernatant was then transferred to clean 
sterile sorval tubes and PEG and NaCl were added at concentrations of 4% and 3% (w/v), 
respectively. The sorval tubes were incubated on ice for 1 hour at 4ºC to allow for phage 
precipitation. Following precipitation the tubes were centrifuged at 15,300 g for 20 minutes 
at 4ºC. The phage supernatant was discarded and residual supernatant was removed by 
inverting the sorval tubes onto dry tissue paper. The phage pellet was then resuspended in 
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500 μL of PBS and 500 μL of 3% (w/v) BSA. This suspension was the phage input. Ten 
microlitres of this phage library input was taken for library titre estimation. 
 
2.7.1 Enrichment of phage library via biopanning against immobilised antigens 
The antigen solution was poured off the immunotube and 3% (w/v) BSA solution was 
added filling the tube entirely, to ensure any immunosorbent sites not occupied by antigen 
are blocked by the BSA. This was left incubating at RT for 2 hours. The input phage was 
pre-blocked by adding it to immunotubes just coated with 1% (w/v) BSA and incubating 
for 1 hour at RT. The pre-blocked phage were then transferred to the halofuginone-coated 
immunotube and left gently shaking at RT for 2 hours. The phage were discarded and the 
tube was washed several times with PBST/PBS, which varied depending on the panning 
stage (see Table 2.0 below, for biopanning conditions). The tube was treated with trypsin to 
elute any bound phage. This was performed by adding 500 μL of trypsin-PBS solution (50 
μL of trypsin 10 mg/mL in 450 μL PBS) to the tube; the trypsin was made in Tris-HCl, pH 
7.4, with 1 mM CaCl2. The trypsin-treated sample was then labelled the ‘output’.  
 
Table 2.0 Biopanning conditions for the generation of the halofuginone-specific chicken 
scFv library using varying concentrations of halofuginone-BTG coated on immunotubes. 
The stringency of each consecutive round of panning was altered by increasing the number 
of washes with PBS (Phosphate buffered saline) and PBST (Phosphate buffered saline with 
0.5% (v/v) Tween 20) and decreasing the coated antigen concentration. 
 
 
Biopanning round Concentration of coated 
antigen (μg/mL) 
Washing frequency 
1 100 3 X PBS, 3 X PBST 
2 50 5 X PBS, 5 X PBST 
3 25 7 X PBS, 7 X PBST 
4 10 10 X PBS ,10 X PBST 
5 5 15 X PBS, 15 X PBST 
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2.7.2 Re-infection of E. coli XL1-Blue cells with eluted phage 
Eluted phage were added to an overnight culture of E. coli XL1-Blue (5 mL) and incubated 
for 15 minutes at room temperature. Pre-warmed SB (6 mL), containing 20 μg/mL 
carbenicillin, was then added and the culture incubated at 37ºC for 1 hour. Ten µL of this 
culture was kept aside for estimation of output titre. Following incubation, carbenicillin 
was added to a final concentration of 30 μg/mL and the culture incubated for 1 hour at 
37ºC, while shaking at 250 rpm. M13 helper phage (2 mL at 1011pfu/mL) and pre-warmed 
SB (39 mL), containing 50 μg/mL of carbenicillin, were added and the culture incubated 
for approximately 2 hours at 37ºC while shaking at 200 rpm. Kanamycin was then added, 
to a final concentration of 60 μg/mL, and the culture incubated overnight at 37ºC with 
shaking at 200 rpm. Following incubation, the culture was centrifuged at 3,220 g in an 
Eppendorf 5810r centrifuge for 15 minutes at 4ºC. The supernatant was transferred to a 
sterile sorval tube and the phage concentrated by PEG/NaCl precipitation, as described in 
Section 2.7. Freshly prepared phage were then used in the next round of panning. After the 
final round of panning, the output was re-infected into the non-suppressor strain of E.coli 
Top10F for soluble scFv expression. 
 
2.7.3 Library titre estimation 
For estimation of input and output titre, infected eluted phage (10 μL) was diluted in 1 mL 
of SB media and plated out (in 10 and 100 μL volumes) on SB agar containing 100 μg/mL 
carbenicillin. The plates were incubated overnight at 37ºC and the total number of 
transformants calculated. 
 
2.8 Polyclonal phage pool ELISA and colony pick PCR 
A Nunc MaxisorbTM plate was coated with 100 μL per well of 1 μg/mL of HFG-transferrin 
conjugate (and a BTG control) and incubated overnight at 4ºC. The excess conjugate was 
discarded and the plate was subsequently blocked with 200 μL PBS containing 3% (w/v) 
BSA for 1 hour at 37°C. Phage (from each round of panning), diluted 3 fold in PBS 
containing 1% (w/v) BSA, was added to the plate in triplicate at 100 μL per well. Negative 
(M13 helper phage) controls were also added to the plate in triplicate. The plate was 
incubated for 2 hours at 37ºC and then washed 3 times with PBST and 3 times with PBS. 
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Bound antibodies were detected following the addition of 100 μL of a HRP-labelled anti-
M13 secondary antibody in PBS containing 1% (w/v) BSA. The plate was incubated for 1 
hour at 37ºC, washed 3 times with PBST and 3 times with PBS, and TMB substrate 
(Sigma) was added (100 μL/well). Following incubation for 30 minutes at 37ºC, the 
reaction was stopped by the addition of 10% (v/v) HCl and the absorbance read at 450nm 
on a Tecan Safire2TM platereader. 
Twenty single colonies were randomly picked from the 5th round of panning and 
incorporated into a ‘colony-pick’ PCR as outlined in Barbas et al., (2001), to ensure the 
vector was harboring the scFv fragment. A sterile tip was used to pick a single colony into 
the following mixture, which was then placed in a Biometra TGRADIENT PCR machine. The 
amplified scFv fragments were subsequently analysed via gel electrophoresis on a 1% 
(w/v) agarose gel.  
 Component     Concentration in 50 μL reaction 
5 X buffer     1 X   
MgCl2      4 mM   
dNTP      0.2 mM    
Forward primer    60 pm 
Reverse primer    60 pm 
Single Colony     1 colony 
 Phusion high fidelity polymerase  
 (5 units/μL)     1 unit 
The colony pick PCR was performed in the Biometra TGRADIENT PCR machine under the 
following conditions: 
 Step 1      94ºC for 5 minutes 
 Step 2 
 25 cycles of;       94ºC for 15 seconds 
    56ºC for 15 seconds 
    72ºC for   2 minutes 
 Step 3          72ºC for 10 minutes 
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2.9 Monoclonal soluble scFv ELISA for the detection of halofuginone-specific scFv 
Individual colonies (192 in total) were picked and grown overnight at 200 rpm and 37ºC in 
single wells containing 100 μL SB media with 100 μg/mL carbenicillin (stock plates). The 
stock plates were then sub-cultured into fresh 2 x TY media (180 μL) containing 1 x 505 
(0.5% (v/v) glycerol, 0.05% (v/v) glucose final concentration), 1 mM MgSO4 and 100 
μg/mL carbenicillin. Glycerol was added to the overnight stock plates to a final 
concentration of 15% (v/v) and then transferred to a -80°C freezer for long-term storage. 
The sub-cultured plates were incubated at 37ºC, while shaking at 200 rpm until cells 
reached an optical density at 600 nm (OD600nm) of ~0.6. Expression was then induced by 
addition of IPTG to a final concentration of 1 mM and incubating at 30ºC (180 rpm) 
overnight. Two Nunc MaxisorbTM plates were coated with 100 μL of 1 μg/mL HFG-
transferrin conjugate and incubated overnight at 4ºC. The excess conjugate was discarded 
and the plates were blocked with 200 μL per well of PBS containing 3% (w/v) BSA for 1 
hour at 37ºC. Meanwhile, the overnight plates of expressed clones were removed from the 
30ºC incubator and subjected to a freeze-thaw protocol for the production of scFv-enriched 
lysate. The plates were placed at -80ºC until frozen and then thawed at 37ºC (this step was 
repeated a total of 3 times). The plates were then centrifuged at 3,220 g for 15 minutes in 
an Eppendorf 5810r centrifuge, to obtain the scFv-enriched lysate supernatant. The lysate 
supernatant (100 μL) was added to the corresponding well in each ELISA plate, mixed 
gently and incubated for 1 hour at 37ºC. The plates were washed three times with PBST 
and three times with PBS, followed by the addition of 100 μL per well of HRP-labelled 
anti-HA antibody, at a 1/2,000 dilution in PBST containing 1% (w/v) BSA. The plate was 
incubated for 1 hour at 37ºC, washed as previously stated, and 100 μL TMB substrate was 
added per well. Following incubation for 30 minutes at 37ºC, the reaction was stopped by 
the addition of 10% (v/v) HCl and the absorbance read at 450 nm on a Tecan Safire2TM 
platereader. 
 
2.9.1 Competitive ELISA for scFv characterization  
Expressed scFv binding immobilised HFG-Tranferrin were subjected to competitive 
analysis, by incubation with free halofuginone (HalocurTM). Nunc MaxisorbTM plates were 
coated with 1 μg/mL HFG-transferrin and blocked as described in Section 2.8. Different 
 46 
halofuginone concentrations were incubated with an equal volume of each of the specific 
lysates chosen from monoclonal ELISA analysis. This mixture was added to the ELISA 
plate for 1 hour at 37ºC. Plates were washed 3 times with PBST and 3 times with PBS and 
100 μL of 1/2,000 dilution of anti-HA HRP-labelled antibody in PBS-Tween containing 
1% (w/v) BSA was added to each well. The plate was incubated for 1 hour at 37ºC, washed 
as before and TMB substrate was added (100 μL/well). Following incubation for 30 
minutes at 37ºC, the reaction was stopped by the addition of 10% (v/v) HCl and the 
absorbance read at 450nm. 
 
2.9.2 Antibody expression and purification 
Approximately 10 mL SB media, containing 1% (w/v) glucose and 100 μg/mL 
carbenicillin was inoculated with 100 μL of transformed scFv stocks and grown overnight 
at 37ºC, while shaking at 250 rpm. The overnight cultures were then used to seed 500mL 
SB media containing 1 x 505 supplement and 100 μg/mL carbenicillin with a cell density 
of 1% and grown at 37ºC, while shaking at 220 rpm, until an O.D600 nm of ~0.6 was 
reached. The culture was then induced by the addition of 1 mM IPTG and incubated 
overnight at 30ºC with shaking at 220 rpm. The following morning the culture was 
centrifuged at 3,220 g for 30 minutes at 4ºC and the supernatant was discarded. The cell 
pellet was thoroughly resuspended in 10 mL of lysis buffer (50 mM Na2H2PO4, 300 mM 
NaCl, 10 mM imidazole, pH 8). This was sonicated on ice three times for 45 seconds (3 
second intervals) at an amplitude of 40, using a microtip Vibra CellTM sonicator. The cell 
debris was then removed by centrifuging at 15,000 g for 10 minutes at 4ºC in an Eppendorf 
5810r centrifuge.  
 
2.9.2.1 Purification of anti-HFG scFv antibody fragments by immobilised metal 
affinity chromatography 
The lysate supernatant was filtered through a 0.2 μm filter to remove any residual cell 
debris. Two mL of nickel resin (Ni-NTA resin slurry-Qiagen) was added to a 20 mL 
column and equilibrated with lysis buffer (50 mM Na2H2PO4H2), 300 mM NaCl, 10 mM 
imidazole, pH 8). The filtered lysate was then added to the equilibrated column and the 
‘flow-through’ collected. The column was then washed with 20 mL of 50 mM 
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Na2H2PO4H2O, 300 mM NaCl, pH 8. Twenty mL of 50 mM Na2H2PO4H2O, 300 mM 
NaCl, 10 mM imidazole, pH 8, was then used to further remove any loosely bound 
proteins. Elution of bound scFv was performed using a high concentration of imidazole by 
adding 5 mL of elution buffer (50 mM Na2H2PO4H2O, 300 mM NaCl, 250 mM imidazole, 
pH 8) to the column.  Antibody-containing fractions were buffer-exchanged against filtered 
PBS using a 5 kDa cut-off Vivaspin™ column (AGB, VS0611). The buffer-exchanged 
scFv was then quantified using the Nanodrop. The resultant antibody solution was 
dispensed in 20 μL volumes and stored at 20ºC until required. The performance of the 
purification process was evaluated using SDS-PAGE and Western-blotting, as described in 
Sections 2.5.2 and 2.5.3. 
 
2.9.3 ELISA characterisation 
2.9.3.1 Checkerboard ELISA for the determination of optimal concentrations of 
immobilised antigen, and dilution of antibody, for the development of a validated ELISA 
for the detection of halofuginone 
Nunc MaxisorbTM plates were coated with varying antigen concentrations (8 μg/mL -1 
μg/mL), with each antigen concentration added to a different row on the ELISA plate. 
Plates were blocked with 3% (w/v) BSA. One hundred µL samples of purified antibody, 
serially diluted 1:5 in PBST containing 1% (w/v) BSA was added to each well and detected 
as described in Section 2.8.  
 
2.9.3.2 Inter/Intra-day variability studies  
The intra-day study was performed to assess the precision and variability within the assay 
by directly comparing three replicate samples within the same assay. Nunc MaxisorbTM 
plates were coated with the appropriate concentration of HFG-BTG conjugate and blocked, 
as described in Section 2.9.3.1. A 500 μg/mL stock of Halocur (free halofuginone) was 
obtained from Janssen (Intervet). Standards of decreasing concentrations of analyte were 
prepared in PBS. Each standard was added to an equal volume (50 μL) of HFG-specific 
antibody at the optimal concentration in PBST containing 1% (w/v) BSA. The samples 
were incubated for 30 minutes at room temperature and added to the microtitre plate in 
triplicate. The plates were washed 3 times with PBST and 3 times with PBS. Bound 
antibody was detected following the addition of HRP-labelled anti-HA antibody in PBST 
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containing 1% (w/v) BSA. The plate was incubated for 1 hour at 37ºC, washed as before 
and TMB substrate was added (100 μL/well). Following incubation for 30 minutes at 37ºC, 
the reaction was stopped by the addition of 10% (v/v) HCl and the absorbance read at 
450nm on a Tecan Safire2TMplate reader. The inter-assay study was performed under the 
same conditions on three separate days to assess the reproducibility of the assay and to 
determine the overall precision and accuracy of the assay. The co-efficients of variation 
(CVs) of the assay were calculated as a percentage from the standard deviation between 
results. 
 
2.9.3.3 Cross-reactivity studies  
The HFG-specific scFv was assessed for cross reactivity against five commonly used 
veterinary drugs, which included, Toltrazuril, Ponazuril, Nicarbazin, Diaveridine, and 
Ethopabate, which were obtained from Teagasc, Ashtown Food Research Centre, Co. 
Dublin, Ireland. Calibration curves were prepared in assay buffer, as per Section 2.9.3.2, 
using each of the individual drugs at concentrations from 1 mg/L to 1 ng/L. The IC50 values 
of the calibration curve for each respective drug were then directly compared to that of 
HFG to determine the degree of cross reactivity. 
 
2.9.3.4 Precision assay and determination of analytical limits 
An inhibition ELISA was performed to determine what concentration of halofuginone 
could be accurately distinguished from blank samples with 95% confidence. To do this, 20 
blank replicas (1% (w/v) BSA in PBST), 20 replicas of 80 pg/mL and 20 replicas of 100 
pg/mL halofuginone, were incubated with approximately 10 µg/mL anti-HFG scFv. The 
mixture was added to a HFG-Transferrin coated plate, whereby free and immobilised HFG 
compete for binding to the scFv.  Binding of anti-HFG scFv was detected using a rat anti-
HA-HRP-labelled antibody. The plate was incubated for 1 hour at 37ºC, washed as before 
and TMB substrate was added (100 μL/well). Following incubation for 30 minutes at 37ºC, 
the reaction was stopped by the addition of 10% (v/v) HCl and the absorbance read at 450 
nm. The precision assay was used to determine the concentration of halofuginone that can 
be detected with 95% confidence. This requires the antibody to be able to identify at least 
19 out of the 20 positive samples when assayed with 20 positive and 20 negative samples. 
 49 
It is the lowest concentration of analyte where a response can be reliably distinguished 
from the background.  
 
2.10 Light chain shuffling and scFv affinity maturation 
In order to find the best combination of VH-VL pairings and to improve antibody affinity 
maturation, light chain shuffling was employed. The heavy chain region from the panned 
library (after pan 5), was amplified from the phage pool (output-Pan 5) by PCR, using the 
same primers listed in Section 2.6.4 and the conditions outlined in Section 2.6.7. This PCR 
amplified the whole heavy chain pool from the enriched HFG-panned library. The light 
chain from the un-panned library pool (PEG-precipitated phage after initial library 
transformation) was also amplified, as previously described. The SOE-PCR of these new 
gene constructs was performed under the conditions outlined in Section 2.6.7.  The SOE-
product was produced on a large-scale and purified, as described in Section 2.6.6.1. This 
new light-heavy chain gene assembly was ligated into the pComb3XSS vector, and 
transformed into XL1-Blue electrocompetent cells (Sections 2.6.9 and 2.6.9.1). The library 
was then subjected to biopanning again using a HFG-BTG conjugate (conditions are 
outlined in Table 2.1), starting from concentrations of 25 μg/mL down to concentrations as 
low as 2.5 μg/mL. The starting conjugate concentration was lower than the preceding 
biopanning selection because the shuffled library was previously enriched with HFG-
specific scFv.  
 
Table 2.1 Biopanning conditions for the light chain-shuffled halofuginone-specific scFv 
library using varying concentrations of halofuginone-BTG coated on immunotubes. The 
stringency of each consecutive round of panning increased by adjusting the number of 
washes and decreasing the coated antigen concentration. 
Biopanning round Immobilised antigen 
concentration (μg/mL) 
Washing frequency 
1 25 3 X PBS, 3 X PBST 
2 12.5 5 X PBS, 5 X PBST 
3 5 7 X PBS, 7 X PBST 
4 2.5 10 X PBS, 10 X PBST 
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2.10.1 Sequencing of anti-halofuginone scFv 
The avian anti-halofuginone scFv were sent to Eurofins MWG for sequencing. The clones 
were sent as plasmid preparations in 1.5 mL centrifugation tubes supplemented with 
carbenicillin (100 µg/mL). The heavy and light chain complementarity determining regions 
(CDRs) of the antibody were identified using the Kabat rules for antibody CDR regions. 
The programs used for the amino acid sequence determination and alignment of the clones 
were located in the Expasy website. 
Expasy translate tool: http://www.expasy.ch/tools/dna.html 
MultiAlin: http://multalin.toulouse.inra.fr/multalin/ 
 
2.11 Surface Plasmon Resonance characterization studies 
2.11.1 Biacore maintenance  
The Biacore instrument was cleaned using a ‘super desorb’ program at 25ºC. This method 
involves thoroughly cleaning the unit prior to starting an assay. It is imperative that the 
instrument is properly sanitized to remove any protein residuals, thus ensuring high-quality 
data and complete confidence in generated results. A maintenance chip was docked and 
primed 5 times with desorb solution 1 (0.5% (v/v) (SDS)), once with water, 5 times with 
desorb solution 2 (50 mM glycine, pH 9.5), and, finally, 5 times with water.  
 
2.11.2 Development of SPR-based immunoassay using a BIAcore 3000TM instrument 
Biacore binding assays were performed using a Biacore 3000™ (GE Healthcare) 
instrument using a Series ‘S’ CM5 sensor chip (GE Healthcare) immobilised with HFG-
BTG conjugate. The chip matrix is carboxymethylated dextran covalently attached to a 
gold surface. The gold on the Biacore sensor chip is covered with a covalently bonded 
monolayer of alkanethiol molecules. This serves to protect the biological samples from 
contact with the gold and at the same time provides a means of attachment of a surface 
matrix (Biacore, Sensor surface handbook, 2005). Data analysis was performed using 
BiaEvaluation™ software. The running buffer for all Biacore experiments was PBST buffer, 
pH 7.4, and 0.05% (v/v) Tween 20.  The running buffer was filtered (pore size of 0.2 μm) 
and degassed using a Millipore Filtration Apparatus (Millipore sintered Glass Filtration unit) 
immediately before use. 
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2.11.3 Preconcentration studies 
In order to optimise the conditions needed for the immobilisation of the halofuginone 
conjugate on the sensor chip surface, an initial ‘preconcentration’ step is performed. Pre-
concentration occurs from electrostatic binding of protonated amine groups on the biological 
component, to the negatively-charged carboxyl groups on the chip surface. Preconcentration 
of a desired molecule on the sensor surface can be facilitated by adjusting the pH below the 
isoelectric point (pI) of the molecule. Therefore, halofuginone conjugate solutions were 
prepared in 10 mM sodium acetate at a range of different pHs and these solutions passed over 
an underivatised chip surface, with the degree of electrostatic binding monitored. HFG-
transferrin conjugate was diluted in 10 mM sodium acetate that had been adjusted to pH 
values of 4.0, 4.2, 4.4, 4.6, and 4.8 using 10% (v/v) acetic acid. The conjugate was diluted 
to a working concentration of 10 µg/mL, for each respective pH value, and sequentially 
passed over an un-activated carboxymethylated CM5 sensor chip. The pH at which highest 
preconcentration of protein on to the underivatised surface was observed, was chosen as the 
pH for immobilisation. 
 
2.11.4 Immobilisation studies 
The carboxymethylated dextran matrix was activated by mixing equal volumes of 100 mM 
NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N-(dimethyl-aminopropyl) 
carbodiimide hydrochloride), and injecting the mixture over the sensor chip surface for 7 
minutes at a flowrate of 5 μL/minute. The HFG-Transferrin to be immobilised was diluted in 
10 mM sodium acetate at the optimised pH (determined by the preconcentration studies), and 
at a typical concentration of 50-100 μg/mL. This solution was then injected over the 
derivatised chip surface for 30-45 minutes at 5 µL/minute. Unreacted NHS groups were 
capped, and non-covalently bound protein removed by injection of 1 M ethanolamine 
hydrochloride, pH 8.5, for 7 minutes. 
 
2.11.5 Regeneration studies  
To assess the stability of immobilised interactant (in this case the HFG-Transferrin 
conjugate) surfaces, a known concentration of antibody was passed over the chip surface, 
and the surface regenerated by passing over various concentrations of NaOH and HCl 
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ranging from 1-30 mM. This cycle of regeneration was usually completed for several 
cycles, and the binding signal measured to assess the stability and suitability of the 
immobilised surface for the development of a sensitive and reproducible assay. 
 
2.11.6 Optimisation of assay parameters for SPR detection of HFG residues in a 
competitive format 
The optimal flowrate and contact time of the anti-HFG scFv for use on the immobilised 
HFG-transferrin chip, was investigated. Contact times of 3, 6, 9 and 12 minutes, each at 
flowrates of 10, 20 and 30 μL/minute, were evaluated. This was to determine which 
parameters gave the highest response change with respect to analyte concentration. To 
assess the stability of the immobilised conjugate, regeneration scouting was performed. A 
known concentration of antibody was passed over the chip surface, and the surface 
regenerated using a panel of different regeneration solutions. The solutions used included 
10 mM glycine at pH 2, 2.5 and 3.0, 1 M NaCl, 10 mM HCl, pH 1.3, 50 mM HCl, pH 1.3, 
20 mM, NaOH, pH 12, 20 mM NaOH/ 1% (v/v) acetonitrile, pH 12, and 200 mM NaOH, 
pH 12. The regeneration studies proved that two pulses of NaOH/1% (v/v) acetonitrile for 1 
minute was the most effective solution for optimal regeneration. This cycle of regeneration 
was completed in excess of 50 times, and the binding signal was measured to assess the 
stability and suitability of the immobilised surface for the development of a sensitive and 
reproducible assay. 
 
2.11.7 Generation of a calibration curve for HFG 
Assay reproducibility may be affected by environmental conditions and lead to significant 
variation in the analytical results. To determine the intra-day (within the same assay) and 
inter-day (between assays) variation of results, a calibration curve was generated for HFG. 
The co-efficients of variation (CV) values between the inter and intra-day batches of 
analyses were calculated from the calibration curve. For the inter/intra-day studies; egg 
samples were spiked with HFG at concentrations of 0, 156, 312, 625, 1,250, 2,500, and 
5000 ng/mL. The spiked-HFG residues were subsequently recovered from the matrix and 
resuspended in PBS/ 5% (v/v) MeOH. They were mixed with an equal volume of the HFG-
specific scFv at a final concentration of 10.6 μg/mL prior to injection over the sensor–chip 
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surface. Report points were recorded before and after sample injection. The surface was 
regenerated after each sample was passed across the chip surface to remove any bound 
scFv. The inter-assay studies were all performed on separate days; whereas, the intra-day 
studies were all performed in unique assays on the same day. 
 
2.12 Extraction procedure for HFG residues from eggs 
Three extraction methods previously employed for the isolation of halofuginone residues 
from eggs were performed and directly compared for percentage recoveries. The first 
method tested used an acetonitrile and hexane extraction, as described by Huet et al. 
(2005). The second method, optimised in the Teagasc Laboratories, Ashtown, utilised an 
acetonitrile separation, whereby the residues are extracted from the acetonitrile layer by 
partitioning into cyclohexane. A solid phase extraction process using C18 silica, facilitated 
the extraction of the residues. The third extraction method, which was subsequently 
employed for all extractions, was previously described by Thompson et al. (2009). This 
method used an acetonitrile separation. Organic egg was homogenised using a Ultra-Turrax 
T18 homogeniser at an output of 50 % for 2 minutes, and 5 g was weighed into separate 
tubes for each corresponding negative and spiked sample. The ‘HFG-positive’ standards 
were spiked with varying concentrations of HFG ranging from 100 ng/mL to 1 ng/mL. All 
samples were allowed to stand for 10 minutes at room temperature. Acetonitrile (10 mL) 
was added to each tube, vortexed vigorously for 10 seconds and then mixed on a roller, at 
room temperature, for 30 minutes. All tubes were centrifuged in a Beckmann 5810r 
centrifuge at 1500 g for 10 minutes at 4ºC. The pellets were discarded and the supernatants 
were evaporated to dryness using a SpeedVac at 50ºC. The resulting extracts were 
reconstituted in PBS/5% (v/v) methanol and then directly compared to HFG standards 
spiked in PBS/5% (v/v) methanol. The SPR format used to assess the efficiency of the 
extraction was a competitive assay format. Purified anti-HFG scFv, added to all samples at 
a fixed dilution, was displaced by free HFG in the samples.  
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2.13 Generation of a murine-derived diclazuril-specific scFv library 
2.13.1. Production of carboxydiclazuril-BTG /carboxydiclazuril-HSA conjugates 
Note: Conjugations were performed with the assistance of Dr. Om Prakash Edupuganti, 
Applied Biochemistry Group, Dublin City University, Ireland. 
 
2.13.1.1 Synthesis of DIC-NHS ester 
DIC-COOH (5 mg) was dissolved in 300 µl pyridine. To this, 1.9 mg/mL of NHS and 3.5 
mg/mL of DCC were added. This was left to react by stirring at room temperature for 4 
hours.  The solvent was concentrated by evaporating the samples in the SpeedVac (Fisher 
Scientific) for 1 hour at 50ºC. This was resuspended in 20% (v/v) methanol/ 30% (v/v) 
DCM. The mixture was subsequently purified by a silica gel column with 20% (v/v) 
methanol in DCM. See Figure 2.0 below for a detailed schematic of the conjugation 
procedure. 
 
Figure 2.0 Schematic of the conjugation procedure for the production of 
carboxydiclazuril-BTG and carboxydiclazuril-HSA proteins. 
 
 
 
 
 
DIC-COOH 
NHS 
DCC 
BTG-NH2/ HSA-NH2 
+ 
NH-Protein 
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2.13.1.2 Purification and de-salting of conjugates by reverse phase column 
chromatography using C18 silica gel 100 
Column Equilibration-Flash chromatography 
The silica gel was placed in an empty pD10 column, which had a final bed volume of 5 mL 
after the mobile phase was added. Molecular grade water (6 mL) was added to the column 
and forced down by the addition of positive air pressure. This process was repeated twice. 
A 6 mL volume of 50% (v/v) acetonitrile was then added to the column and passed through 
by the addition of air pressure. This process was then repeated. Methanol (100%) was 
added to the column under air pressure and this step was then repeated. The column was 
then ready for the sample to be loaded. Water was added to the column once more before 
the sample was loaded. The diclazuril succinate ester to be purified was added to the 
column. No air pressure was added during this step. The diclazuril derivative was passed 
through the column 4 times under gravity flow without any additional air pressure, to allow 
maximum interaction time with the column bed for efficient separation. Elution was 
achieved by addition of acetonitrile to the column under air pressure 5 times. In total a 
volume of 30 mL was eluted from the column. The column was then washed with methanol 
and stored for re-use. The 30 mL eluted fraction was then concentrated to a volume of 500 
μL using an Amicon Vivaspin 5 kDa MW ‘cut-off’ column (GE Healthcare). 
 
2.13.1.3 Conjugation of HSA-DIC. 
To prepare the diclazuril-HSA conjugate, 8 mg of HSA was added to 4 mg of the succinic 
ester (outlined in Section 2.13.1.1) in potassium phosphate buffer at pH 8.2. The mixture 
was allowed to react by stirring overnight at room temperature. The conjugate was then 
buffer exchanged into PBS and concentrated by ultrafiltration (Amicon, Vivaspin). The 
conjugate mixture was then concentrated further by evaporation in the SpeedVac. 
 
2.13.1.4 Conjugation of BTG-DIC 
To prepare the diclazuril-BTG conjugate, 8 mg of BTG was added to 4 mg of the succinic 
ester (outlined in Section 2.13.1.1) in Potassium Phosphate buffer at pH 8.2. The mixture 
was allowed to react by stirring overnight at room temperature. The conjugate was then 
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buffer exchanged into PBS and concentrated by ultrafiltration (Amicon, Vivaspin,). The 
conjugate mixture was then concentrated further by evaporation in the SpeedVac. 
 
2.13.2 Immunisation schedule for the production of anti-diclazuril scFv 
A leghorn chicken was initially immunised sub-cutaneously with a mixture of equal parts 
of diclazuril-HSA (DIC-HSA) conjugate and Freund’s complete adjuvant. The final 
concentration of the initial immunisation was 200 μg/mL. The first boost (day 14) was then 
administered using 100 µg/mL of DIC-HSA in PBS, mixed in a 1:1 ratio with Freund’s 
incomplete adjuvant, in a final volume of 1mL. The 3 boosts that followed (days 36, 52 and 
66) all contained 100 μg/mL of DIC-HSA and were administered in the same manner as the 
first boost. After all 4 boosts, no response was observed using the DIC-HSA conjugate.  
 
2.13.2.1 Evaluation of the diclazuril-conjugates using a commercial anti-diclazuril 
polyclonal antibody (Randox) 
To assess the integrity of the ‘in-house’ prepared conjugates, the DIC-BTG/DIC-HSA 
conjugates received from Queen’s University Belfast and the conjugates produced in-
house, a direct ELISA was performed. Concentrations of 1 μg/mL of each conjugate was 
added to a Nunc MaxisorbTM plate and left overnight at 4ºC. The conjugate-containing 
solution was decanted  from the plate in the morning and the plate was blocked with 200 
μL of 3% (v/v) BSA in PBS for 1 hour at 37ºC. Dilutions of the commercial anti-diclazuril 
antibody from 100 µg/mL (Randox) were prepared in 1% (v/v) BSA/PBS. The plate was 
washed 3 times with PBST and 3 times with PBS. The antibody dilutions were added to 
each conjugate-coated plate and left incubating for 1 hour at 37ºC. Following washing as 
described previously, a 1/2,000 dilution (0.5 µg/mL) of anti-rabbit-HRP-labeled antibody 
(Sigma) was added to the plate. The plate was incubated for 1 hour at 37°C, washed as 
before, and TMB substrate was added (100 μL/well). Following incubation for 30 minutes 
at 37ºC, the reaction was stopped by the addition of 10% (v/v) HCl and the absorbance read 
at 450nm on a Tecan Safire2TM plate reader. 
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2.13.3 Immunisation of BALB/c mice with diclazuril-HSA conjugate 
BALB/c mice aged 5-8 weeks were initially immunised with a final concentration of 100 
µg/mL DIC-HSA, mixed in a 1:1 ratio with Freund’s complete adjuvant. A volume of 200 
µL was injected into the peritoneal cavity of the BALB/c mice for immunisation. 
Subsequent injections were performed with 25 µg/mL DIC-HSA mixed in a 1:1 ratio with 
Freund’s incomplete adjuvant. A tail bleed was taken from the mice 7 days after injection 
and the antibody titre against diclazuril determined. Once a high titre response was reached, 
the mice were given a final boost into the peritoneal cavity and then sacrificed 7 days later. 
 
2.13.4 Extraction and isolation of total RNA from immunised mice 
Prior to the extraction procedure, several preparatory steps are taken. Oakridge tubes are 
cleaned with Virkon® to ensure no contamination is present. They were then washed with 
‘Rnase free’ water (Sigma), sprayed with RnaseZap® (Sigma) and left overnight to ensure 
no contaminating Rnases remain. The homogenizer to be used is incubated in PreceptTM, 
washed thoroughly with ‘Rnase free’ water, autoclaved and then baked in a 60ºC oven 
overnight. Ethanol (75% (v/v) in ‘Rnase free’ water) was prepared in ‘Rnase free’ tubes 
and stored at -20ºC. A laminar flow hood was de-contaminated by cleaning with 70% (v/v) 
IMS in ‘Rnase free’ water and RnaseZap. Materials and reagents to be used during the 
extraction procedure are also decontaminated. The mice were sacrificed by cervical 
dislocation. The spleen was removed, placed in an ‘Rnase free’ tube and homogenized in 
10 mL of TriZol reagent (Sigma) using a sterile homogenizer. The tubes were centrifuged 
in an Eppendorf 5810r centrifuge at 1575 g for 10 minutes at 4ºC. The supernatant was 
removed into 50 mL Oakridge tubes containing 2 mL of chloroform. This was mixed well 
by shaking and incubated at room temperature for 15 minutes. The samples were then 
centrifuged at 17,500 g for 20 minutes at 4ºC. After this centrifugation step, three visible 
layers are produced. The upper aqueous layer is carefully removed ensuring that none of 
the organic layer of protein is transferred from the interphase. This aqueous layer was then 
added to a large Oakridge tube with 5 mL of isopropanol for precipitation. This is mixed 
and left at room temperature for 10 minutes. It is then centrifuged at 17,500 g for 20 
minutes at 4ºC. The supernatant is carefully removed and discarded ensuring that the pellet 
is not disrupted. The RNA pellet is washed by adding 10 mL of 75% (v/v) ethanol. This is 
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centrifuged again at 17,500 g for 10 minutes at 4ºC in an Eppendorf 5810r centrifuge and 
the supernatant is again discarded. The pellet is air dried in the laminar flow cabinet and 
then gently resuspended in 250 µl of molecular grade water (Sigma). The RNA is 
subsequently quantified on the Nanodrop and cDNA synthesis is performed. 
 
2.13.5 Reverse transcription of total RNA to cDNA 
This protocol is performed as outlined in Section 2.6.2 
 
2.13.6 cDNA synthesis 
This protocol is performed as outlined in Section 2.6.2 
 
2.13.7 PCR Primers for the construction of a murine scFv library (pComb3XSS 
vector). 
All primers were synthesized by MWG. 
 
Vκ5’ Sense primers 
 
MSCVK-1 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TCC AGC TGA CTC AGC C 3´  
MSCVK-2 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C 3  ´ 
MSCVK-3 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT C 3´  
MSCVK-4 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C 3  ´ 
MSCVK-5 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 3´  
MSCVK-6 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT C 3´  
MSCVK-7 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT C 3´  
MSCVK-8 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA C 3´  
MSCVK-9 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT C 3´  
MSCVK-10 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT C 3´  
MSCVK-11 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C 3´  
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MSCVK-12 
5´ GGG CCC AGG CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C 3  ´ 
MSCVK-13 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK C 3´  
MSCVK-14 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG A 3´  
MSCVK-15 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW T 3´  
MSCVK-16 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC C 3´  
MSCVK-17 
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C 3  ´ 
 
 
Vκ 3’ Reverse primers 
 
MSCJK12-BL 
5´ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC 
ACC AGA GGA TTT KAT TTC CAG YTT GGT CCC 3´  
 
MSCJK4-BL 
5´ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC 
ACC AGA GGA TTT TAT TTC CAA CTT TGT CCC 3´  
 
MSCJK5-BL 
5´ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC 
ACC AGA GGA TTT CAG CTC CAG CTT GGT CCC 3´  
 
 
Vλ 5’ Sense primer 
 
MSCVL-1 
5´ GGG CCC AGG CGG CCG AGC TCG ATG CTG TTG TGA CTC AGG AAT C 3  ´
 
V λ 3’ Reverse Primer 
MSCJL-BL 
5´ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC GCC 
ACC AGA GGA GCC TAG GAC AGT CAG TTT GG 3´ 
 
 
VH 5’ Sense primers 
MSCVH1 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG CTT CAG GAG TC 3´  
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MSCVH2 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG CTB CAG CAG TC 3´  
MSCVH3 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG CTG AAG SAS TC 3  ´ 
MSCVH4 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR CTG CAA CAR TC 3´  
MSCVH5 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG CTB CAG CAR TC 3´  
MSCVH6 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR CTG CAG CAG TC 3´  
MSCVH7 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC GTG AAG CAG TC 3´  
MSCVH8 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS STG GTG GAA TC 3  ´ 
MSCVH9 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG YTG GTG GAG TC 3´  
MSCVH10 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG SKG GTG GAG TC 3´  
MSCVH11 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM CTG GTG GAG TC 3´  
MSCVH12 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG CTG ATG GAR TC 3´  
MSCVH13 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR CTT GTT GAG TC 3  ´ 
MSCVH14 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT CTC GAG TC 3  ´ 
MSCVH15 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR STT GAG GAG TC 3´  
MSCVH16 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT CTR AAA GWG TST G 
3´  
MSCVH17 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA CTV CAG CAR CC 3´  
MSCVH18 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAC TTG GAA GTG TC 3´  
MSCVH19 
5´ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG GTC ATC GAG TC 3´  
 
 
VH 3’Reverse primers 
MSCG1ab-B 
5´ CCT GGC CGG CCT GGC CAC TAG TGA CAG ATG GGG STG TYG TTT TGG C 
3´  
MSCG3-B 
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5´ CCT GGC CGG CCT GGC CAC TAG TGA CAG ATG GGG CTG TTG TTG T 3´  
MSCM-B 
5´ CCT GGC CGG CCT GGC CAC TAG TGA CAT TTG GGA AGG ACT GAC TCT C 
3´  
Overlap extension primers 
RSC-F (sense) 
5´ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 3  ´
 
RSC-B (reverse) 
5´ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG 3´ 
 
 
2.13.8 Amplification of antibody variable domain genes using pComb series primers 
The standard PCR reaction components and conditions were as follows; 
 Component     Concentration in 50 μL reaction 
cDNA    0.5 μg 
dNTP’s    0.2 mM 
Forward primer    60 pm 
Reverse primer    60 pm 
MgCl2    4 mM 
5X buffer    1 X 
Go Taq Polymerase (5units/μL)  1 unit 
This mixture is made up to 50 μL with MgH2O 
The polymerase used was Go Taq polymerase (Polymerase) and the corresponding buffer.  
The PCR amplification of the variable regions from murine cDNA was performed in a 
Biometra TGradient PCR machine under the following conditions: 
 
 Step 1      94ºC for 5 minutes 
 Step 2 
 30 cycles of;       94ºC for 15 seconds 
    56 ºC for 30 seconds 
    72 ºC for 90 seconds 
 Step 3      72 ºC for 10 minutes 
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After successfully optimizing the amplification of the variable regions, five microlitres of 
each reaction was analysed on a 2 % (w/v) agarose gel, as described in Section 2.5.1. The 
reaction was scaled up (10X) and the PCR products were pooled and ethanol-precipitated. 
The PCR products were purified from a 2 % (w/v) agarose gel, and DNA was quantified by 
measuring the absorbance at 260 nm on the Nanodrop.  
 
2.13.8.1 Ethanol-precipitation and purification of PCR fragments 
PCR fragments were ethanol-precipitated and purified via a gel clean-up kit as described in 
Sections 2.6.6 and 2.6.6.1. 
 
2.13.9 Splice by overlap extension PCR 
In the SOE-PCR, the appropriate purified variable heavy and variable light chain (VH and 
VL) gene fragments are mixed in equal ratios to generate the overlap product. The VH and 
VL purified fragments were joined using an SOE-PCR via a glycine-serine linker (G4S)4, 
producing a fragment of approximately 800 bp. 
 
SOE PCR components for amplification of joined antibody light and heavy chain 
genes; 
 Component     Concentration in 50μL reaction 
5 X buffer     1 X   
MgCl2      4 mM   
dNTP      0.2 mM    
VH      10 ng 
VL      10 ng 
Forward primer    60 pm 
Reverse primer    60 pm 
Phusion high fidelity polymerase 
(5 units/μL)      1 unit  
This mixture is made up to 50 μL with MgH2O 
 
The PCR amplification of the SOE product was performed in a Biometra TGradient PCR 
machine under the following conditions: 
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 Step 1      94ºC for 5 minutes 
 Step 2 
 20 cycles of;       94ºC for 15 seconds 
       56 ºC for 15 seconds 
       72 ºC for 2 minutes 
 Step 3      72 ºC for 10 minutes 
 
2.13.10 Restriction-digest of the purified overlap PCR product and vector DNA 
 
Restriction digest of the purified overlap PCR product: 
Component Concentration per reaction   (1X) 
Purified overlap PCR product     10 μg 
SfiI (36U per μg of DNA)     360 U 
NEB Buffer 2 (10X)       20 μL 
BSA (100X)          2 μL  
Molecular grade water was added to a final volume of 200 μL. 
 
Restriction-digest of the purified vector DNA: 
Component Concentration per reaction    (1X) 
Vector DNA (pComb3XSS)      20 μg 
SfiI (6U per μg of DNA)      120 U 
NEB Buffer 2 (10X)       20 μL 
BSA (100X)         2 μL  
Molecular grade water was added to a total volume of 200 μL. 
 
The digests were incubated for 5 hours at 50ºC. PCR products were pooled and ethanol-
precipitated. The digested PCR fragment, and the pComb3XSS vector and stuffer 
fragments were purified on a 1% (w/v) agarose gel and 0.6% (w/v) agarose gel, 
respectively, by electroelution. DNA was quantified by measuring the absorbance at 260 
nm on the Nanodrop.  
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2.13.11 Ligation of the digested overlap PCR product with vector DNA 
The gel-purified SfiI restricted scFv insert fragment was cloned into the digested 
pComb3XSS facilitated by the use of T4 DNA ligase.  
Component Concentration per reaction    (20X) 
pComb3XSS (digested and purified)     1.4 μg 
Overlap PCR product (digested and purified)             700 ng 
T4 DNA ligase buffer       40 μL  
T4 DNA Ligase        10 μL 
Molecular grade water was added to a total volume of 400 μL. 
 
Ligations were incubated at 16ºC overnight. The ligation was then ethanol-precipitated, as 
described in Section 2.6.6. The DNA pellet was resuspended in 20 μL of molecular grade 
water and transformed into E. coli XL1-Blue electrocompetent cells (Stratagene) by 
electroporation.      
 
2.13.12 Transformation of E.coli XL1-Blue electrocompetent cells with pComb3XSS 
vector containing light and heavy chain genes and measurement of transformation 
efficiencies 
The transformation of the ligated pComb3XSS-scFv plasmid and calculation of 
transformation efficiencies was performed via electroporation into XL1-Blue E.coli cells as 
previously described in Section 2.6.9.1. Following incubation, cells were plated out on SB 
agar plates and incubated at 37°C overnight. Transformants were also titred, using SB 
media as a diluent, and each dilution was plated on SB plates. Plates were scraped using 
SB, from which glycerol library stocks were prepared. Library stocks were flash frozen in 
liquid nitrogen and stored at -80°C. 
 
2.13.13 Rescue and subsequent precipitation of scFv-displaying phage 
The transformed library stock was inoculated into 400 mL of SB media with 100 μg/mL 
carbenicillin. The culture was grown at 37ºC/250rpm until an O.D 600 of 0.4 - 0.5 was 
reached. Helper phage M13K07 (200 μL) was added to the culture, which was then 
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incubated at 37ºC stationary for 30 minutes. The culture was then incubated while shaking 
at 30ºC/250rpm for 1 hour. Kanamycin was added to the culture to a final concentration of 
60 μg/mL and the culture was incubated overnight shaking at 30ºC/250rpm. 
An immunotube was coated with 500 μl of 100 μg/mL of diclazuril-BTG and left at 4ºC 
stationary, overnight.  An overnight culture of XL1-Blue was also prepared. This was sub-
cultured in the morning by adding 500 μL of the overnight culture to 50 mL of fresh 2xTY 
and growing until an O.D 600 of 0.4- 0.5 was reached. Agar plates were prepared with 100 
μg/mL of carbenicillin incorporated. The overnight phage culture was then removed from 
the 30ºC incubator, transferred to sterilin tubes and centrifuged for 10 minutes at 3,220 g in 
an Eppendorf 5810r centrifuge. The phage supernatant was transferred to sterile sorval 
tubes and centrifuged at 15,300 g for 20 minutes. The supernatant was then decanted into 
sterile sorval tubes again and Peg and NaCl were added at concentrations of 4% and 3% 
(w/v) respectively. The sorval tubes were incubated on ice for 1 hour at 4ºC to allow for 
phage precipitation. Following precipitation, the sorvals were centrifuged at 15,300 g for 
20 minutes at 4ºC. The phage supernatant was discarded and residual supernatant was 
removed by inverting the sorval tubes onto dry tissue paper. The phage pellet was then 
resuspended in 500 μL of PBS and 500 μL of 3% BSA. This solution was the phage input. 
Ten µL of this was taken for library titre estimation. 
 
2.13.14 Enrichment of phage library via biopanning against immobilised antigens 
The antigen solution was poured off and 3% BSA solution was added, filling the tube to the 
top. This was left incubating at RT for 2 hours. The input phage was pre-blocked by adding 
it to the immunotubes that were coated with 1% BSA and incubating for 1 hour at RT. The 
BSA solution was then poured off and the immunotubes were washed once gently with 
PBS. The pre-blocked phage was then added to the immunotubes and left gently shaking at 
RT for 2 hours. The phage was discarded and the tube was washed several times with 
PBST/PBS. This varied depending on the panning stage (See Table 2.2) for biopanning 
conditions. The tube was treated with trypsin to elute any bound phage. This was 
performed by adding 500 μL of trypsin-PBS solution (50μL of trypsin 10mg/mL in 450μL 
PBS) to the tube; the trypsin was made in Tris-HCl pH 7.4 with 1mM CaCl2. The eluted 
phage was labelled the ‘output’. 
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Table 2.2 Biopanning conditions for diclazuril-specific murine scFv library using varying 
concentrations of diclazuril-BTG coated on immunotubes. The stringency of each 
consecutive round of panning increased by altering the number of washes with PBS and 
PBST and decreasing the coated antigen concentration. 
Biopanning round Concentration of coated 
antigen (μg/mL) 
Washing frequency 
1 100 3 X PBS, 3 X PBST 
2 50 5 X PBS, 5 X PBST 
3 25 7 X PBS, 7 X PBST 
4 10 10 X PBS ,10 X PBST 
 
2.13.15 Re-infection of E. coli XL1-Blue cells with eluted phage/Library titre 
estimation 
Subsequent rounds of panning were performed by re-infecting XL1-Blue cells with the 
eluted phage. This was performed as described in Section 2.7.2 and the library titre 
estimation was carried out as described in Section 2.7.3. 
 
2.13.16 Polyclonal phage pool ELISA and colony pick PCR 
Two Nunc MaxisorbTM plates were coated with 100 μL per well of 1 μg/mL DIC-HSA 
conjugate and with 100 μL per well of 1 μg/mL DIC-BTG conjugate, respectively, and 
incubated overnight at 4ºC. The excess conjugate was discarded and the plate was then 
blocked with 200 μL PBS containing 3% (w/v) BSA for 1 hour at 37°C. Phage, from each 
round of panning diluted 3 fold in PBS containing 3% (w/v) BSA, was added to the plate in 
triplicate at 100 μL per well. Negative (M13 helper phage) controls were also added to the 
plate in triplicate. The plate was incubated for 2 hours at 37°C and washed 3 times with 
PBST and 3 times with PBS. Bound antibodies were detected following the addition of 100 
μL of an anti-M13 HRP-labelled secondary antibody in PBS containing 1% (w/v) BSA. 
The plate was incubated for 1 hour at 37°C, washed as before, and TMB substrate (Sigma) 
was added (100 μL/well). Following incubation for 30 minutes at 37ºC, the reaction was 
stopped by the addition of 10% (v/v) HCl and the absorbance read at 450nm on a Tecan 
Safire2TM plate reader. 
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Twenty single colonies were randomly picked from the 4th round of panning and 
incorporated into a ‘colony-pick’ PCR to ensure the vector was harboring the scFv 
fragment. A sterile tip was used to pick a single colony into the following mixture, which 
was then placed in a Biometra TGRADIENT PCR machine. The amplified scFv fragments 
were then analysed via gel electrophoresis on a 1% (w/v) agarose gel. 
 
 Component     Concentration in 50 μL reaction 
5X buffer     1X   
MgCl2      4 mM   
dNTP      0.2 mM    
Forward primer    60 pm 
Reverse primer    60 pm 
Single Colony     1 colony 
 Phusion high fidelity polymerase  
 (5 units/μL)     1 unit 
 
The SOE-PCR was performed in the Biometra TGRADIENT PCR machine under the 
following conditions: 
 Step 1      94ºC for 5 minutes 
 Step 2 
 20 cycles of;       94ºC for 15 seconds 
       56ºC for 15 seconds 
       72ºC for 2 minutes 
 Step 3      72ºC for 10minutes 
 
2.13.17 Monoclonal soluble scFv ELISA 
Individual colonies (192 in total) were picked and grown overnight at 200 rpm and 37°C in 
single wells containing 100 μL SB media with 100 μg/mL carbenicillin (stock plates). The 
stock plates were then sub-cultured into fresh 2 x TY media (180 μL) containing 1 x 505 
(0.5% (v/v) glycerol, 0.05% (v/v) glucose final concentration), 1 mM MgSO4 and 100 
μg/mL carbenicillin. Glycerol was then added to the overnight stock plates to a final 
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concentration of 15% (v/v) and then transferred to a -80°C freezer for long-term storage. 
The sub-cultured plates were incubated at 37°C while shaking at 200 rpm, until cells 
reached an optical density at 600 nm (OD600nm) of ~0.6. Expression was then induced by 
adding IPTG to a final concentration of 1 mM and incubating at 30°C (180 rpm) overnight. 
Two Nunc MaxisorbTM plates were coated with 100 μL of 1 μg/mL DIC-BTG conjugate 
and two were coated with 100 μL of 1 μg/mL DIC-HSA and incubated overnight at 4ºC. 
The excess conjugate was discarded and the plates were blocked with 200 μL per well of 
PBS containing 3% (w/v) BSA for 1 hour at 37°C. Meanwhile, the overnight plates of 
expressed clones were removed from 30°C and subjected to a freeze-thaw protocol for the 
production of scFv-enriched lysate. The plates are placed at -80°C until frozen and then 
thawed at 37°C. This step was repeated 3 times in total. The plates were then centrifuged at 
3,220 g for 15 minutes to obtain the scFv-enriched lysate supernatant. The lysate 
supernatant (100 μL) was added to the corresponding well in each ELISA plate, mixed 
gently and incubated for 1 hour at 37ºC. The plates were washed three times with PBST 
and three times with PBS, followed by the addition of 100 μL per well of HRP-labelled 
anti-HA antibody, at a 1 in 2,000 dilution in PBST containing 1% (w/v) BSA. The plate 
was incubated for 1 hour at 37°C, washed as before and TMB substrate was added (100 
μL/well). Following incubation for 30 minutes at 37ºC, the reaction was stopped by the 
addition of 10% HCl and the absorbance read at 450nm. 
 
2.13.18 Competitive ELISA for scFv characterization 
 To determine if any clones were specific for binding to free diclazuril, a competitive 
ELISA was performed. Clones exhibiting binding towards both of the diclazuril conjugates 
were taken forward for competitive analysis. An ELISA plate was coated with 1 μg/mL of 
DIC-HSA. Single clones were grown and expressed as described in Section 2.13.17. The 
scFv-enriched lysate (50 μL) was added to one half of the plate with 50 μL of PBS (A0) 
and to the other half of the plate with 50 μL of 20 μg/mL free diclazuril (competitor). The 
free and immobilised diclazuril compete for binding to the scFv. The plates were washed 3 
times with PBST and 3 times with PBS, followed by the addition of 100 μL per well of 
HRP-labelled anti-HA antibody, at a 1 in 2,000 dilution in PBS containing 1% (w/v) BSA. 
The plate was incubated for 1 hour at 37°C, washed as before, and TMB substrate was 
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added (100 μL/well). Following incubation for 30 minutes at 37ºC, the reaction was 
stopped by the addition of 10% (v/v) HCl and the absorbance read at 450 nm. 
 
2.14 Production and characterization of polyclonal antibodies to toltrazuril 
2.14.1 Production of trifluoraminoether hapten-protein conjugates 
Diazonium groups react with active hydrogens on aromatic rings to give covalent diazo-
bonds. Generation of a diazonium-reactive group usually occurs when an aromatic amine is 
reacted with sodium nitrite under acidic conditions (Hermanson, 2005). Trifluoraminoether 
(TFAE) was conjugated to BSA and BTG by exploiting this diazo-coupling method. See 
Figure 5.0 for a schematic of the reaction mechanism for the preparation of the conjugate. 
TFAE (10 mg) was initially dissolved in 0.5 M H2SO4. 1 mL of sodium nitrite was then 
added drop wise to the TFAE over three minutes. This was allowed to react for a further 
three minutes. The diazotized derivative was then added to BSA (5mg) and BTG (5mg) 
each dissolved in borate buffer. This was reacted for 4 hours at room temperature. The 
conjugate was then concentrated by ultrafiltration (Amicon, Vivaspin,). 
 
2.14.2 Immunisation of New Zealand white rabbits and antibody titre determination 
The immunisation of ten New Zealand white rabbits was performed externally by the CER 
Groupe, Belgium. Five rabbits were immunised with the prepared TFAE-BSA conjugate 
and five rabbits were immunised with a commercially purchased toltrazuril-BSA conjugate 
(Randox, Cat. No PAS9456). An immunisation schedule was performed over a period of 9 
months, upon which time the animals were sacrificed. Serum from each of the rabbits was 
obtained from the CER Groupe, and analysed by ELISA. 
 
2.14.3 Non-competitive ELISA for estimation of rabbit serum antibody titre 
Nunc MaxisorbTM immunoplates were coated with 100 μL per well of the toltrazuril-BTG 
(Randox) and the TFAE-BTG conjugates at a concentration of 1 μg/mL and incubated 
overnight at 4ºC. Excess conjugate was discarded. The plates were then blocked with PBS 
containing 5 % (w/v) Milk Marvel for 1 hour at 37ºC. Serial dilutions of each of the rabbit 
anti-serum in PBS containing 1% (w/v) Milk Marvel were added to the wells and allowed 
to bind at 37ºC for 1 hour. The plate was washed once with PBS. This was followed by the 
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addition of a 1 in 2,000 dilution of HRP-labelled goat anti-rabbit antibody (Sigma) in PBS 
containing 1 % (w/v) Milk Marvel. The plate was incubated for 1 hour at 37°C, washed as 
before, and TMB substrate was added (100 μL/well). Following incubation for 30 minutes 
at 37ºC, the reaction was stopped by the addition of 10% (v/v) HCl and the absorbance read 
at 450nm on a Tecan Safire2TM platereader. 
 
2.14.4 Competitive ELISA for rabbit antiserum 
Nunc MaxisorbTM plates were coated with the appropriate concentration of conjugate and 
blocked as described in Section 2.14.3. Standards with decreasing concentrations of free 
analyte, were prepared in PBS from a 1 mg/mL stock solution of ponazuril. Toltrazuril is 
metabolized to toltrazuril-sulfone or ‘ponazuril’, as it is commonly referred to, which is the 
marker residue for toltrazuril. Each ponazuril standard was added to the microtitre plate 
with an equal volume (50 μL) of each of the rabbit anti-sera, prepared in PBST containing 
1 % (w/v) Milk Marvel, at the optimal dilution. Bound polyclonal antibody was detected as 
before (Section 2.14.3). 
 
2.14.5 Protein G purification of anti-toltrazuril polyclonal antibody from rabbit 
serum 
A 2 mL suspension of immobilised protein G (immobilised on Sepharose 4B, stored in 
sterile-filtered PBS containing 20% (v/v) ethanol), was equilibrated in a column with 30 
mL of sterile-filtered PBS. Five mL of serum from each of the ‘toltrazuril-specific’ serum 
batches, as determined by ELISA (Section 2.14.4), were pooled and made up to a final 
volume of 20 mL with sterile-filtered 1 x PBS (pH 7.4). All 20 mL of the diluted pAb-rich 
serum was then passed through the column, the eluant collected and passed through the 
column a second time. A total of 30 mL of wash buffer (sterile-filtered PBS) was passed 
through the column and, finally, the retained protein was eluted with 0.1 M glycine-HCl 
buffer (pH 2.5). Fractions of eluate were collected in micro-centrifuge tubes containing 150 
μL of neutralisation buffer (2 M Tris-HCl, pH 8.5). This served to rapidly neutralise the 
highly acidic environment of the elution buffer, thereby, preventing denaturation of the 
eluted IgG fraction. Each of the fractions was quantified on the Nanodrop, using the pre-
programmed ‘IgG’ option (mass extinction coefficient of 13.7 at 280 nm). The fractions 
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containing high concentrations of IgG were pooled. The purified IgG was then buffer 
exchanged into PBS and concentrated using an Amicon 5 kDa cut-off (Vivaspin). This was 
stored at -20°C until required for further use.  
 
2.15 Toltrazuril antibody characterisation 
2.15.1 Development of an enzyme-linked immunosorbent assay (ELISA) for the 
detection of toltrazuril 
2.15.1.1. Checkerboard ELISA for determination of optimal polyclonal antibody 
dilution and optimal coating concentration of protein conjugates 
A Nunc MaxisorbTM plate was coated with 100 μL of varying concentrations (1- 8 μg/mL) 
of Toltrazuril-BTG, prepared in PBS overnight at 4ºC. Plates were blocked with 200 μL of 
PBS containing 5 % (w/v) Milk Marvel for 1 hour at 37ºC. The plates were then washed 3 
times with PBST and 3 times with PBS. Serial dilutions (1:5) of the purified polyclonal 
antibody were prepared in PBST containing 1% (w/v) Milk Marvel and 100 μL of each 
dilution was added to the plates in triplicate. The plates were then incubated at 37ºC for 1 
hour and washed as previously described. This was followed by the addition of 100 μL of a 
1 in 2,000 dilution (0.5 µg/mL) of HRP-labelled goat anti-rabbit antibody (Sigma) in PBST 
containing 1% (w/v) Milk Marvel. The plates were again incubated for 1 hour at 37°C, 
washed as before, and TMB substrate was added (100 μL/well). Following incubation for 
30 minutes at 37ºC, the reaction was stopped by the addition of 10% (v/v) HCl and the 
absorbance read at 450 nm on a Tecan Safire2TM. 
 
2.15.1.2 Determination of optimal conjugate coating buffer for ELISA detection of 
toltrazuril 
A Nunc MaxisorbTM plate was coated with 100 μL of the optimal concentration of TLZ-
BTG prepared in several different buffers at 4ºC overnight. One μg/mL of TLZ-BTG was 
coated in each of the buffers; 100mM acetate buffer, pH 4.8, 100mM TBS buffer, pH 7.4, 
100mM TBS, pH 4.2, 100mM carbonate buffer, pH 10.3 and 100mM PBS, pH 7.4. Plates 
were blocked with 200 μL of PBS containing 5 % (w/v) Milk Marvel for 1 hour at 37ºC. 
The plates were then washed 3 times with PBST and 3 times with PBS. Serial dilutions 
(1:5) of the purified polyclonal antibody were prepared in PBST containing 1% (w/v) Milk 
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Marvel and 100 μL of each dilution was added to the plates. The plates were then incubated 
at 37ºC for 1 hour and washed as before. This was followed by the addition of 100 μL of a 
1 in 2,000 dilution of HRP-labelled goat anti-rabbit antibody (Sigma) in PBST containing 
1% (w/v) Milk Marvel.The plates were again incubated for 1 hour at 37°C, washed as 
before, and TMB substrate was added (100 μL/well). Following incubation for 30 minutes 
at 37ºC, the reaction was stopped by the addition of 10% (v/v) HCl and the absorbance read 
at 450nm on a Tecan Safire2TM. 
 
2.15.1.3 Inter/Intra-day variability studies for the detection of toltrazuril 
Nunc MaxisorbTM plates were coated with 2 μg/mL of TLZ-BTG conjugate and blocked, as 
described in Section 2.15.1.2. A 1 mg/mL stock of Ponazuril (toltrazuril-derivative) was 
prepared in 10% (v/v) Methanol. Standards of decreasing concentrations of analyte were 
prepared in PBS. Each standard was added to an equal volume (50 μL) of toltrazuril-
specific antibody at the optimal concentration in PBST containing 1% (w/v) Milk Marvel. 
The samples were incubated for 30 minutes at room temperature and added to the 
microtitre plate in triplicate. Bound antibody was detected following the addition of HRP-
labelled anti-rabbit antibody in PBST containing 1% (w/v) Marvel. The plate was 
incubated for 1 hour at 37°C, washed as before and SureBlue TMB substrate (Sigma) was 
added (100 μL/well). Following incubation for 30 minutes at 37ºC, the reaction was 
stopped by the addition of 10% (v/v) HCl and the absorbance read at 450nm on a Tecan 
Safire2TM. This was the intra-day study, performed in triplicate within the same assay. The 
inter-assay study was performed in the exact same manner, except it was performed on 
three separate days.  
 
2.15.1.4 Precision assay and determination of the analytical limits of the ELISA for 
toltrazuril-detection 
 A Nunc MaxisorbTM plate was coated with 2 μg/mL of TLZ-BTG conjugate and blocked, 
as described in Section 2.15.1.2. An inhibition ELISA was performed using 20 blank 
replicas (1 % (w/v) Milk Marvel in PBST) with 20 replicas of 900 pg/mL of ponazuril 
diluted in 1 % (w/v) Milk Marvel PBST. Binding of anti-toltrazuril antibodies was detected 
using a 1/2,000 dilution of goat-anti-rabbit-HRP-labelled antibody. The plate was 
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incubated for 1 hour at 37°C, washed as before and TMB substrate was added (100 
μL/well). Following incubation for 30 minutes at 37ºC, the reaction was stopped by the 
addition of 10% (v/v) HCl and the absorbance read at 450nm. The precision assay was used 
to determine the concentration of toltrazuril that can be detected with 95 % confidence, 
where at least 19 out of 20 positive samples are mixed with 20 negative samples. 
 
2.15.2 Development of a SPR-based immunoassay for the detection of toltrazuril using 
a BIAcore 3000TM instrument 
Biacore binding assays were performed using a Biacore 3000™ (GE Healthcare) 
instrument on a Series ‘S’ CM5 sensor chip (GE Healthcare) immobilised with a TLZ-BTG 
conjugate using EDC/NHS coupling. The chip matrix is carboxymethylated dextran 
covalently attached to a gold surface. Data analysis was performed using BiaEvaluation™ 
software. The running buffer for all Biacore experiments was PBST buffer, pH 7.4, and 
0.05% (v/v) Tween 20.  The running buffer was filtered (pore size of 0.2 μm) and degassed 
using a Millipore Filtration Apparatus (Millipore Sintered Glass Filtration Unit) immediately 
before use. 
 
2.15.2.1 Preconcentration studies for the immobilization of toltrazuril on a CM5 
Biacore sensorchip 
Preconcentration studies were performed as described in Section 2.11.3. TLZ-BTG solutions 
were prepared in 10 mM sodium acetate at a range of different pH values. These solutions 
were passed over an underivatised chip surface, with the degree of electrostatic binding 
monitored. TLZ-BTG conjugate was diluted in 10 mM sodium acetate that had been 
adjusted to pH values of 4.0, 4.2, 4.4, 4.6, and 4.8, using 10% (v/v) acetic acid. The 
conjugate was diluted to a working concentration of 10 µg/mL for each respective pH value 
and sequentially passed over an un-activated carboxymethylated CM5 sensor chip. The pH 
at which highest preconcentration of protein on to the underivatised surface was observed, 
was chosen as the pH for immobilisation. 
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2.15.2.2 Immobilisation studies for toltrazuril-BTG on the surface of a CM5 
sensorchip 
The carboxymethylated dextran matrix was activated by mixing equal volumes of 100 mM 
NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N-(dimethyl-aminopropyl) 
carbodiimide hydrochloride), and injecting the mixture over the sensor chip surface for 7 
minutes at a flowrate of 5 µl/minute. Toltrazuril-BTG was diluted in 10 mM sodium acetate 
at the optimised pH, and at a typical concentration of 50-100 μg/mL. This solution was then 
injected over the derivatised chip surface for 30-45 minutes at 5 µl/minute. Unreacted NHS 
groups were capped, and non-covalently bound toltrazuril-BTG was removed by injection of 
1 M ethanolamine hydrochloride, pH 8.5, for 7 minutes. 
 
2.15.2.3 Biacore inhibition immunoassay on immobilised sensor chip surface  
Standards of free ponazuril were prepared at varying concentration ranges. Each standard 
was incubated with an equal volume of toltrazuril-specific antibody and allowed to 
equilibrate for 30 minutes at RT. Each sample was then injected over the immobilised 
sensor surface in triplicate and the surface was regenerated with 20mM NaOH. A 
calibration curve was constructed by plotting the change in response (RU) for each 
standard, against the log of the concentration. A four-parameter equation was then fitted to 
the data using BIAevaluation software 4.0.1. 
 
2.15.3 Development of a lateral-flow based immunoassay for toltrazuril-detection 
using coloured carboxylated-polystyrene microspheres 
Preliminary lateral-flow studies were performed using a toltrazuril-BTG conjugate, 
toltrazuril-specific polyclonal antibodies, a HRP-labelled anti-rabbit secondary antibody 
and TMB substrate. This format was assessed for proof-of-concept of the lateral-flow 
immunoassay, prior to the development of the final lateral flow ‘multianalyte’ assay. The 
final assay was performed using coloured carboxylated microspheres. 
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2.15.3.1 Development of a competitive lateral-flow based assay for the detection of 
toltrazuril using TMB substrate 
HiFlow Plus HF135 nitrocellulose membrane (Millipore) was sprayed using a Linomat 5 
system (CAMAG) machine with 20 μL of approximately 10 μg/mL anti-toltrazuril 
polyclonal antibody across the bottom of a 3 cm wide nitrocellulose strip. This process was 
repeated for both the toltrazuril-BSA conjugate (20 μg/mL) at the test line, and a HRP-
labelled anti-rabbit antibody (1 μg/mL) at the control line. This was performed at a flow-
rate of 600 nL/sec using the Linomat 5 system (CAMAG). Several different spotting 
buffers were tested for optimal performance, these included; 2mM borate buffer pH 7.0 
(0.1% (w/v) BSA, 0.05% (v/v) Tween, 0.01% (v/v) Triton X), 50mM sodium phosphate, 
pH 7.5, (1% (w/v) trehalose) and 15mM sodium citrate, pH 7.0, (0.01% (v/v) Triton X). 
The trehalose is used in the spotting buffer to stabilise the conjugate when it is dried onto 
the conjugate pad. The membranes were incubated at 37°C for 10 minutes and the sprayed 
membrane was cut into 3 identical strips each 1 cm thick. All 3 strips were then blocked by 
incubation with 5% (w/v) Milk Marvel at room temperature for 2 hours with agitation. The 
blocking solution was discarded and the membranes were washed once with PBS.  The 
running buffer utilized in the assay was optimised by assessing the performance of the 
following running buffers; 2mM borate buffer, pH 7.0, (0.05% (v/v) Tween), 50mM 
sodium phosphate, pH 7.5, (0.05% (v/v)  Tween) and 15mM sodium citrate, pH 7.0, 
(0.05% (v/v)  Tween). Each of the strips was placed into 5 mL solutions containing varying 
concentrations of ponazuril in the optimal running buffer. Once the solution had visibly 
travelled to the top of the strip, the ponazuril solutions were discarded and the membranes 
were washed in the appropriate running buffer (x3) with 0.05% (v/v) Tween included (x3). 
Following the wash step, the membranes were incubated with a 1 μg/mL solution of HRP-
labelled anti-rabbit antibody in running buffer. The anti-rabbit antibody was allowed to 
interact with the membrane for 2 hours at room temperature with agitation, and 
subsequently the membranes were washed as previously described. Development of each 
of the membrane strips was achieved via the addition of 1 mL of liquid TMB substrate to 
each membrane strip. This reaction was stopped by multiple washes with distilled water  
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2.15.3.2 Covalent coupling of antibodies to carboxylated polystyrene microparticles 
by carbodiimide coupling 
Five hundred µL of green-coloured carboxylated microspheres were diluted in 0.1 M 
carbonate buffer, pH 10.8. This mixture was centrifuged for 5 minutes at 17,500 g in a 
microcentrifuge. The supernatant was carefully removed and discarded. The pellet was 
resuspended in 1.5 mL of 0.1 M carbonate buffer and the centrifugation/resuspension 
process was repeated another three times. The pellet was then resuspended in 750 μL of 0.1 
M MES buffer. This was centrifuged, as previously described, and the supernatant 
discarded. This process was repeated a further two times. The pellet was resuspended in 
625 μL of 0.1 M MES buffer.  An equal volume of carbodiimide (2%) was added dropwise 
to the resuspended particles. This mixture was allowed to incubate for 3-4 hours at room 
temperature. The particles were pelleted by centrifugation as before, and the pellet was 
once again resuspended in 750 μL of 0.1 M MES buffer. The centrifugation/resuspension 
process was repeated a further three times to get rid of any unreacted carbodiimide. 
Following this, the pellet was resuspended in 1.2 mL of 0.2 M borate buffer. 
Approximately 400 μg of antibody was added to the solution and allowed to mix gently 
overnight at room temperature on an end-to-end mixer. The following day the mixture was 
centrifuged for 10 minutes at 15,300 g, the pellet was then resuspended in 1.2 mL of borate 
buffer. Fifty µL of 0.25 M ethanolamine was added to the solution and allowed to mix 
gently for 30 minutes to block any unreacted carbodiimide sites on the microparticle. The 
blocked microspheres were then centrifuged at 15,300 g for 10 minutes and the pellet was 
resuspended in 1 mL of a 10 mg/mL (w/v) BSA solution in 0.2 M borate buffer. The 
resuspended microparticles were mixed gently at room temperature for 30 minutes. This 
step serves to block any remaining non-specific protein binding sites. The treated 
microparticles were centrifuged in a microcentrifuge at 15,300 g for 5 minutes, the 
supernatant discarded and the pellet resuspended in the BSA solution again. This process 
was repeated twice. Finally the microparticles were resuspended in 0.01 M phosphate 
buffer (pH 7.4), 1% (w/v) BSA, 0.1% (w/v) sodium azide and 5% (v/v) glycerol. 
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2.15.3.3 Analysis of antibody-polystyrene microsphere covalent coupling via lateral-
flow immunoassay 
To determine whether coupling of antibody to the polystyrene beads had occurred 
efficiently a lateral flow-immunoassay was performed. HiFlow Plus HF135 nitrocellulose 
membrane (Millipore) was sprayed with 20 μL of approximately 1 μg/mL secondary 
antibody specific for each of the three covalently bound antibodies. For analysis of anti-
halofuginone bound microspheres, anti-HA antibody was used, for anti-toltrazuril, anti-
rabbit polyclonal antibody was used and for anti-diclazuril rabbit anti-goat antibody was 
used. The antibodies were sprayed across the top of a 3 cm wide nitrocellulose strip at a 
flow-rate of 600 nL/sec, using the Linomat 5 system (CAMAG). Thirty µL of the antibody-
bead complex was sprayed at the bottom of the strip at the same flowrate previously 
mentioned. The strip was then dipped into running buffer to allow the antibody-
microsphere complex to migrate up the nitrocellulose and bind to the secondary antibody 
control line. 
 
2.15.3.4 Adsorption of recombinant/polyclonal antibodies onto coloured-polystyrene 
microparticles 
Adsorption of antibodies onto microspheres is primarily through hydrophobic interactions 
such as Van Der Waals’ attractions between the hydrophobic portion of the adsorbed 
ligands and the polymeric surface of the microspheres. The microspheres used in this assay 
are carboxylated, hence, adsorption is achieved via both ionic and hydrophobic 
interactions. Five hundred microlitres of the green carboxylyated microparticles were 
diluted with 1 mL of 0.1 M borate buffer, pH 8.5. The beads were pelleted by 
centrifugation in a microcentrifuge at 15,300 g. The supernatant was discarded and the 
beads were resuspended in 1 mL of 0.1 M borate buffer once again. This 
centrifugation/resuspension process was repeated a further two times. Following the final 
centrifugation the beads were resuspended in 1 mL of borate buffer, and 400 μg of the 
antibody to be coupled. This suspension was left to react overnight at room temperature. 
The following day the mixture was centrifuged at 15,300 g for 10 minutes. The pellet was 
resuspended in 1 mL of 10 mg/mL BSA in borate buffer and left to incubate for 30 minutes 
at room temperature with gentle mixing. The blocked-beads were centrifuged again, and 
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BSA was added as before. This process was repeated a further two times. Finally, the pellet 
was resuspended in 1mL of PBS, pH 7.4, containing 10 mg/mL BSA, 0.1% (w/v) sodium 
azide, and 5% (v/v) glycerol. The beads were then stored at 4 ºC. 
 
2.15.3.5 Dynamic Light Scattering (DLS) protocol 
To determine whether the carboxylated polystyrene beads were conjugated with antibody, 
size analysis through light scattering was performed. The Delsa Nano C light scatterer 
provides information regarding the size of particles in a suspension. It does this by 
measuring the cumulatant result, the intensity, volume and number distributions and the 
polydispersity index (PDI) of the suspension to be analysed. Six hundred µL of the 
antibody-conjugated carboxylated green polystyrene beads were added to a cuvette and 
placed into the DLS apparatus. Measurements were carried out in triplicate at room 
temperature at an angle of 90º. Results were analysed by the Delsa Nano UI 2.21 software, 
which in turn showed the polydispersity index, viscosity, average diameter of particles and 
refractive index for the solution. 
 
2.15.3.6 Multi-analyte detection of toltrazuril, halofuginone and diclazuril using a 
competitive lateral-flow based format.  
Antibody-coated-colored microspheres are diluted 1 in 4 in sodium citrate buffer 
supplemented with 1.4% (v/v) Triton X-100 and 0.1% (w/v) SDS to reduce microsphere 
aggregation.  HiFlow Plus HF135 nitrocellulose membrane (Millipore) was sprayed with 
the antibody-coated microspheres at a flow-rate of 600 nL/sec using the Linomat 5 system 
(CAMAG) across the width of the bottom of the strip. A control test line was then sprayed 
at the top of the strip with a species-specific antibody, analogous to the antibody-coated on 
the microspheres. Test lines of conjugates were also sprayed on the middle of the strip 
pertaining to each of the drugs to be tested. For preliminary analysis, only one of each of 
the conjugates was sprayed on separate strips, to determine the detection range of the assay 
for each antibody. The three conjugates, halofuginone-HSA, toltrazuril-BSA and diclazuril-
BTG were sprayed at concentrations of 20 μg/mL across three different areas of the strip. 
The membranes were incubated at 37°C for 10 minutes. The sprayed membrane was cut 
into 3 identical strips each 1 cm thick. All 3 strips were then blocked by incubation with 
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5% (w/v) Milk Marvel at room temperature for 2 hours with agitation. The blocking 
solution was discarded and the membranes were washed once with PBS.  The running 
buffer for the next step was optimised by assessing the performance of the following 
running buffers; 2mM borate buffer, pH 7.0, (0.05% (v/v) Tween), 50mM sodium 
phosphate, pH 7.5, (0.05% (v/v) Tween) and 15mM sodium citrate, pH 7.0, (0.05% (v/v) 
Tween). When extracted egg samples were used the buffers included 5% (v/v) methanol 
also. Each of the strips were placed into 5 mL extracted egg solutions containing 
concentrations of halofuginone, ponazuril and diclazuril at 10 μg, 1 μg, 100 ng, 10 ng, 1 ng 
and 0 ng/mL in the optimal running buffer. Once the beads had visibly travelled up the 
strip, the membranes were washed in the appropriate running buffer (x3) and with 0.05% 
(v/v) Tween included (x3). This was a one-step competition assay, whereby high 
concentrations of free drug in solution were bound to the antibody on the coloured 
polystyrene beads, inhibiting its binding to any of the test lines during transport up the 
strip. In the presence of no free drug, three coloured test lines and a control line are clearly 
visible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
Development of validated ELISA and Biacore 
detection methods for Halofuginone, using a 
light-chain shuffled scFv 
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Chapter outline 
The focus of this chapter was to generate highly-specific antibody fragments, for the 
detection of halofuginone (HFG). A chicken was subjected to a typical immunisation 
routine with a HFG-HSA conjugate. After each injection, a bleed was taken, and the 
serum titre analysed. Following three boosts, the spleen cells were harvested from the 
chicken and the RNA was subsequently extracted. This RNA was converted to cDNA 
and a scFv library was constructed. The library was biopanned against a HFG-
transferrin conjugate, to enrich and select for HFG binders. A monoclonal ELISA was 
performed to identify single clones exhibiting HFG binding. The best clone isolated 
from the library had a detection capability of 30 ng/mL as determined by ELISA. 
However, the minimum ‘Maximum Residue Limit’ (MRL) for HFG in certain 
foodstuffs can be as low as 1 ng/mL, far below the sensitivity of the selected antibody. 
The HFG phage pool was then affinity maturated by light chain shuffling to further 
improve the selected antibodies. The HFG-specific heavy chain pool of the biopanned 
library was assembled with the light chain repertoire amplified from the original pre-
panned library. This resulted in a heavy chain-biased library, from which a scFv with 
the potential to detect HFG residues as low as 80 pg/mL was isolated, a 185-fold 
improvement over the original scFv. This new chain shuffled scFv was incorporated 
into validated (according to EU regulation 2002/657-EC) ELISA and Biacore assays 
for the sensitive detection of HFG in spiked processed egg samples. 
 
3.1 Introduction 
Coccidiosis is one of the most economically important diseases of poultry (Cantecessi 
et al., 2008) as these animals are very susceptible to the disease due to the intensive 
rearing conditions employed, particularly with broilers. Halofuginone (HFG), an 
antiprotozoal agent, is a quinazolinone derivative used for the prevention of 
coccidiosis. HFG is licensed for use in broilers and turkeys and is marketed by 
Intervet, either in the hydrobromide form as Stenerol® (Intervet, Mechelen, Belgium) 
or the lactate salt form as Halocur® (Intervet, Mechelen, Belgium). Ingestion of HFG 
is recognised to have adverse effects in the cardiovascular and central nervous 
systems in rat and mouse models (Mortier et al., 2005a). For this reason, the European 
Agency for the Evaluation of Medicinal Products (EMEA) has set maximum residue 
limits for HFG in certain foodstuffs. HFG was named as the marker residue for HFG 
detection. The EU has specific legislation in place under Commission Regulation 
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(EC) No. 2430/1999 which permits HFG for use in laying hens but no residues may 
be found in eggs. In February 2009, under EU legislation, a commission decision 
regarding “unavoidable contaminating residues’’ of coccidiostats was amended 
(2009/8/EC). This introduced MRLs for HFG in certain foodstuffs that were not 
previously required. The MRLs for HFG for food of animal origin from animal 
species other than chickens for fattening, turkeys and bovines (except dairy cattle) 
were set as follows: eggs, 6 μg/kg; liver and kidney, 30 μg/kg; milk, 1 μg/kg; and 
other food, 3 μg/kg.  
To ensure that food is safe for human consumption, the EU have legislation in place 
whereby any detection test must be validated according to the methodologies outlined 
in the implementation of the Commission Decision (2002/657/EC) if intended for 
regulatory use within the EU. This ensures that all results of tests implementing 
directive 96/23/EC are interpreted in a standardised manner.  The LOD is defined as is 
the lowest analyte concentration likely to be reliably distinguished from the blank 
standard and at which detection is feasible. The LOQ is the lowest concentration of 
the standard curve that can be measured with acceptable accuracy and precision. 
Similarly, the detection capability (CCβ) is defined as the smallest concentration of 
HFG that may be identified with an error probability of ‘β’.  This β-error relates to 
incorrectly declaring truly non-compliant samples as compliant (Van Loco et al., 
2007). The decision limit (CCα) is defined as the limit above which it can be 
concluded with an error probability of ‘α’ (i.e. the number of truly compliant samples 
that may be erroneously declared as non-compliant) that a sample is non-compliant 
(Van Loco et al., 2007). It should be noted that in this chapter the CCα and CCβ were 
determined via the verification of the identification criteria on fortified solutes, and 
not by ISO 11843-2 weighted regression calculations. 
Currently, there are several detection systems available for the monitoring of HFG 
residues in foodstuffs (See Table 3.0). These are primarily based around detection 
methods such as chromatography (Mortier et al., 2003; Mortier et al., 2005a), mass 
spectrophotometry (Dubois et al., 2004) and immunoassay technology (Yakkundi et 
al., 2002). Enzyme immunoassays are advantageous in residue detection due to their 
reliability, ease-of-use, cost effectiveness and rapidity.  
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Table 3.0. Functional limit of detection values from literature of previously reported 
halofuginone detection methods.  
 
Assay Method Functional Limit of 
Detection 
Reference 
Time resolved 
flurometry 
    1  ng/mL Hagren et al., 2005 
Competitive ELISA <500 pg/mL Huet et al., 2005 
LC-MS  600 pg/mL Yamada et al., 2006 
LC-MS/MS  770 pg/mL Dubreil-Chéneau et al., 
2009 
HPLC     1  ng/mL Kinabo et al., 1989 
LC-MS-MS 1.62 ng/mL Mortier et al., 2004 
LC-MS-MS      2 ng/mL Mortier et al., 2003 
Monoclonal Ab-based 
Immunoassay/HPLC 
           38 ng/mL and 
    50 ng/mL 
Beier et al., 1998 
LC-MS-MS   600 pg/mL Dubois et al., 2004 
LC     40 ng/mL Yamamoto et al., 2001 
Mass spectrometry   35.4 ng/mL Yakkundi et al., 2002 
LC-MS      10 ng/mL Ding et al., 2005 
 
 
Critical to immunoassay development is the generation of a high affinity antibody that 
is specific for the target analyte. In this chapter the development of a recombinant-
avian antibody to HFG and its subsequent incorporation into validated ELISA and 
Biacore assays for HFG are reported. 
Avian immunoglobulin sequences consist of one variable segment at both the heavy 
and light chains. These loci can be re-arranged into functional immunoglobulin V-D-J 
or V-J sequences (Leonard et al., 2007). Individual recombination events are further 
diversified by transplanting blocks of sequences from upstream pseudogenes in both 
the VH and VL chain regions. Single primer sets for each of the heavy and light chain 
sequences, complementary to the conserved regions flanking the unique functional 
VH and VL genes can, therefore, be used to amplify the complete spectrum of 
rearranged variable fragments. This conserved recombination enables the cloning of 
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highly diverse chicken immunoglobulin repertoires with relative ease (Leonard et al., 
2007). These advantages over other animal-models made chicken a good choice for 
immune library production for HFG.  
 Repertoires of polymerase chain reaction (PCR) amplified variable heavy and 
variable light chain antibody gene fragments from the RNA of a halofuginone-
sensitised chicken were cloned into a phagemid vector to produce a library of scFv-
displaying phage particles. Phage display technology, an important tool in molecular 
biology for the isolation of proteins or peptides against specific targets, was used to 
enrich for antibodies capable of binding HFG. The phage display vector pComb3XSS 
was employed to express HFG-specific scFvs on the surface of filamentous phage 
particles. The phage library was subjected to rounds of panning against a HFG-bovine 
thyroglobulin (BTG) conjugate. Clones with good binding specificity towards HFG 
were isolated and characterised by competitive ELISA.  The clone exhibiting the 
highest displacement of free HFG did not meet the sensitivity required to be used for a 
validated HFG detection method.  Hence, an antibody with greater sensitivity towards 
HFG and the potential to detect free HFG at the MRL was required. In order to isolate 
an antibody of higher affinity, the library was diversified via chain shuffling. A new 
library was constructed by amplifying the VH region from the HFG-panned library 
pool and re-assorting this with the VL regions from the unpanned library pool. This 
heavy chain-biased library was subjected to more stringent panning than the previous 
selection to isolate an antibody with greater specifity than the original scFv.  
Validated ELISA and Biacore methods, using the chain-shuffled anti-HFG scFv, are 
described for the detection of HFG from egg in this chapter. 
Biosensors use a combination of receptor compounds (e.g. antibody, enzyme, or 
nucleic acid) and physiochemical detector components, to observe a specific 
biological event in ‘real-time’ (e.g. antibody-antigen interaction). They can detect a 
broad spectrum of analytes in complex sample matrices, have the advantage of 
automated measurement capability and have demonstrated great promise in areas such 
as clinical diagnostics, food analysis and bioprocess and environmental monitoring 
(Ivnitski et al., 1999; Fitzpatrick et al., 2000).  
One such sensor is the Biacore. The detection principle of Biacore™ sensor systems 
is based on surface plasmon resonance (SPR). When a plane-polarized light beam 
propagates through a medium of higher refractive index (e.g. glass prism) and meets 
an interface of lower refractive index (e.g., sample solution), the light is reflected 
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above a certain critical angle. Under these conditions, an evanescent wave penetrates 
into the low refractive media to a magnitude of one wavelength. The evanescent wave 
propagates in the metal layer component of the sensor surface and causes the 
plasmons to resonate, resulting in a surface plasmon wave (Dunne et al., 2005). In a 
typical hapten-based immunoassay, the ligand, usually a hapten-protein conjugate or 
directly immobilised hapten, is chemically attached to a sensor chip surface, which 
consists of a thin metal film bound to a glass surface. When the sensor is exposed to a 
sample containing the specific analyte, the binding of the analyte to the immobilised 
ligand causes a change in SPR response which is related to the concentration of 
analyte in the sample. 
 Current EU legislation regarding sampling for the official control of veterinary 
residues in feed is regulated under commission E.C No. 152/2009 (Huet et al., 2005) 
This method uses high performance liquid chromatography (HPLC). However, when 
HPLC and SPR technology were compared for the detection of toxins, it was 
observed that for high throughput screening of large amounts of samples, SPR could 
be employed to substantially reduce the number of samples requiring confirmatory 
tests, thus reducing costs to the regulatory authorities (Thompson et al., 2009). Hence, 
a method was developed for the extraction and subsequent rapid screening of samples 
for HFG using a Biacore 3000TM instrument. A schematic representation of the SPR 
assay developed for HFG using a recombinant anti-HFG scFv is illustrated in Figure 
3.0. SPR technology allows the interactions of biomolecules to be studied in ‘real-
time’ in an automated setting. SPR is an attractive detection method in food 
monitoring for regulated substances, since it is possible to easily regenerate, re-use 
and store sensor chips for long periods of time. The method developed was directly 
compared to the validated ELISA method for HFG detection which is also described 
in this chapter.  
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Figure 3.0. Schematic representation of an SPR inhibition assay for the detection of 
HFG residues. The HFG-transferrin conjugate is immobilised on the surface of a 
CM5 sensor chip. HFG present in the samples to be tested competes with immobilised 
HFG for binding to the anti-HFG scFv. The binding of HFG to the immobilised scFv 
causes a change in SPR response which is inversely related to the concentration of 
HFG in the sample. 
 
3.2 Results 
3.2.1  Immunisation of Leghorn variety chicken with halofuginone 
A Leghorn chicken was immunised with a mixture of equal parts of HFG-HSA 
conjugate and Freund’s complete adjuvant. The drug-conjugate was at a concentration 
of 200 μg/mL. A primary boost was performed by administration with 100 μg/mL of 
drug conjugate diluted with Freund’s incomplete adjuvant. Subsequent boosts were 
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performed 7-10 days apart, with seven boosts in total being administered. After four 
boosts, a primary serum titre was determined. 
 
3.2.1.1 Avian serum antibody titre determination  
An ELISA was performed on a HFG-BTG coated immunosorbent 96-well plate using 
varying dilutions of serum. A very high immune response was observed for HFG, 
following six boosts (Figure 3.1). The specific antibody titre obtained was 
1/1,000,000 when screened against HFG-BTG. The chicken was sacrificed to harvest 
the B cells from the spleen for recombinant antibody library generation.  
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Figure 3.1 Titration of avian serum antibodies, following HFG immunisations. Serum 
was harvested intravenously from the chicken immunised with the HFG-HSA 
conjugate and the antibody serum titre determined by ELISA.  
Avian antibody serum 
response to HFG conjugate 
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3.2.2 Isolation of RNA from avian B cells (spleen) and first-strand DNA synthesis 
The spleens were removed from the immunised mice and carefully homogenised in 
TriZol reagent. The total RNA was extracted from the tissue sample, quantified using 
a Nanodrop ND-1000 and first-strand cDNA synthesised by reverse transcription. The 
cDNA template was used in the amplification of the mouse variable heavy and light 
chain genes. 
 
3.2.3 PCR optimisation for murine variable heavy and variable light chain 
generation 
A standard PCR protocol, outlined in Barbas et al. (2001), was employed to amplify 
the VH and VL chain genes (Figure 3.2) from the reverse transcribed cDNA. The VH 
region amplified successfully with no subsequent optimisation required. However, the 
VL region did not amplify.  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Amplification of variable regions from synthesised cDNA derived from a 
HFG-immunised chicken. Amplification was performed using Go Taq polymerase and 
standard PCR conditions optimised by Barbas et al. (2004). Lane 1= 1kb ladder; 
Lane 2= VH amplification; Lane 3= VL amplification; Lane 4= Control PCR without  
polymerase; Lane 5= Control PCR without template/primers and Lane 6= 1kb 
ladder. 
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To optimise the amplification of the VL gene, the PCR was repeated for both the VH 
and VL genes. However, the concentration of MgCl2 was increased to 6mM for the VL 
amplification. Figure 3.3 shows successfully amplified VH and VL chains. This 
suggests that a pipetting error may have occurred in the previous PCR as no product 
was observed. The gel-purified VH and VL fragments were linked by splice by overlap 
extension PCR (SOE-PCR). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Variable light chain amplification from the synthesised cDNA of a HFG-
sensitised chicken. The amplification was performed using a magnesium chloride 
concentration of 6mM and standard PCR conditions. Lane 1= 1kb ladder; Lane 2= 
VH amplification as before; Lane 3= VL amplification using 6mM MgCl2 and Lane 4= 
1kb ladder. 
 
3.2.4 Avian SOE-PCR of variable heavy and light chains 
The gel-purified avian variable heavy and light chain genes were used for the 
generation of the full-length scFv by PCR amplification. The initial PCR was 
performed under standard conditions, as outlined in Section 2.6.7. Several non-
specific products were amplified in addition to the 800bp desired product (Figure 
3.4).  
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Figure 3.4 Splice by Overlap Extension-PCR of the amplified VH and VL chain genes 
from the synthesised cDNA of HFG-sensitised mice. This primary amplification check 
used standard conditions for avian-derived variable domain overlap amplification, 
consisting of a 560C annealing temperature and Phusion high fidelity polymerase. 
Non-specific bands are observed alongside the 800bp product. Lane 1= 1kb Ladder; 
Lane 2 and 3= SOE amplification. 
 
The annealing temperature of a PCR influences the specificity of primer binding.  
Non-specific binding was occurring in the SOE-reaction. To circumvent this, a 
touchdown PCR was performed to eliminate these non-specific products. In the 
touchdown PCR, the annealing temperature of the reaction was incrementally 
decreased from 60oC down to 56oC over 25 cycles. This touchdown PCR increased 
the specificity of the reaction, resulting in only the desired 800bp product being 
amplified (Figure 3.5). 
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Figure 3.5: SOE-PCR using a touchdown PCR to optimise the product yield. The 
touchdown PCR was performed with the annealing temperature decreasing from 60 
oC to 56 oC incrementally with each subsequent cycle. Lane 1= 1kb Ladder; Lane 2 
and 3= SOE amplification; Lane 4= Blank well and Lane 5 and 6= gel-purified VH 
and VL chain genes (it should be noted that the large bands observed in lanes 5 and 6 
are due to overloading of the DNA). 
 
3.3 Halofuginone-library construction and subsequent enrichment via 
biopanning. 
After large-scale amplification of the 800bp desired PCR fragment, it was gel 
purified, precipitated in ethanol, quantified and digested using SfiI restriction enzyme. 
The scFv fragment was ligated into a digested pComb3XSS vector and then 
transformed into high efficiency electrocompetent XL-1 blue cells, rescued and the 
library size calculated. The avian HFG-scFv library size was 2.5 x 107 cfu/mL. HFG-
specific antibody fragments were selected on HFG-BTG immobilised on the surface 
of an immunotube, as described in Section 2.7.1. 
 
3.3.1 Selection of halofuginone-specific phage-scFv particles by biopanning 
Five rounds of panning were performed and input and output titres for each round of 
selection determined (Table 3.1). During the selection process, the concentration of 
HFG was decreased and the number of washes was increased. Biopanning essentially 
mimics the in vivo process of selective pressure (Hoogenboom, 2005). Hence, this 
increase in biopanning stringency after each successive round of panning is important 
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to ensure positive clones are selected and it significantly reduces the levels of clones 
which have no specificity for the target antigen. Following the fourth round of 
panning, monoclonal analysis was performed as described in Section 2.9. From this 
monoclonal analysis, it was determined that 90% of the clones were HFG-specific; 
hence, a further round of panning was performed increasing the stringency of the 
process, to select for only high-affinity clones. 
 
Table 3.1 Panning conditions employed for each round of selection of the avian anti-
halofuginone scFv library. HFG-BTG was coated on the surface of immunotubes. 
Phage input and output titres over the 5 rounds of biopanning are reported with each 
round of biopanning varying in conditions and stringency. 
 
Panning 
round 
HFG coating 
concentration 
Washing steps Input titres 
Cfu/mL 
Output titres 
Cfu/mL 
1 100 μg/mL 3 X PBS, 3 X PBST 6.15 x 1011 3.4 x 106 
2 50 μg/mL 5 X PBS, 5 X PBST 3.5 x 1010 1.75 x 104 
3 25 μg/mL 7 X PBS, 7 X PBST 1.3 x 108 2.0 x 103 
4 10 μg/mL 10 X PBS ,10 X PBST 1.5 x 1010 9.0 x 105 
 5 5 μg/mL 15 X PBS ,15 X PBST 2.2 x 1010 3.4 x 106 
 
The precipitated input phage from each round of panning was incorporated into a 
polyclonal phage ELISA to test for enrichment against the HFG-BTG conjugate. 
Successful enrichment was signified by an increase in absorbance signal in the fourth 
round after incubating phage with an immobilised HFG conjugate and detecting 
bound phage, following the addition of a HRP-labelled anti-M13 secondary antibody. 
This can be observed in Figure 3.6.  
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Figure 3.6 Polyclonal phage ELISA screening for anti-HFG scFv displayed on phage, 
following five rounds of panning. Phage pools obtained after each round of panning 
were tested for binding to the HFG-BTG/HFG-Transferrin (T) conjugate by ELISA. 
The phage pools were also screened against BTG during each round, to ensure no 
non-specific binding was occurring to the conjugate carrier proteins. The scFv-
displaying phage were detected using a HRP-conjugated anti-M13 antibody and the 
absorbance was read at 450 nm using a Tecan Safire™ plate reader following a 20 
minute incubation with TMB substrate. The sharp increase in absorbance from round 
4 onwards suggested the presence of HFG-specific scFv-harbouring phage within the 
panned library.  
 
 
 
 
 
 
Conjugate coated 
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3.3.1.1 Monoclonal analysis of soluble clones from halofuginone biopanning 
The outputs from the fifth round of panning were infected into Top10F, a non-
suppressor strain of E.coli.  In this non-suppressor strain, the amber stop codon 
between the scFv and the gIII gene is not suppressed (as it is in the XL1-Blue cells), 
allowing production of soluble scFv antibodies fused to a C-terminal histidine (His6) 
and influenza hemagglutinin (HA) (YPYDVPDYAS) tag. One hundred and ninety-
two single transformants were grown, induced with IPTG for expression of scFv 
antibody fragments and the cell lysates tested by ELISA for binding to HFG-
transferrin. Any bound antibody was detected following the addition of a HRP-
conjugated anti-M13 antibody (Figures 3.7 and 3.8). Approximately 5% of the 
selected clones showed binding to HFG coated on the surface of an ELISA plate from 
the Pan 5 output. This is quite a low percentage of specific clones, probably due to the 
increased specificity of the selection process, hence, these 5% of clones were 
subjected to competitive studies for further analysis. 
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Figure 3.7 Monoclonal ELISA to select for specific anti-HFG scFvs from randomly 
selected clones in the fiftth round of biopanning. The clones were solubly expressed in 
Top10F cells. Nunc MaxiSorp ELISA plates were coated with 1μg/mL of HFG-
transferrin and  specific scFvs were detected using a HRP-labelled anti-HA antibody.  
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Figure 3.8 Monoclonal ELISA to select for anti-HFG scFvs from randomly selected 
clones in the fifth round of biopanning). The clones were solubly expressed in Top10F 
cells. Nunc MaxiSorp ELISA plates were coated with 1μg/mL of HFG-Transferrin. 
ScFv were detected using a HRP-labelled anti-HA antibody.  
 
Six individual clones displaying HFG specificity from the monoclonal ELISA plates 
were taken forward for further characterisation. A titre of the clones against 1 μg/mL 
HFG-transferrin was initially performed with lysate dilutions ranging from 1 in 4 to 1 
in 4,000. Figure 3.9 shows that only three clones, namely, B4, G6, and H4 titre out on 
the HFG-coated plate. To verify this, a single dilution of each of the clones was 
screened against all three HFG conjugates; HFG-HSA, HFG-BTG, HFG-transferrin, 
to ensure that there was no problem with the HFG-transferrin conjugate. A BTG 
control was included, to ensure non-specific binding to the conjugate proteins was not 
occurring. Figure 3.10 shows the specific binding of clones B4, H6 and H4 to HFG, 
with no cross-reactivity apparent with BTG. Very little binding is observed for clones 
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H1, H7 and B8 which confirms the results shown in Figure 3.9. This low signal may 
be due to problems with expression levels. The three positive clones were taken 
forward for further analysis. 
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Figure 3.9 Antibody Titre of HFG-specific clones, screened against HFG-transferrin. 
Dilutions of lysate from 1/4 to 1/4,000 were tested, and bound antibody was detected 
following the addition of a HRP-labelled anti-HA antibody. 
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Figure 3.10 Direct ELISA, using three different HFG conjugates, for screening of 
positive clones taken following monoclonal analysis. HFG-Transferrin (T), HFG-
BTG, HFG-HSA and BTG, all at concentrations of 1μg/mL, were coated on the wells 
of an ELISA plate. Six of the positive clones identified were screened against all three 
of the HFG-conjugates and the BTG control. 
 
3.3.1.2 Expression studies of positive clones in both Top10F and XL1Blue 
To optimise the expression of the three positive clones, plasmid preparations of each 
were transformed into the XL1-Blue E. coli strain by electroporation, as outlined in 
Section 2.6.9.1. The lysates from each of the clones in both Top10F and XL1-Blue, 
Conjugate coated on 
ELISA plate 
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were incubated on an ELISA plate coated with all three HFG conjugates and a BTG 
control. A single competitive study was performed by incubating the scFv lysates with 
5 μg/mL of free HFG and observing if displacement of antibody occurred (i.e. a 
decrease in absorbance). Figure 3.11 illustrates the direct ELISA performed with 
lysates from the three clones; B4, G6 and H4, in both Top10F and Xl1Blue cell lines. 
The graph also shows that binding of all three clones to immobilised HFG is inhibited 
in the presence of excess free HFG. This suggests that all of the clones are HFG 
specific. It is also apparent that for all of the clones in either cell type XL1-Blue or 
Top10F, the expression levels of the antibodies stayed the same, as similar results are 
observed in both cells. All the clones in Top10F were taken forward for competitive 
analysis. 
 
 
 
 
 
 
 
 
 
 
 100 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
H4 Top10F H4 XL1-
Blue
B4 Top10F B4 XL1-
Blue
G6 Top10F G6 XL1-
Blue
Clone and cell type
Ab
so
rb
an
ce
 @
 4
50
 n
m
HFG-HSA
HFG-BTG
HFG-T
BTG
Competitive with 5μg/mL
halofuginone
 
Figure 3.11 Expression analysis of HFG-specific clones B4, G6 and H4 in both 
Top10F and XL1-Blue cells. A direct ELISA was performed using three different HFG 
conjugates, all at concentrations of 1 μg/mL. A competitive ELISA was performed 
using 5 μg/mL of free HFG incubated with each of the cell lysates, on HFG-
transferrin (T)-coated wells. Bound antibody was detected following the addition of a 
HRP-labelled anti-HA antibody. 
 
The expression of the three HFG-specific clones in both Top10F and XL1-Blue was 
very similar, hence, for further competitive analysis studies, the clones were 
expressed in their soluble form in Top10F. It should be noted that it appears from 
Figure 3.11 that the G6 clone did not actually express, however, this may have been a 
problem with the specific overnight culture. This was postulated since when 
sequenced, the G6 and B4 clones were identified as the exact same clone. A 
competitive ELISA was performed, as per Section 2.9.1, whereby cell lysates were 
Conjugate coated on 
ELISA plate 
and HFG-inhibition 
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incubated with decreasing concentrations of HFG from 5,000 down to 39 ng/mL. It 
can be observed in Figure 3.12 that all of the clones exhibit HFG specificity, and so 
they were sent for sequencing with MWG as outlined in Section 2.10.1. 
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Figure 3.12 Competitive analysis of HFG-specific clones B4, G6 and H4 in Top10F 
cells. A 1/1000 dilution of HFG-specific antibodies from each of the three clones, was 
incubated with decreasing concentrations of HFG from 5,000 to 39 ng/mL. Any bound 
antibody was detected following the addition of a HRP-labelled anti-HA antibody. 
The results are shown as A/A0, where the absorbance values of the evaluated samples 
(A), are normalised by expressing them as a function of the blank standard (A0). 
 
 
 
Anti-HFG scFv 
 102 
3.3.1.3 Sequence analysis of the halofuginone-specific recombinant antibodies 
Plasmid preparations of E. coli Top10F (containing the pComb3X bearing the anti-
HFG B4, G6 and H4 genes) were sent to MWG for sequencing. The DNA sequences 
were received and subsequently translated into their amino acid sequence using 
ExPASy translation tool. The amino acid sequences were aligned and the 
complementary determining binding (CDR) regions of the scFv evaluated using 
MultiAlin software.  The CDR regions of the antibodies were highlighted according to 
the Kabat scheme (Figure 3.13).  The light and heavy chain CDRs are highlighted in 
green and purple, respectively. The heavy and light chain sequences of the scFv B4 
and G6 were found to be identical. The diversity between the B4/G6 scFv and the H4 
scFv is evident, as there is only a 48 % sequence homology of the CDRs, with the 
CDRH3 having no sequence homology whatsoever.  
 
Figure 3.13 Avian anti-HFG scFv gene sequences were translated into amino acid 
sequences using Expasy Translate tool and aligned using MultiAlin sequence 
alignment program. The highlighted sequences in green and purple show the CDRs 
(heavy and light chain) of the recombinant antibody fragments. The framework 
regions are highlighted in red and variation from the consensus of the sequences is 
shown in black. 
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3.3.1.4 Expression and immobilised metal chromatographic purification of clones 
‘B4’ and ‘H4’ 
Large-scale expression of the avian anti-HFG clones B4 and H4 was performed in 500 
mL cultures, as outlined in Section 2.9.2. The scFv B4 and G6 have the same 
sequence as shown in Figure 3.13, so only the B4 scFv was purified. The protein was 
extracted by sonication and the bacterial pellet removed by centrifugation. The protein 
lysate was passed through a 0.2 µM filter to reduce clogging of the nickel resin. It was 
then applied to the resin and any histidine-tagged expressed proteins captured by the 
nickel resin. Nickel has a high affinity for histidine residues and other proteins just 
pass through the column. Non-specifically bound proteins were removed by washing 
the resin twice. The absorbed protein was then successfully eluted using high 
concentrations of imidazole. Histidine has an imidazole side-chain. When high 
concentrations of imidazole are added to the column, in the elution buffer, they 
compete with histidine moieties (e.g. as in a His tag) for binding to the nickel-resin 
and displaces any bound His-tagged proteins. The H4 scFv was found to be very 
difficult to purify as a lot of non-specific binding was occurring, and to circumvent 
this extra wash steps were performed prior to elution (Figure 3.14 (A)). The IMAC-
purified fractions containing the scFv were pooled, centrifuged and analysed by SDS-
PAGE (Figure 3.14).  
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Figure 3.14 SDS-PAGE analyses of the fractions obtained during IMAC purification 
of anti-HFG scFvs H4 and B4. Figure ‘A’ shows the purification of the ‘H4’ scFv, 
Lane 1 = Colour Burst molecular weight markers (Fermentas); Lane 2 = Lysate 
samples diluted 10-fold in PBS; Lane 3 = ‘flow-through’; Lanes 4, 5, and 6 = 
washings from the column and, Lane 7 = Eluted purified antibody fractions pooled 
and tested undiluted. 
Figure ‘B’ shows the purification of the ‘B4’ scFv, Lane 1 = Colour Burst molecular 
weight marker (Fermentas); Lane 2 = Lysate samples diluted 10-fold in PBS; Lane 3 
= ‘flow-through’; Lane 4 =Washes 1 + 2 pooled and Lane 5 = Eluted purified 
antibody fractions pooled and tested undiluted. In both SDS images one distinct band 
is visible at the level of the 27 kDa marker, representing the purified scFv. The 
primary band in the eluate in Figure B appears slightly larger than in Figure A. This 
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may be due to some of the scFv not being fully solubly expressed and still containing 
part of the p3 protein. 
 
3.3.1.5 Competitive analysis of purified ‘B4’ and ‘H4’ anti-halofuginone scFv 
To determine which scFv had the greatest sensitivity to HFG and the lowest detection 
capability, a competitive ELISA was performed. Ten μg/mL (as determined by 
analysis on the Nanodrop) of each of the purified antibodies were incubated with 
30,000, 10,000, 3,333, 1,111, 370, 123, 41, 13, 4.5, 1.5 and 0 ng/mL of HFG (Figure 
3.15). The assays were performed in triplicate, and standard deviations determined, 
and illustrated by the error bars. The LOD for HFG for each of the scFvs was 
extrapolated from the competitive curves. The LOD for the H4 scFv was 
approximately 300 ng/mL, whereas, the LOD of the B4 scFv was approximately 100 
ng/mL. However, the scFv requires even greater sensitivity than this, to be able to 
detect HFG below the MRL, which is approximately 1 ng/mL. 
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Figure 3.15 Competitive analysis of purified anti-HFG scFvs, B4 and H4, in Top10F 
cells. Ten μg/mL of the antibodies were incubated with decreasing concentrations of 
halofuginone from 30,000 to 1.5 ng/mL. Bound antibody was detected following the 
addition of a HRP-labelled anti-HA antibody. 
 
 
3.4 Light chain shuffling from the halofuginone-biased phage pool 
To circumvent the limited detection potential of the B4 scFv, it was postulated that 
mutagenesis in the form of light chain shuffling would be the most efficient method 
for improving the sensitivity of the antibody.  This resulted in a ‘heavy chain-biased’ 
light chain-shuffled phage display library (Figure 3.16). This process ensures the 
construction of a library which contains antigen-specific heavy chains enriched during 
the panning process and introduces further diversity into the new library by 
recombining this with the un-panned arrangement of light chain encoding genes.   
Anti-HFG scFv 
Halofuginone c / ) 
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Figure 3.16 Illustration of variable chain amplification for construction of heavy 
chain-biased light chain-shuffled library. The ‘light chain-shuffled’ library was 
constructed from the enriched HFG-specific heavy chain pool of the biopanned 
library, along with the light chain repertoire amplified originally from the cDNA. This 
resulted in a heavy chain-biased library. 
 
3.4.1 Construction of the light chain-shuffled halofuginone scFv library 
In order to find the best combination of VH-VL pairings and to improve antibody 
affinity maturation, light chain shuffling was employed. The heavy chain region from 
the panned library, after pan 5, was amplified by PCR using the same primers that 
were used to construct the initial VH fragments from the cDNA. This PCR reaction 
amplified the whole heavy chain pool from the enriched HFG-panned library (Figure 
3.17). The light-chain was amplified from the original un-panned library, using the 
same conditions as previously described (Section 2.6.5). Both of these amplifications 
were successful at the first attempt.  
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Figure 3.17 PCR amplification of the halofuginone-sensitised VH gene from the fifth 
round of panning and the VL gene from the original un-panned library. Using the 
same primers employed from the initial amplification, both the variable heavy-chain 
region from the round 5 phage pool, and the variable light-chain region from the un-
panned library, were successfully amplified. The PCR conditions are outlined in 
Section 2.6.5. Lane 1= 1kb Ladder; Lane 2 =VH amplification and Lane 3= VL 
amplification. 
 
3.4.1.1 Avian SOE-PCR of variable heavy chain from the halofuginone-panned 
library with the variable light chain from the un-panned library 
The gel-purified avian variable heavy and light chain genes were used for the 
generation of the full-length chain-shuffled scFv by PCR amplification as outlined 
previously in Section 3.2.4. The SOE-product (Figure 3.18) was amplified with no 
modifications to the original PCR (Section 2.6.7). 
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Figure 3.18 Splice by overlap extension PCR of the halofuginone-sensitised heavy 
chain, and the light chain from the original constructed library. The SOE was 
performed under conditions as outlined in Section 2.6. This overlap yielded an 800bp 
heavy-chain biased scFv construct. Lane 1= 1kb Ladder; Lane 2= SOE  
amplification; Lane 3 = 100bp ladder 
 
After large-scale amplification of the 800bp required PCR fragment, it was gel-
purified, precipitated in ethanol, quantified and digested using the SfiI restriction 
enzyme. The scFv fragment was ligated into a digested pComb3XSS vector and then 
transformed into high efficiency electrocompetent XL-1 blue cells, rescued and the 
library size calculated. The avian light-chain shuffled HFG-scFv library size was 1.2 
x107 cfu/mL. HFG-specific antibody fragments were selected by incubation with 
HFG-BTG immobilised on the surface of an immunotube, as described in Section 
2.7.1. 
 
3.4.2 Biopanning of the halofuginone light chain-shuffled scFv library 
Biopanning was performed as previously described in Section 3.3.2. However, as the 
library was already biased for HFG, the stringency for selection was increased. Table 
3.1 shows the conditions used for biopanning the chain-shuffled scFv library.  
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Table 3.1 Biopanning conditions for the light chain-shuffled halofuginone-specific 
scFv library using varying concentrations of halofuginone-BTG coated on 
immunotubes. The stringency of each consecutive round of panning was increased by 
increasing the number of washes and decreasing the coated antigen concentration. 
 
Biopanning 
round 
Immobilised 
antigen 
concentration  
Washing frequency Input titres 
(Cfu/mL) 
Output titres 
(Cfu/mL) 
1 25 μg/mL 3 X PBS, 3 X PBST 5.1 x 1012 4.2 x 106 
2 12.5 μg/mL 5 X PBS, 5 X PBST 1.2 x 1011 3.7 x 106 
3 5 μg/mL 7 X PBS, 7 X PBST 3.6 x 1011 4.8 x 106 
4 2.5 μg/mL 10 X PBS, 10 X PBST 5.5 x 1011 6.0 x 107 
 
The precipitated input phage from each round of panning was incorporated into a 
polyclonal phage ELISA to test for enrichment against the HFG-BTG conjugate. 
Successful enrichment was signified by an increase in absorbance signal in the second 
round after incubating the phage with an immobilised HFG conjugate and detecting 
bound phage with a HRP-labelled anti-M13 secondary antibody. This can be observed 
in Figure 3.19. High-level enrichment was observed following each round of 
panning, alongside high input and output phage titres for each round. 
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Figure 3.19 Polyclonal phage ELISA screening for anti-HFG scFv displayed on 
phage, from the light chain shuffled library. Phage pools obtained after each round of 
panning were tested for binding to the HFG-BTG/HFG-transferrin (T) conjugate by 
ELISA. The phage pools were also screened against BTG during each round, to 
ensure no non-specific binding was occurring with the conjugate proteins. The scFv-
displaying phage were detected using 500 ng/mL of a HRP-conjugated anti-M13 
antibody and the absorbance was read at 450 nm using a Tecan Safire™ plate reader 
following a 20 minute incubation with TMB substrate. The increase in absorbance 
from round 2 onwards suggested the presence of HFG-specific scFvs.  
 
3.4.3 Monoclonal analysis of soluble clones from halofuginone biopanning 
Single clone analysis of the chain shuffled library was performed as described in 
Section 3.3.2.1. From the 192 clones screened, 60 % were positive for HFG-binding 
Conjugate coated 
on ELISA plate 
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(Figure 3.20 A & B). These 115 clones were screened in a competitive ELISA to 
determine if their scFvs could bind to free HFG in solution. 
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Figure 3.20(A) Monoclonal ELISA to select for anti-HFG scFv from the chain-
shuffled library in the fourth round of biopanning (Plate 1). The clones were solubly 
expressed in Top10F cells. Nunc MaxiSorp ELISA plates were coated with 1μg/mL of 
HFG-transferrin. ScFv were detected using a HRP-labelled rat-anti-HA antibody.  
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Figure 3.20(B) Monoclonal ELISA to select for anti-HFG scFv from the chain-
shuffled library in the fourth round of biopanning (Plate 2). The clones were solubly 
expressed in Top10F cells. Nunc MaxiSorp ELISA plates were coated with 1μg/mL of 
HFG-transferrin. ScFv were detected using a HRP-labelled rat-anti-HA antibody.  
 
3.4.4 Competitive ELISA analysis of anti-halofuginone light chain-shuffled 
clones 
The 115 positive clones were taken forward for competitive studies. This competition 
ELISA incorporated lysates from each of the clones, with a high concentration (10 
μg/mL) of HFG. The lysates were also analysed in the absence of HFG and the two 
results were compared to determine if HFG binding was inhibited by the large 
concentration of free HFG present. This competition ELISA identified numerous 
clones that appeared HFG-specific. From this, 10 clones were taken forward for 
broad-range competitive studies with decreasing concentrations of HFG ranging from 
25 μg/mL to 127 pg/mL. Firstly, the clones were titred against HFG-transferrin to 
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determine the expression level of each (Figure 3.21). All of the clones appear to 
express functional scFv which titred out against HFG. The LOD of each of these 
clones was extrapolated from the competitive ELISA calibration curve, the results of 
which can be observed in Table 3.2. E9 displayed the lowest limit of detection with 
the capability to detect less than 8 ng/mL of HFG. At least five of the anti-HFG clones 
identified were more sensitive than the B4 wild-type clone.  
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Figure 3.21 Expression analysis of each of the competitive HFG-specific clones from 
the HFG chain-shuffled library. The scFv were tested at dilutions of 1/10 to 1/2,560. 
Any bound scFv was detected by the addition of a HRP-labelled anti-HA antibody. 
 
 
 
 
Anti-HFG scFv 
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Table 3.2 Limit of detection of each of the HFG-specific clones identified following 
monoclonal analysis from the light-chain shuffled HFG scFv library. The limits of 
detection were extrapolated from the competitive calibration curve for each clone. 
 
3.4.5 Sequencing of anti-halofuginone clones from light chain-shuffled library 
Plasmid preparations of E. coli Top10F (containing the pComb3X bearing the anti-HFG 
chain-shuffled scFv E9, E7, H4 and C2) were sent to MWG for sequencing. These four 
clones exhibited the greatest sensitivity and were able to detect HFG well below the 
detection capability of the ‘B4’ clone at 100 ng/mL. The amino acid sequences were 
aligned and the CDRs of the antibody evaluated using MultiAlin software.  The CDR 
regions of the antibodies were highlighted according to the Kabat scheme (Figure 
3.22).  The light and heavy chain CDRs are highlighted in green and purple, 
respectively. The heavy chain sequences of all three chain-shuffled scFv and the wild-
type B4 scFv are all identical, with the exception of the C2 scFv which has 8 amino acid 
differences in the heavy chain. This sequence homology of the heavy chains was 
expected, as the heavy chain of the library was predisposed to bind to HFG and 
enrichment of individual clones with high affinity towards HFG occurred. Comparing  
E9, the best clone from the chain shuffled library, and the wild-type clone, B4, it is 
apparent from the consensus sequencing (Figure 3.22) of both, that the major sequence 
differences occur in the CDRL-3 region. These differences primarily include favoured 
substitutions such as asparagine at position 81 to serine (N81S), both of which are small 
polar amino acids or glycine at position 88 to alanine (G88A). Both amino acids are 
small and non-polar and hence, neither of these substitutions are likely to have a major 
effect on antigen binding.  Also, at position 89 in the chain-shuffled E9 scFv, isoleucine 
Clone IC50 (ng/mL) 
E9 >8 
E7 15 
H4(A) 20 
C2 40 
C7 100 
F11 120 
B3 120 
D4 140 
H2 150 
B4(A) 200 
Wild Type-B4 100 
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was substituted for the smaller alanine. The carbonyl group of the isoleucine could 
potentially interact and form hydrogen bonds with any of the upstream hydroxyl groups 
from the numerous tyrosines that are in close proximity to the CDRs of the light chains. 
It has previously been highlighted how framework region residues, that have atomic 
interaction with CDR residues, were found to indirectly influence the antibody binding 
affinity by altering the conformation of the CDR loops (Xiang et al., 1999). This 
isoleucine to alanine substitution is the only non-conservative substitution in the 
CDRL3. In order to determine specific residues that contribute to the functionality of a 
protein, alanine mutagenesis is commonly employed to identify the contribution of 
individual amino acid side-chains to protein function, stability and shape (Morrison and 
Weiss, 2001). The pre-dominant substitution in the CDRL3 from the chain-shuffled 
clone was an alanine substitution.  This indicates that the side-chain from the isoleucine 
may have partially blocked the antigen binding site or promoted steric hindrance effects 
during antigen binding. 
The E9 scFv had the lowest IC50, and therefore was taken forward for intra/inter day 
competitive studies in comparison with the B4 (original) clone, to produce a validated 
ELISA assay. 
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Figure 3.22 Avian anti-HFG scFv gene sequences of selected clones following chain-
shuffling. The highlighted sequences in green and purple show the CDRs (heavy and light 
chain) of the recombinant antibody fragments. The framework regions are highlighted in red 
and variations from the consensus of the sequences are shown in black. 
 
3.4.6 Expression and purification of the scFv E9 and subsequent characterisation 
by SDS-Page and Western Blotting 
Large-scale expression of the avian anti-HFG E9 scFv was performed in 500 mL 
cultures, as outlined in Section 2.9.2. The scFvs were purified as described in Section 
3.3.2.4. The IMAC-purified scFv-containing fractions were pooled, centrifuged and 
analysed by SDS-PAGE (Figure 3.23) and western-blotting (Figure 3.24) 
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Figure 3.23 SDS-PAGE analysis on the fractions obtained during IMAC purification 
of the E9 anti-HFG chain-shuffled scFv. Lanes 1 and 5 = Colour Burst molecular 
weight markers (Fermentas); Lane 2 = Lysate diluted 10-fold in PBS; Lane 3 = Wash 
‘A’; Lane 4 = Wash ‘B’; Lane 5 = Eluted purified antibody fractions pooled and used 
undiluted. One distinct band is visible at approximately 28 kDa in the purified 
fractions, representing the purified scFv. 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 Western blot analysis of the purified E9 anti-HFG scFv. Lanes 1 = 
Colour Burst molecular weight marker (Fermentas); Lane 2 = Lysate diluted 10-fold 
in PBS; Lane 3 = Wash ‘A’; Lane 4 = Wash ‘B’; Lane 5 = Eluted purified antibody 
fractions pooled and used undiluted. One distinct band is visible at approximately 28 
kDa in the purified fraction representing the purified scFv. 
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3.5 Optimisation of an ELISA for the detection of halofuginone spiked into eggs, 
using the purified E9 chain-shuffled scFv 
Following purification of the E9 scFv, its use in a competitive immunoassay for the 
detection of HFG was investigated. In order to maximise the performance of the 
assay, several parameters were optimised. These included the optimal coating 
concentration of the conjugate and the optimal buffer for coating. Once these 
parameters were determined, intra/inter-day assays were performed to establish the 
reproducibility of the assay alongside comparison of assay results with the B4 wild-
type scFv. 
 
3.5.1 Selection of conjugate coating buffer for the competitive ELISA for 
halofuginone   
To investigate the optimal pH for coating the HFG-transferrin conjugate onto the 
Nunc MaxiSorp plates, five different coating buffers were employed at five different 
pH levels. The buffers investigated were: 0.1 M acetate buffer, pH 4.8; 0.1 M 
phosphate buffer, pH 5.0; 0.1 M carbonate buffer, pH 10.3; 0.1 M citrate buffer, pH 
3.0 and 0.01 M PBS, pH 7.4. The results are illustrated in Figure 3.25. The results 
show that the amount of antigen bound to the plate was greatest when using PBS at a 
pH level of 7.4, or carbonate buffer at a pH level of 10.3. PBS at a pH level of 7.4 was 
chosen as the conjugate coating buffer for use in subsequent assays. 
 
3.5.2 Checkerboard ELISA for the determination of the optimum scFv dilution 
and optimum coating concentration for HFG-transferrin in competitive assays 
 It is essential to optimise both the coating concentration of the conjugate and the 
optimal dilution of the antibody employed in a competitive ELISA.  Nunc MaxiSorp 
ELISA plates were coated with varying concentrations of the HFG-transferrin 
conjugate in the optimal conjugate coating buffer, as previously established. To 
determine the concentrations which would give the best assay sensitivity, a 
checkerboard ELISA was performed with varying dilutions of the affinity-purified 
antibodies. The results shown in Figure 3.26 indicate that an optimum coating 
concentration of 1 µg/mL HFG-transferrin gave the highest absorbance using the most 
economical conjugate concentration. The optimal antibody dilution chosen, was a 
1/10,000 dilution. 
 
 120 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
10 1,000 100,000 10,000,000 1,000,000,000
1/Lysate Dilution
Ab
so
rb
an
ce
 @
 4
50
nm PBS
Carbonate
Acetate
Citrate
Phosphate
 
Figure 3.25 Selection of optimal coating buffer for use in ELISA for the detection of 
HFG. One µg/mL of HFG-Transferrin conjugate was used. Coating buffers tested 
were; 0.1 M acetate buffer, pH 4.8; 0.1 M phosphate buffer, pH 5.0; 0.1 M carbonate 
buffer, pH 10.3; 0.1 M citrate buffer, pH 3.0 and 0.01 M PBS, pH 7.4. The anti-HFG 
scFv was serially diluted in buffer and added to the coated/blocked wells. Bound 
polyclonal antibody was then detected using HRP-labelled anti-HA secondary 
antibody. 
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Figure 3.26 Checkerboard ELISA for the determination of the optimal conjugate 
coating concentration and scFv dilution for use in a competitive ELISA for HFG. 
HFG-transferrin (T) concentrations of 8, 4, 2 and 1 µg/mL were used in a direct 
ELISA with varying dilutions of scFv ranging from 1/10 to 1/100,000,000. A 1 µg/mL 
HFG-transferrin (T) concentration and a 1/10,000 dilution of the scFvs were chosen 
for use in a competitive assay format. 
 
3.5.3 Cross reactivity profile of the E9 anti-halofuginone scFv 
The E9 HFG-specific scFv was assessed for cross reactivity against five structurally 
similar veterinary drugs, which included; Toltrazuril, Ponazuril, Nicarbazin, 
Diaveridine, and Ethopabate, as described in Section 2.9.3.3. The cross reactivity 
profile of the E9 scFv showed 100 % cross-reactivity with the primary drug of 
interest, HFG, and less than 4 % cross-reactivity with any other structurally similar 
drug. This 4% cross-reactivity may be due to non-specific binding of the E9 scFv as it 
occurred with all 5 structurally similar drugs tested. The specificity of the antibody 
HFG-T 
Coating 
concentration 
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towards HFG alone suggests that the antibody is binding to the bromine and chlorine 
atoms on HFG, as these atoms are not present in any of the other drugs. 
 
3.5.4 Intra and inter-assay variability studies of the inhibition ELISA for 
halofuginone extracted from egg samples 
Using the optimised parameters established, a competitive assay (free HFG in solution 
competing against immobilised conjugate for binding to the antibody), was performed 
in extracted egg samples as described in Section 2.9.3.2. Standards of HFG were 
prepared in 0.01 M PBS, pH 7.4, and were diluted with equal volumes of the scFv at a 
1/10,000 (final) dilution. The final concentrations of HFG ranged from 5 μg/mL down 
to 254 pg/mL. This scFv-HFG preparation was added to an immunoplate coated with 
HFG-Transferrin in 0.01M PBS, pH 7.4, and blocked with 5% (w/v) Milk Marvel. 
HRP-labelled anti-HA antibody was then used to detect the HFG-bound scFv. 
Calibration curves were prepared using BiaEvaluation, and the detection capability 
could be extrapolated from the curve. Co-efficients of variation (CV) were determined 
to assess the reproducibility of the HFG assay. These are listed for 11 concentrations of 
free HFG within intra/inter-day assay results in Table 3.3 with the highest CV recorded 
at 15.9 %. According to the 2002-657-EC Commission decision, the method 
reproducibility should not be greater than the corresponding reproducibility CV at a 
concentration of 0.5 × the permitted limit. The CVs were calculated for samples at just 
below half the MRL (335 pg/mL) as 9.4 % for intra-day and 10.9 % for inter-day 
assays, and overall CVs were calculated as 8.4 % and 9.2 % for intra and inter-day 
values, respectively. Hence, this assay complies with the EU guidelines for validation. 
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Table 3.3 Assay performance characteristics for Halofuginone detection. Inter-day 
assays were plotted in BiaEvaluationTM. The average percentage recovery was 
calculated at 91.1%. 
 
A calibration curve was constructed from inter-assay results using a 4-parameter 
equation in BiaEvaluation™ software; from this the decision limit was calculated 
(Figure 3.27). This was estimated to be approximately 162 pg/mL for E9 and 
approximately 30 ng/mL for B4. The detection capability (CCβ) was then established 
by measuring 20 samples at the decision limit and adding 1.64 times the standard 
deviation of the samples to the concentration of the decision limit. This was calculated 
to be 163 pg/mL for E9 and 31 ng/mL for B4. These results were extrapolated from the 
calibration curve. However, when experimentally determining the functional limit of 
detection using the E9 scFv and 20 samples of varying concentrations of HFG, the 
lowest concentration of analyte that could be detected with 95% certainty above the 
blank standard was determined to be 80 pg/mL. This is illustrated in Figure 3.28 where 
it can be observed that at least 19 out of 20 of the fortified samples with 80 pg/ml HFG 
could be correctly distinguished from the blank standard.  This is a 185-fold 
improvement in antibody sensitivity over the original scFv. 
Halofuginone 
Conc. (pg/mL) 
Intra-day 
(% C.V) 
Inter-day 
(% C.V) 
Percentage 
Accuracy (%) 
32768 15.9 12.5 95.0 
13107.2 14.1 11.4 97.0 
5242.8 9.8 10.8 95.1 
2097.1 5.1 7.3 95.2 
838.8 3.1 6.9 89.1 
335.5 9.4 10.9 99.4 
134.2 11.6 11.7 93.5 
53.6 6.7 9.3 53.2 
21.4 5.5 6.2 97.6 
8.5 7.2 6.4 - 
3.4 3.8 7.2 - 
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Chain shuffling has been previously shown to enhance the properties of certain 
recombinant antibodies several fold. This notable increase in sensitivity highlights the 
importance of investigating heavy-light chain pairings. 
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Figure 3.27 Calibration curve of Inter-day assays for both the wild-type ‘B4’ and chain 
shuffled ‘E9’ scFv. The calibration curves were constructed by using a 4-parameter 
equation in BiaEvaluationTM. The limit of detection was calculated in BiaEvaluation to 
be 162 pg/ml and 30 ng/mL for E9 and B4, respectively. The absorbance of the 
evaluated HFG samples was normalised by expressing the absorbance as a function of 
the blank standard (A/A0). The functional limit of detection of the E9 scFv was then 
experimentally determined to be below this value at 80 pg/mL. 
B4 
scFv E9 
scFv 
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Figure 3.28 Determination of limit of detection of the HFG-specific E9 scFv using 20 
replicates of the blank standard, 20 replicates of 80 pg/mL HFG and 20 replicates of 
100 pg/mL HFG in a competitive ELISA format with 1 μg/mL HFG-transferrin coated 
on the immunosorbent plate. HRP-labelled anti-HA Mab was used to probe for bound 
scFv. The dashed line indicates 95 % compliance, i.e. the ability of the antibody to 
detect 95 % of the samples as positive for HFG residues when compared to the blank 
standard. 
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3.6 Development of an scFv-based Biacore assay for the detection of 
halofuginone in egg samples 
Using the E9 chain-shuffled anti-HFG scFv previously described, a surface plasmon 
resonance-based assay on the Biacore 3000 system was optimised to detect HFG. 
 
3.6.1 Preconcentration studies for the immobilisation of halofuginone onto the 
CM5 sensor chip surface 
Preconcentration studies were performed to determine the optimum pH at which the 
electrostatic interactions between the HFG-transferrin and a CM5 sensor chip surface 
are most favourable for maximum binding to occur. A broad pH range was 
investigated using buffers with different buffering capacities, as described in Section 
2.11.3. The conjugate was passed over the activated chip surface in the different 
buffers with pH below the isoelectric point (pI) of the protein. Figure 3.29 
demonstrates that the amount of HFG conjugate electrostatically absorbed onto the 
CM dextran surface is dependant on the pH of the buffer. The pH level allowing the 
optimum amount of conjugate to be immobilised on the surface was pH 4.0. This 
buffer was selected for the immobilisation of the conjugate onto the CM5 sensor chip. 
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Figure 3.29 The HFG-transferrin conjugate in 10 mM solutions of sodium acetate at 
pH levels of 4.0, 4.2, 4.4, 4.6, and 4.8, was passed over the surface of a CM5 dextran 
chip at a flowrate of 10 μl/min. The optimal pH for the immobilisation of the HFG-
Transferrin conjugate to the CM5 dextran surface was 4.0 with the highest levels of 
apparent binding observed. 
 
3.6.2 Production of a directly immobilised halofuginone-transferrin CM5 sensor 
chip surface 
HFG-Transferrin was directly immobilised onto the surface of a CM5 chip as 
described in Section 2.11.4, by coupling with free primary amine groups on the 
conjugate. This immobilisation process can be observed in Figure 3.30. The 
carboxymethyl groups on the chip are activated by passing a mixture of EDC/NHS 
over the surface. The EDC solution, in the presence of NHS, activates the CM dextran 
carboxyl groups into functional ester groups. The surface NHS esters react with 
10mM sodium 
acetate, pH 4.0 
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primary amino groups on the protein causing covalent binding of the protein to the 
surface. In the last step the remaining esters are transformed into amides by reaction 
with ethanolamine, essentially ‘capping’ any unreacted sites. A final level of 3880 RU 
of covalently attached HFG-transferrin was achieved. 
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Figure 3.30 Sensorgram illustrating the direct coupling of HFG-transferrin to a CM5 
sensor chip surface. The surface was activated with EDC/NHS solution, and the 
HFG-transferrin was passed over the activated carboxyl surface. Deactivation of any 
unbound or free functional ester groups was achieved by treating the chip surface 
with ethanolamine-HCl, resulting in the capping of any reactive groups. The surface 
was then regenerated with a solution of NaOH. A final level of 3880 RU of covalently 
attached HFG-transferrin was achieved. 
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3.6.3 Evaluation of optimal flowrate, contact time and scFv dilution for SPR 
detection of HFG residues in a competitive format 
The optimal flowrate, contact time and dilution of the anti-HFG scFv for use on the 
covalently attached HFG-transferrin chip, was investigated. Contact times of 3, 6, 9 
and 12 minutes, each at flowrates of 10, 20 and 30 μl/minute were evaluated. This 
was designed to determine which parameters gave the highest response change with 
respect to analyte concentration. It can be observed in Figure 3.31 that a contact time 
of 6 minutes, a flowrate of 10 μl/minute and a scFv dilution of approximately 1/4,000 
yields response units between 100-150 RU, which is an ideal maximum response for a 
competitive assay, without the assay being too time-consuming or using large 
quantities of antibody. 
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Figure 3.31 Optimisation of halofuginone Biacore assay parameters including flow-
rate, contact time and scFv dilution. Three different flowrates 10, 20 and 30 
μl/minute, four different contact times 3, 6, 9, and 12 minutes, and six different scFv 
dilutions, 1/800, 1/1,600, 1/3,200, 1/6,400, 1/12,800, and 1/25, 600, were assessed to 
determine the optimal conditions for the SPR detection of HFG. 
 
3.6.4 Preliminary Biacore inhibition-analysis for the detection of halofuginone in 
PBS. 
To ensure that the assay was functional in a competitive format, a preliminary 
competitive assay was performed in PBS using six different concentrations of free 
HFG ranging from 100 to 1.56 ng/mL. Each of these concentrations of HFG were 
incubated with a 1/4,000 (final) dilution of the E9 scFv prior to passing over the 
surface of the HFG-immobilised sensor-chip. Figure 3.32 shows the sensorgram data 
for the preliminary competitive analysis. It is apparent from the graph that the greater 
the concentration of free HFG in the samples, the less scFv is available for binding to 
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the sensor surface. When comparing the data from the 100 ng/mL of HFG to 1.56 
ng/mL of HFG, it can be observed that there is at least 200 RU less of antibody 
binding occurring when the higher concentration of HFG is present. 
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Figure 3.32 Overlay plot demonstrating the decrease in binding of purified anti-HFG 
scFv to the immobilised HFG-transferrin surface when incubated with increasing 
concentrations of free HFG at 100, 25, 12.5, 6.25, 3.125, and 1.56 ng/mL in PBS. 
 
3.6.5 Analysis of Biacore-based halofuginone-detection assay performed in egg 
matrices. 
Assay reproducibility may be affected by environmental conditions and can lead to 
significant variations in the analytical results. To determine the intra-day (within the 
same assay) and inter-day (between assays) variation of results, a calibration curve 
was generated for HFG. For the inter/intra-day studies, egg samples were spiked (as 
described in Section 2.11.7) with HFG at concentrations of 0, 0.78, 1.5, 3.1, 6.3, 12.5, 
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25, and 50 ng/mL. The spiked-HFG residues were subsequently recovered from the 
matrix and resuspended in PBS/ 5% (v/v) MeOH. They were mixed with an equal 
volume of the HFG-specific scFv at a final concentration of 10.6 μg /mL (1/4,000 
dilution) prior to injection over the sensor–chip surface. Each standard was injected in 
triplicate at a flow-rate of 10 µL/minute for 6 minutes.  Response units (RU) were 
recorded before and after sample injection. The normalised responses were calculated 
and a four-parameter equation was fitted to the data. The co-efficients of variation 
(CV) values between the inter and intra-day batches were calculated from the 
calibration curve. These are outlined in Table 3.4. From the CV values, it is apparent 
that the reproducibility of the Biacore assay is very good, as the CVs for the intra-day 
assay are an average of 4.2 % with the highest CV recorded at 10.6 %. For the inter-
day assays the average CVs are at 4.5 % with the highest at 9.8 %. The percentage 
accuracy of the assay was extrapolated from the calibration curve and the average 
calculated at 99.5 % which is excellent for a competitive assay performed in extracted 
egg matrix. The effects of egg matrix and extraction recoveries are discussed further 
in Chapter 5. 
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Table 3.4 Calculated co-efficients of variation for the chain-shuffled E9 scFv in a 
competitive assay format with concentrations of HFG ranging from 50 ng/ml to 780 
pg/mL. Inter and intra day assays were performed. Bound scFv was recorded as 
response units. Percentage recoveries were extrapolated from the four-parameter 
calibration curve of the inter-day assays plotted in BiaEvaluationTM. The average 
percentage recovery was calculated at 99.5%. 
 
Figure 3.33 shows the inter-assay mean calibration curve in extracted egg matrix 
using the anti-HFG scFv. The red dashed line indicates the lowest level of HFG 
detectable in this matrix. The LOD of the assay in egg samples was found to be 
approximately 3.4 ng/mL, as extrapolated from the calibration curve.   
 
Halofuginone 
Conc. (ng/mL) 
Intra-day 
(% C.V) 
Inter-day 
(% C.V) 
Percentage 
Accuracy (%) 
50 1.2 1.2 97.8 
25 1.2 1.1 102.1 
12.5 0.4 1.0 99.9 
6.25 10.6 7.6 95.9 
3.12 9.6 9.8 122.8 
1.56 2.5 6.6 99.5 
0.78 3.9 4.7 78.9 
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Figure 3.33 Intra-day assay results for HFG extracted from eggs. Data was  
expressed as R/R0 (i.e. response at different free analyte concentrations are expressed 
as a proportion of response in the presence of no competing analyte.) Analysis was 
performed in triplicate on different sets of standards. The limit of detection of HFG as 
denoted by the dashed line is 3.4 ng/mL.  
 
The analytical limit ‘CCα’ (decision threshold) as discussed in Section 3.1, was 
calculated as the average analyte concentration of the blank standards plus 2.33 times 
the standard deviation of the blank samples. This was approximately 3.28 ng/mL. 
Using this value, the ‘CCβ’ (detection capability) could be determined by adding the 
result for CCα with 1.64 times the standard deviation of the samples spiked at half the 
MRL or 3 ng/mL ( i.e. 3.28 + 1.64 (0.082)). This was calculated as 3.41 ng/mL. This 
is illustrated in Figure 3.34 whereby 20 samples spiked at half the MRL and 20 blank 
samples were analysed. These response values were all normalised (R/R0) to estimate 
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the standard deviations and extrapolate corresponding concentrations from the 
standard curve (Figure 3.33). The functional LOD was experimentally verified by 
analysing 20 samples at concentrations of 2.8 ng/mL. It can be observed from Figure 
3.34 that 20/20 of these samples can be reliably distinguished from the blank standard. 
The false negative rate of (≤5%) as required by the 2002/657/EC legislation is 
adhered to and, therefore, after experimental verification, 2.8 ng/mL was calculated as 
the actual detection capability for the halofuginone Biacore-based detection assay. 
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Figure 3.34 Determination of limit of detection of HFG-specific E9 scFv using 20 
replicates of the blank standard, 20 replicates of 3 ng/mL HFG (half the MRL in eggs) 
and 20 replicates of 2.8 ng/mL HFG in a competitive assay format. The samples were 
passed across the HFG-immobilised chip and the response units recorded. The 
dashed line indicates 100 % compliance, i.e. the ability of the antibody to differentiate 
20/20 samples, spiked with 2.8 ng/mL of HFG, from the blank standard. 
Halofuginone  
concentration 
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3.7 Discussion and Conclusion 
In this chapter light chain shuffling was employed to improve the properties of an 
avian-derived HFG-specific scFv antibody pool. A 185-fold improvement in 
sensitivity of a HFG-specific scFv was achieved. This affinity improvement stresses 
the importance of optimising light and heavy chain pairings for recombinant 
antibodies. The E9 scFv has the potential to detect down to 80 pg/mL of HFG in assay 
buffer and extracted samples in ELISA.  Hence, this assay would be highly applicable 
in the diagnostic monitoring of HFG residues in the food industry. 
The decision limit was calculated according to the guidelines outlined in the 2002-657-
EC Regulation. A calibration curve was constructed from inter-assay results using a 
four-parameter equation in BiaEvaluation™ software; from this the decision limit was 
calculated. This was estimated to be approximately 162 pg/mL for E9 and 
approximately 30 ng/mL for B4. The detection capability (CCβ) was then established 
by measuring 20 samples at the decision limit and adding 1.64 times the standard 
deviation of the samples to the concentration of the decision limit. This was calculated 
to be 163 pg/mL for E9 and 31 ng/mL for B4. These results were extrapolated from the 
calibration curve. However, when experimentally determining the functional limit of 
detection using the E9 scFv and 20 samples of varying concentrations of HFG, the 
lowest concentration of analyte that could be detected with 95% certainty above the 
blank standard was determined to be 80 pg/mL.  
From reviewing the literature, it is apparent that the lowest previously reported 
functional limit of detection for HFG detection was approximately 500 pg/mL. The 
functional limit of detection of the HFG-specific E9 scFv in the ELISA was calculated 
to be 80 pg/mL as shown in Figure 3.28. The lowest MRL listed by the EU for HFG 
is 1 ng/mL and, even when taking into account the limit of detection calculated from 
the inter-day calibration curve, which was approximately 162 pg/mL, the E9-scFv still 
has the capability of detecting significantly below the current MRL.  
Comparing the results of the ELISA to the Biacore assay for HFG detection, the 
ELISA proves to be superior. In the Biacore assay, the detection capability was 
calculated as 3.4 ng/mL. The functional limit of detection was experimentally verified 
by analysing 20 samples at concentrations above and below this detection capability. 
As 2.8 ng/mL was detectable with 95 % confidence, this was classed as the actual 
detection capability of the Biacore assay. The development of this recombinant anti-
HFG scFv and its subsequent incorporation into an automated detection system has 
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the potential to replace the current routine applications in the surveillance of HFG 
residues in food. The current MRL for HFG in eggs is 6 ng/mL and the analytical 
limit of detection of this Biacore assay is 2.8 ng/mL, verifying the ability of this assay 
to distinguish between compliant and non-compliant samples. This SPR assay also 
proved very reproducible with the highest percentage of variation between separate 
assays shown at 10.6 %. Such a recombinant antibody-immunosensor could 
potentially be the starting point for the development of a multi-residue detection 
sensor chip, which would allow rapid screening for a range of different anti-protozoan 
drug residues. 
The measurement of affinity interactions between two molecules can prove 
challenging, particularly when dealing with drug compounds with molecular weights 
lower than 500 Da. A significant problem is the lack of signal strength due to the 
target analyte being too small to produce a substantial signal itself. If greater Biacore 
assay sensitivity was required for the detection of HFG, directly immobilising the 
target analyte onto the sensor chip surface may be an alternative solution (Townsend 
et al., 2006), as this would enable a greater density of HFG to be packed on the 
surface of the chip. Mitchell et al. (2005) showed several ways of enhancing SPR 
biosensing of small molecules by nanoparticle labelling with gold, observing a 13-
fold improvement in the limit of detection when a sequential binding format with 
labelled secondary antibody was employed. SPR biosensors are very useful for food 
safety analysis as they are sensitive, ‘real-time’ interactive devices that can allow a 
timely response in the detection of food contaminants, as well as permitting the rapid 
quantification of trace drug residues in food. Also, in SPR technology, false positives 
are minimised due to the short contact times of analyte and antibody which favour 
high affinity interactions instead of low affinity matrix effects, thereby making SPR 
detection highly favourable in food monitoring when compared to conventional 
methods (Dubois et al., 2004).  
A previous study reported how light chain shuffling was employed to overcome poor 
stability when no actively expressing clones were observed from the initial un-
shuffled library, whereas functional antibody fragments were readily selected from the 
chain-shuffled library (Rojas et al., 2004). The effect of light chain shuffling on the 
affinity of antibodies, without detrimental effects to antigen specificity, have also 
been noted previously (Yoshinaga et al., 2008). In that case a light chain-shuffled 
variant of an MCP-1 specific antibody displayed a 15-fold increase in affinity when 
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compared to the wild-type. Another observable benefit of antibody engineering, in 
conjunction with recombinant display technologies, is the selection of clones with 
improved expression levels.  
Overall this chapter describes how chain shuffling enabled a 185-fold improvement in 
antibody affinity which is a very significant result with important implications for 
sensitive and accurate analysis of halofuginone in foodstuffs. Subsequent steps in 
environmental monitoring of large samples due to the ease and cost-efficiency of the 
assays are outlined. This work also demonstrates the simplicity of mimicking an 
immune process, such as somatic-hypermutation for the isolation of superior 
antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Development of a diclazuril-specific scFv library  
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Chapter outline 
This chapter gives an insight into the generation of recombinant antibody fragments, 
phage library construction, and selection of anti-diclazuril scFv fragments. Chickens 
were immunised with a ‘diclazuril’-HSA conjugate. However, no diclazuril-specific 
immune response was observed. Mice were then immunised with the same conjugate, 
which induced a diclazuril-specific immune response in the murine models.  Several 
expression problems were encountered during the amplification of the recombinant 
gene fragments. To overcome these problems the cDNA was re-synthesised and the 
library was constructed a second time. The scFv gene fragment was cloned into a 
phage-display vector, to allow for the selection of diclazuril-specific scFv on the 
surface of phage particles, via biopanning. However, when the scFv library was 
screened, no diclazuril-binding scFv fragments were present. 
 
4.1 Introduction 
Antibody engineering and production was revolutionised by the development of 
modern molecular biological methods for the expression of recombinant DNA. 
Among the various strategies developed for tailoring the affinity and specifity of 
recombinant antibodies, phage display has proven to be a robust and versatile 
technology. The two predominant formats for recombinant antibodies in phage 
display are generally either the single chain Fv (scFv) or Fab antibody fragments. 
Both antibody formats have their advantages and disadvantages. The format selected 
should be ideal for the purpose of the assay. In the scFv format, the Fc region, is 
eliminated as it contributes to immune effector functions, which may cause 
interference with secondary antibodies used in the assay format. In contrast, Fab 
fragments are generally more stable than scFv fragments and are less prone to 
aggregation. Quintero-Hernanádez and colleagues (2007) re-formatted a scFv to a Fab 
fragment and tested both in the presence of guanidium chloride and found that the 
stability of the antibody fragment substantially increased when it was re-formatted to 
a Fab fragment.  The major disadvantage of Fabs relative to scFvs is the lower 
expression levels generally found in E. coli (Barbas et al., 2004). ScFvs were the 
format of choice for the generation of an anti-diclazuril recombinant antibody library 
due to the presence of only one polypeptide chain in the scFv, easier production in 
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bacteria, and small size (25-30 kDa), which may allow increased assay sensitivity, 
due to more dense packing on the assay platform surface. 
Diclazuril has a low molecular mass of 407.64 Daltons. It is necessary, therefore, to 
conjugate it to an immunogenic carrier protein in order to elicit an immune response 
in host animals. This is primarily performed by the linkage of suitable functional 
groups on the drug to a reactive grouping on the carrier protein. The presence of an 
accessible functional group (not a target epitope) on the hapten governs the selection 
of the conjugation method to be employed. Common procedures use amine, 
carboxylic acid, hydroxyl, or sulfhydryl groups on the hapten and the protein (Singh 
et al., 2004). When this technique is not successful, or is not possible due to the lack 
of suitable functional groups on the hapten, alternative strategies must be sought. The 
only available functional group in the diclazuril entity is thought to be the primary 
epitope for antibody recognition of diclazuril and is, therefore, unsuitable for linking 
to a carrier protein. Fodey and colleagues (2007) report the use of antigen mimics for 
the generation of diclazuril-specific antibodies, whereby, an intermediate compound 
produced during the manufacture of diclazuril was deemed an ideal candidate for use 
as a diclazuril mimic. This compound, carboxydiclazuril, was conjugated to both BTG 
and HSA proteins using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and n-hydroxysuccinimide (NHS) coupling chemistries (Fodey 
et al., 2007). These conjugates were obtained from Queen’s University Belfast and 
used for immunisation.  
 
4.2 Results 
4.2.1 Immunisation of Leghorn chicken with diclazuril 
A chicken was immunised with a mixture of equal concentrations of a ‘diclazuril-
mimic’-HSA and halofuginone-HSA conjugates over a period of three months. After 
four boosts, a primary serum titre was determined by performing a direct ELISA. 
 
4.2.1.1 Avian serum antibody titre determination  
A direct ELISA was carried out using varying dilutions of serum incubated on a 
‘diclazuril’-BTG coated Nunc MaxiSorp 96-well ELISA plate. It can be observed in 
Figure 4.0 that no antibody response was generated to diclazuril after four boosts. 
However, a very high antibody response was observed for halofuginone, when the 
same serum was analysed. This suggested, firstly, that the ‘diclazuril’-HSA conjugate 
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used was not satisfactory for generating an antibody response and, secondly, that the 
avian host’s immune system was actively responding to the immunisation. 
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Figure 4.0 Antibody serum titre from a chicken immunised with ‘diclazuril’-HSA and 
halofuginone-HSA after four boosts. The antibody response for each target was 
determined by performing a direct ELISA on Nunc MaxiSorp 96-well plates coated 
with each of the screening conjugates (i.e. with a different carrier protein to that 
which was immunised). ‘Diclazuril’-BTG and halofuginone-transferrin were coated 
on separate ELISA plates, which were subsequently blocked with an appropriate 
blocking agent. Bound avian antibodies were detected using a HRP-labelled rabbit 
anti-chicken IgG antibody. No significant response was observed when analysing the 
serum for anti-diclazuril antibodies. 
 
4.2.1.2 Further diclazuril boosts 
Three more boosts were administered to the chicken. Seven to ten days after each 
boost, a bleed was taken and an antibody serum titre was performed to determine the 
Antibody response 
to each respective 
conjugate 
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presence of anti-diclazuril antibodies in the serum. This antibody serum titre is shown 
in Figure 4.1. No diclazuril-binding antibodies were present in the serum after all 
seven boosts. This implied that the ‘diclazuril’ hapten was not recognised as a foreign 
antigen, and thus was not producing a diclazuril-specific immune response. In turn, no 
anti-diclazuril antibodies were being generated. 
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Figure 4.1 Antibody serum titre from a chicken immunised with ‘diclazuril’-HSA, and 
halofuginone-HSA after seven boosts. The antibody response for each target was 
determined by performing a direct ELISA on Nunc MaxiSorp 96-well plates coated 
with each of the screening conjugates. ‘Diclazuril’-BTG and halofuginone-transferrin 
were coated on separate ELISA plates which were subsequently blocked with an 
appropriate blocking agent.  Bound avian antibodies were detected using a HRP-
labelled anti-chicken antibody. No significant response was observed when analysing 
the serum for anti-diclazuril antibodies, after seven boosts.  
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4.2.1.3 Evaluation of ‘diclazuril’-conjugates using a commercial anti-diclazuril 
polyclonal antibody 
To determine if the diclazuril derivative ‘carboxydiclazuril’ was still present and 
intact on the conjugates used for immunisation and screening, an ELISA was 
performed using a commercial anti-diclazuril polyclonal antibody (Randox Ltd.). A 
checkerboard ELISA was carried out to analyse two ‘diclazuril’-BTG and two 
‘diclazuril’-HSA conjugates; one set was obtained from Queen’s University Belfast 
(QUB) and one set was prepared ‘in-house’ as described in Section 2.13.1. A range of 
concentrations of each of the ‘diclazuril’-conjugates were coated on the surface of an 
ELISA plate, which was then blocked with an appropriate blocking agent. Anti-
diclazuril antibody (produced in rabbit) was serially diluted and added to the ELISA 
plate coated with each of the respective conjugates. Bound anti-diclazuril antibody 
was detected using a HRP-labelled goat-anti-rabbit secondary antibody. As shown in 
Figure 4.2 the anti-diclazuril commercial antibody titred out when incubated on a 
plate coated with decreasing concentrations of each of the ‘diclazuril’-
BTG/‘diclazuril’-HSA conjugates. This suggested that the drug-carrier protein 
complex is still intact, that the ‘diclazuril’ derivative is still present on the conjugate, 
and that the commercial antibody is specific for the bound ‘diclazuril’ drug on all four 
conjugate complexes. The presence of the ‘diclazuril’ derivative on the conjugates 
was verified. Therefore, another immunisation was carried out. No chickens were 
available for immunisation at this time, hence, three mice were immunised with the 
‘diclazuril’-HSA conjugate from QUB. 
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Figure 4.2 Checkerboard ELISA to determine the presence/absence of the ‘diclazuril’ 
derivatives on each of the ‘diclazuril’-conjugate complexes. Varying concentrations 
of each conjugate was coated on a Nunc MaxiSorp 96-well ELISA plate, and the plate 
was subsequently blocked by the addition of an appropriate blocking reagent. 
Dilutions of the anti-diclazuril polyclonal antibody were added to the plate. Antibody 
that bound to the immobilised ‘diclazuril’ on the plate surface was then detected 
following the addition of a HRP-labelled goat-anti-rabbit secondary antibody. 
 
4.2.2 Immunisation of balb/c mice with ‘diclazuril’ 
Balb/C mice aged 5-8 weeks were initially immunised with a mixture of equal parts of 
‘diclazuril’-HSA conjugate and Freund’s complete adjuvant. Subsequent boosts were 
performed with Freund’s incomplete adjuvant 7-10 days apart, with five boosts given 
in total. 
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4.2.2.1 Mouse anti-serum titre determination 
An antibody serum titre was performed from a tail bleed taken from mice treated with 
an extensive 3 month immunisation schedule for diclazuril (Figure 4.3). ELISAs 
were performed using varying dilutions of serum antibody on a ‘diclazuril’-BTG-
coated 96-well plate. The finding of an anti-diclazuril antibody titre of greater than 
1:100,000 signified that diclazuril-antibody generation had occurred. The mice were 
sacrificed to harvest the B cells from the spleen for recombinant antibody library 
generation and selection of positive antibodies to diclazuril. 
.  
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Figure 4.3 Average antibody serum titre from three mice immunised with the 
‘diclazuril’-HSA, conjugate (received from QUB) after six boosts. The antibody 
response for diclazuril from the serum was determined by performing a direct ELISA 
on plates coated with ‘diclazuril’-BTG. The plates were blocked with an appropriate 
blocking agent and varying dilutions of the murine serum were incubated on the plate. 
Bound murine antibodies were detected using a HRP-labelled rabbit-anti-mouse IgG. 
The mean diclazuril-antibody titre of serum from the three mice is illustrated, with the 
standard deviations from the mean depicted by the error bars. A negative control of 
serum taken prior to the immunisation protocol is also shown. 
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4.2.3 Isolation of RNA from murine B cells (spleen) and first-strand DNA 
synthesis 
The spleens were removed from the immunised mice and carefully homogenised in 
Trizol reagent. The total RNA was extracted from the tissue sample, quantified using 
a Nanodrop ND-1000 and first-strand cDNA synthesised by reverse transcription. The 
cDNA template was used in the amplification of the mouse variable heavy and light 
chain genes. 
 
4.2.4 PCR optimisation for murine variable heavy and variable light chain 
generation 
A standard PCR protocol, as outlined in Barbas et al. (2001), was employed to 
amplify the VH and VL chain genes (Figure 4.4) from the reverse transcribed cDNA. 
The VH region amplified successfully with no subsequent optimisation required. 
However, the VL region did not amplify.  
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Amplification of variable regions from synthesised cDNA of ‘diclazuril’ 
sensitised mice. Amplification was performed using Go Taq polymerase and standard 
PCR conditions. Lane 1= 1kb ladder; Lane 2= VL amplification; Lane 3= VH 
amplification and Lane 4= 1kb Ladder. 
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To optimise the amplification of the VL gene, several steps were taken. Initially, a 
high fidelity polymerase, Phusion polymerase, was used with varying concentrations 
of magnesium chloride. The role of MgCl2 in the PCR is to increase the stringency of 
the DNA interactions, as many components in the PCR reaction bind magnesium ions 
including primers, template, PCR products and dNTPs. DNTPs quantitatively bind 
magnesium ions (Cobb and Clarkson, 1994) and, because it is necessary for free 
magnesium ion to serve as an enzyme cofactor in PCR, the total magnesium ion 
concentration must exceed the total dNTP concentration and, subsequently, may 
require optimisation for every PCR. Hence, a magnesium chloride gradient was 
performed (Figure 4.5) to determine the optimum concentration of magnesium ions 
required for successful amplification of the desired product. It can be observed from 
Figure 4.5 that the magnesium chloride concentration which yielded the greatest 
amplification was 2 mM, whereas the original concentration used was 4mM. The gel-
purified VH and VL fragments were linked by splice by overlap extension PCR (SOE-
PCR), whereby the purified fragments are joined by an 18 amino acid glycine-serine 
linker (G4S)4.  This long linker provides sufficient flexibility for the VH and VL 
domains to associate predominantly as scFv monomers, whereas the use of a smaller 
linker may cause multimerisation of the scFvs. 
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Figure 4.5 Optimisation of variable light chain amplification from the synthesised 
cDNA of ‘diclazuril’-sensitised mice. The amplification was performed using Phusion 
polymerase, a magnesium chloride gradient, and standard PCR conditions. Lane 1= 
1kb ladder; Lane 2= 2 mM MgCl2; Lane 3= 4 mM MgCl2 and Lane 4= 8 mM MgCl2. 
 
4.2.5 Murine SOE-PCR of variable heavy and light chains 
The sense and reverse extension primers used in this SOE-PCR recognise the 
sequence tails that were generated in the previous amplifications of the VH and VL 
domain. A longer extension time is used here to favour the generation of a full length 
800bp product. An overlap SOE product appeared to be amplified as shown in Figure 
4.6, but the product was amplifying at 550bp instead of the desired 800bp. 
Optimisation of the SOE-PCR was required for a clean amplification to occur without 
any non-specific overlap products being generated.  
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Figure 4.6 Splice by Overlap Extension-PCR of the amplified VH and VL chain genes 
from the synthesised cDNA of ‘diclazuril’-sensitised mice. This primary amplification 
check employed standard conditions for murine-derived variable domain overlap 
amplification, consisting of a 560C annealing temperature and Phusion high fidelity 
polymerase. Lane 1= 1kb Ladder; Lane 2= SOE amplification and Lane 3= 1kb 
Ladder. 
  
A magnesium chloride gradient was the first optimisation step undertaken. It can be 
observed from Figure 4.7 that no specific product was amplified when the 
magnesium chloride concentration was varied. The suggested annealing temperature 
for murine derived SOE-scFv products (as outlined in Barbas et al., 2004) to use for 
this amplification was 56oC. The next step taken to optimise the amplification of the 
desired product was to vary this annealing temperature. 
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Figure 4.7 Optimisation of the anti-diclazuril scFv SOE product amplification using 
a magnesium chloride gradient, Phusion polymerase and a 560C annealing 
temperature. Lane 1= 1kb ladder; Lane 2= 2 mM MgCl2; Lane 3= 4 mM MgCl2; 
Lane 4= 8 mM MgCl2  and Lane 5= 1kb ladder. 
 
The melting temperature (Tm) of the primer-template pairs is affected differentially by 
the individual buffer components and also the primer and template concentrations. 
Generally, any calculated Tm value is regarded as an approximation. Several 
reactions, run at temperature increments above and below the calculated Tm, will give 
a good approximation of the optimum annealing temperature for a given set of 
reaction conditions (Roux, 1995). Annealing temperature optimisation was carried out 
by performing the SOE-PCR at a range of different annealing temperatures. During 
the annealing temperature optimisation a product was amplified, which is shown in 
Lane 4, in Figure 4.8. However, this product was not at the desired 800bp range for 
the SOE product. Instead it was lower, at approximately 200bp. 
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Figure 4.8 Optimisation of the diclazuril scFv SOE product amplification using 
different annealing temperatures. Standard PCR conditions, Phusion polymerase and 
4 mM MgCl2 were used. Lane 1= 1kb ladder; Lane 2= 520C; Lane 3= 540C; Lane 4= 
580C and Lane 5= 600C. 
 
New PCR reagents were obtained and the template ratio of variable heavy: variable 
light chain constructs was subsequently optimised. The optimal template ratio of 
variable heavy: variable light chain constructs was investigated by performing the 
SOE-PCR under ratios of; 1: 2 (variable heavy: variable light), 2: 1 (variable heavy: 
variable light), 1: 3 (variable heavy: variable light), and 3: 1 (variable heavy: variable 
light). The PCR products from each of these reactions were resolved on a gel, as 
shown in Figure 4.9. The DNA smears present on the resolved gel may be caused by 
the increased number of PCR cycles, which were used to favour the amplification of 
the full length 800bp product. The ratio of three times the concentration of light: 
heavy chain produced a weak band at the desired 800bp range. 
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Figure 4.9 Optimisation of the diclazuril scFv SOE product amplification using 
different ratios of variable heavy: variable light chains. Standard PCR conditions 
were used as previously outlined. Lane 1= 1kb ladder; Lane 2= 1:2  
(variable heavy: variable light); Lane 3= 2:1 (variable heavy: variable light); Lane 
4= 1:3 (variable heavy: variable light); Lane 5= 3:1 (variable heavy: variable light) 
and Lane 6= 1kb ladder. 
 
Using the optimal concentration ratio of variable heavy: variable light chains and new 
primers, a PCR was performed with a magnesium chloride gradient. The PCR 
products were resolved on the gel as shown in Figure 4.10. It can be observed that no 
PCR product was amplified after performing the SOE-PCR, using the optimised 
template ratio, the recommended annealing temperature, new PCR primers and 
varying the magnesium ion concentration. 
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Figure 4.10 Anti-diclazuril scFv SOE product amplification using the optimised 
template ratio of 3:1 VH: VK, an annealing temperature of 56oC, new primers, 
Phusion polymerase and a magnesium chloride gradient. Lane 1= 1kb ladder; Lane 
2= 2 mM MgCl2; Lane 3= 4 mM MgCl2; Lane 4= 6 mM MgCl2; Lane 5= 8 mM 
MgCl2 and Lane 6= 1kb ladder. 
 
The last variable to optimise was the selected polymerase. Five different polymerases, 
Go-TaqTM, PhusionTM, AccuzymeTM, BioTaqTM and Platinum TaqTM were used under 
standard amplification conditions of a 560C annealing temperature with 4 mM MgCl2. 
The products of these amplifications were resolved on an agarose gel as shown in 
Figure 4.11. Phusion was the only polymerase that appeared to amplify the desired 
800bp SOE product (Lane 5). However, it can be observed that DNA smearing was 
still occurring when the product was resolved on a gel.  
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Figure 4.11 Anti-diclazuril scFv SOE product amplification with polymerase 
optimisation. The product was amplified using the optimised template ratio of 3:1 
VH: VK, new primers, 4 mM MgCl2 and a panel of polymerases. Lane 1= 1kb ladder; 
Lane 2= BioTaqTM polymerase; Lane 3= AccuzymeTM polymerase; Lane 4= 
PlatinumTM polymerase; Lane 5= PhusionTM polymerase; Lane 6= GoTaqTM 
polymerase and Lane 7= 1kb ladder. 
 
The full-length SOE product was proving too difficult to optimise with the purified 
gene fragments. Hence, it was decided to repeat the cDNA synthesis from the RNA 
preparation and amplify the variable gene regions again. It can be observed in Figure 
4.12 that, even when using the re-synthesised cDNA, the amplification of the 800bp 
product is still very weak. This is because the annealing of both variable regions is not 
occurring efficiently. The large band observed between 400-500bp corresponds to 
both of the variable chain genes which have not annealed. 
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Figure 4.12 Anti-diclazuril scFv SOE amplification using variable heavy and 
variable light chain domains amplified from the re-synthesised cDNA preparation. 
The SOE-PCR was amplified using standard amplification conditions. Lane 1= 1kb 
ladder; Lane 2= SOE amplification using Phusion polymerase; Lane 3= SOE 
amplification using GoTaq  polymerase and Lane 4= 1 kb Ladder. 
 
Previous experience in the laboratory (data not shown) has proved that DreamTaqTM 
polymerase worked efficiently when no other polymerase would work. The 
DreamTaqTM product claims that their proprietary formulation of the DreamTaq TM 
buffer is optimised for robust performance in PCR, subsequently minimising any 
extensive optimisation stages. Therefore, DreamTaqTM polymerase (Fermentas) was 
employed to determine if the amplification of the SOE product could be enhanced. 
When DreamTaqTM polymerase was used with a standard annealing temperature of 
560C, and 8 mM MgCl2, the desired 800bp product was efficiently produced, as shown 
in Lane 4 in Figure 4.13.  
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Figure 4.13 Anti-diclazuril scFv SOE product amplification, using DreamTaqTM 
polymerase, and variable chain genes amplified from the re-synthesised cDNA 
preparation. The SOE-PCR was performed under standard amplification conditions 
incorporating a magnesium chloride gradient. Lane 1= 1kb ladder; Lane 2= 2 mM 
MgCl2; Lane 3= 4 mM MgCl2; Lane 4= 8 mM MgCl2 and Lane 5= 1kb ladder. 
 
4.2.6 Library construction and subsequent enrichment via biopanning 
After large-scale amplification of the 800bp product, it was gel-purified, ethanol 
precipitated, quantified and digested using Sfi1 restriction enzyme as described in 
Section 2.13.8.1. The digested overlap product and vector DNA were then purified 
from a 1% (w/v) and 0.6% (w/v) agarose gel, respectively. The purified SOE product 
and vector were concentrated via ethanol precipitation and quantified using the 
Nanodrop ND-1000. Following quantification, the SOE product was then cloned into 
the pComb3XSS phage display vector using the restriction enzyme SfiI. The 
successfully ligated product, as shown in Figure 4.14 was transformed into 
electrocompetent E. coli cells by electroporation using a Gene Pulser™ apparatus. 
Several methods exist for the introduction of DNA into a bacterial host. One 
commonly used method is the chemical transformation or ‘heat-shock’ technique, 
which may be employed when high efficiencies are not essential. In the case of 
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diverse library building when high transformation efficiencies are required, a method 
such as electroporation is favourable (Dower et al., 1988). The transformed mouse 
anti-diclazuril scFv library produced had a size of 1.26 x 107 cfu/mL.  Barbas et al. 
(2004) suggest that for antibody libraries derived from immune animals, reasonable 
library sizes are in the range of 107 to 108 transformants. This library would generally 
be classed as medium in size, as highly diverse phage libraries with up to 1011 
transformants have previously been reported (Sblattero and Bradbury, 2000; Lloyd et 
al., 2009). However, high affinity antibodies specific for environmental contaminants 
have been isolated from libraries as small as 106 library transformants (Shaw et al., 
2008). The murine-derived diclazuril-scFv library was then subjected to phage display 
biopanning against an immobilised ‘diclazuril’-BTG conjugate. 
 
 
. 
Figure 4.14 Analysis of the ligation reaction product of the Sfi1-digested murine-
derived SOE product and the Sfi1-digested pComb3XSS phage display vector. Lane 
1= 1kb ladder; Lane 2= digested and purified SOE product at 800bp; Lane 3= 
digested and purified double-cut pComb3XSS vector at 3300bp; Lane 4= ligated SOE 
and vector at approximately 4100bp and Lane 5= 1kb ladder. 
 
 
 1       2        3        4         5 
  1       2        3        4         5 
1kb ladder 
designation 
3000bp  
800bp  
5000bp  
4000bp  
 160 
4.2.6.1 Selection of -specific phage-scFv particles by biopanning 
Four rounds of affinity selection through biopanning were performed on ‘diclazuril’-
BTG-coated immunotubes. Enrichment of the library was facilitated by altering the 
stringency of each consecutive panning step. This was achieved by increasing the 
number of wash steps and decreasing the concentration of immobilised antigen on the 
immunotube. The panning conditions are outline in Table 4.0.  
 
Table 4.0 Panning conditions employed for each round of selection of the mouse anti-
diclazuril scFv library. Phage input and output titres over the 4 rounds of biopanning 
are reported with each round of biopanning varying in conditions and stringency. 
 
Panning 
round 
‘Diclazuril’ 
coating 
concentration 
Washing steps Input titres 
cfu/ mL 
Output titres 
Cfu/ mL 
1 100 μg/mL 3 X PBST 3 X PBS 7.3 x 1011 3.4 x 106 
2 50 μg/mL 5 X PBST 5 X PBS 1.2 x 10 12 4.8 x 107 
3 25 μg/mL 7 X PBST 7 X PBS 6.9 x 1011 2.6 x 106 
4 5 μg/mL 10 X PBST 10 X PBS 1.0 x 1012 4.3 x 107 
  
The precipitated input phage from each round of panning was incorporated into a 
polyclonal phage ELISA to test for enrichment against the ‘diclazuril’-BTG 
conjugate. Successful enrichment was signified by an increase in absorbance signal 
after incubating phage with the immobilised ‘diclazuril’ conjugate and detecting 
bound phage with a HRP-labelled anti-M13 secondary antibody. This can be observed 
in Figure 4.15. A competitive polyclonal phage ELISA was also performed to ensure 
diclazuril-specific scFv-displaying phage were present (Figure 4.16).   
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Figure 4.15 Polyclonal phage ELISA screening for anti-diclazuril scFv displayed on 
phage, following four rounds of panning. Phage pools obtained after each round of 
panning were tested for binding to the ‘diclazuril’-HSA conjugate by ELISA. BTG and 
HSA were also coated on an ELISA plate as negative controls. The phage pool from 
round 4 was added to the BTG/HSA wells to determine if the phage was non-
specifically binding to the conjugate proteins. The scFv-displaying phage were 
detected using 500 ng/mL of a HRP-conjugated anti-M13 antibody and the 
absorbance was read at 450 nm using a Tecan Safire™ plate reader following a 20 
minute incubation with TMB substrate. The sharp increase in absorbance from round 
2 onwards suggested the presence of diclazuril-specific scFv-harbouring phage 
within the panned library.  
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A competitive phage ELISA (Figure 4.16) was performed to determine the presence 
of diclazuril-specific scFv in each of the phage pools. Phage from each round was 
incubated with a high concentration (20 μg/mL) of free diclazuril. This phage-mixture 
was then incubated on a ‘diclazuril’-HSA-coated ELISA plate. The free diclazuril 
would displace any diclazuril-binding phage present, and a low signal would be 
expected. This was directly compared to phage incubated on the ‘diclazuril’-HSA 
coated plate, without any competing analyte present. It can be observed in Figure 
4.16 that no significant displacement of phage occurred from any round of 
biopanning. This suggests that apparent phage binding in the polyclonal ELISA were 
binding non-specifically to the carrier protein or linker region of the conjugate. This 
indicated that no phage-displaying scFv were diclazuril-specific. 
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Figure 4.16 Competitive phage ELISA, analysing the phage pools from rounds 2, 3 
and 4 of panning, for binding to free diclazuril. Phage from each round were 
incubated with an equal volume of a high concentration (20 μg/mL) of free diclazuril. 
This was directly compared to phage from each round incubated with an equal 
volume of PBS. The phage and free diclazuril mixtures were then added to a 
‘diclazuril’-HSA coated Nunc MaxiSorp 96-well ELISA plate, whereby free and 
immobilised diclazuril compete for binding to the scFvs. Diclazuril-binding phage 
were displaced and bound phage were detected by the addition of a HRP-labelled 
anti-M13 secondary antibody. 
 
To determine whether any diclazuril-binding phage were present, even in low copy 
number, the library was screened by solubly expressing randomly selected scFv. ScFv 
are solubly expressed by infection of the phage pool into a non-suppressor E. coli 
strain as described in Section 2.13.17. The phage display vector Pcomb3XSS contains 
an amber stop codon (TAG) between the scFv and the gene III of the phage. When the 
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phage are infected into a non-suppressor E. coli strain which reads the amber stop 
codon, it facilitates the soluble expression of scFv particles. However, it has been 
noted that native scFv expression can be achieved without infection into a non-
suppressor strain. Even in suppressor strains such as XL1-Blue, suppression is only 50 
% and, after the addition of IPTG, adequate amounts of scFv can be produced (Marks 
and Bradbury, 2004). 
Phage from rounds three and four of selection were infected into Top10F cells for 
soluble expression of scFv. Ninety-six clones were picked from each round and 
expressed via IPTG induction. The scFvs were harvested from the cells by performing 
a freeze-thaw procedure for cell lysis. The lysate was then screened for anti-diclazuril 
scFv by performing a direct ELISA (Figures 4.17 and 4.18). ‘Diclazuril’-HSA was 
coated on an ELISA plate, and the plate was blocked by the addition of an appropriate 
blocking agent. Bound scFv was then detected using a commercial HRP-labelled anti-
HA antibody (Sigma). Figures 4.17 and 4.18 show the binding of individually 
selected scFv fragments to the ‘diclazuril’-HSA conjugate from rounds three and four 
of panning.  
Eleven of the clones selected were taken for further characterisation. Each clone was 
expressed in 5 mL small-scale cultures. The scFvs were grown overnight and 
expression was induced by the addition of IPTG. The eleven expressed clones were 
titred on a ‘diclazuril’-HSA-coated and blocked ELISA plate, and bound scFv was 
detected by the addition of a HRP-labelled anti-HA secondary antibody. However, 
none of these scFv exhibited any binding towards diclazuril in a direct ELISA format 
(data not shown). The polyclonal ELISA results suggested the presence of anti-
diclazuril scFv, yet the monoclonal ELISA results suggest no diclazuril-binding scFv 
were present after four rounds of selection. The phage used for the polyclonal ELISA 
was possibly too concentrated and a significant amount of non-specific binding may 
have occurred, leading to a false-positive result. In a library of 107 clones, the 
incidence of diclazuril-binding clones should be far greater than eleven, after four 
rounds of affinity selection. This may indicate that the library was not sufficiently 
diverse initially, and many of the clones analysed were multiple copies of the same 
clone. It may also indicate that the panning conditions at the start of the selection 
process were too stringent and did not allow for enrichment of all of the clones in the 
library, hence library diversity was lost too soon.   
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Figure 4.17 Monoclonal ELISA with randomly selected clones from round three of 
panning. The clones were solubly expressed in Top10F cells. Nunc MaxiSorp ELISA 
plates were coated with 1 μg/mL of ‘diclazuril’-HSA and blocked with an appropriate 
blocking agent. ScFv were detected using a HRP-labelled anti-HA antibody. Six of 
these clones were grown overnight in 5 mL cultures for further characterisation 
studies. 
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Figure 4.18 Monoclonal ELISA to select for anti-diclazuril scFv from randomly 
selected clones in the fourth round of biopanning. The clones were solubly expressed 
in Top10F cells. Nunc MaxiSorp ELISA plates were coated with 1μg/mL of 
‘diclazuril’-HSA and blocked with an appropriate blocking agent. ScFv were detected 
using a HRP-labelled anti-HA antibody. Five of these clones were grown overnight in 
5 mL cultures for further characterisation studies. 
 
It was decided to decrease the stringency of the panning, by increasing the initial 
antigen concentration, yet keeping the number of washes the same. This method does 
not involve selection by ‘off-rate’. It relies on a balance of both ‘off-’ and ‘on-rate’ 
selection by antigen reduction. If high affinity binders were solely required, they 
could be selected afterwards via antigen-challenge. Biopanning was repeated again 
using the conditions shown in Table 4.1. 
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Table 4.1 Panning conditions employed for each round of the repeated selection for 
the mouse anti-diclazuril scFv library. Phage input and output titres over the 4 
rounds of biopanning are shown, with each round of biopanning varying in conditions 
and stringency. 
 
Panning 
round 
Diclazuril 
coating 
concentration 
Washing steps Input titres 
cfu/ mL 
Output titres 
cfu/ mL 
1 200 μg/mL 3 X PBST 3 X PBS 4.4 x 1011 5.3 x 105 
2 10 μg/mL 3 X PBST 3 X PBS 2.1 x 10 11 1.9 x 105 
3 50 μg/mL 3 X PBST 3 X PBS 1.6 x 1010 2.6 x 105 
4 10 μg/mL 3 X PBST 3 X PBS 2.4 x 1011 6.7 x 105 
 
The results of the polyclonal ELISA, after repeating the biopanning selection process, 
indicate a very low number of phage binding to the ‘diclazuril’-conjugate (Figure 
4.19). These results suggest that little or no phage are displaying diclazuril-specific 
scFv. To confirm this, a monoclonal ELISA was performed on randomly selected 
individual clones from rounds three and four. This is illustrated in Figures 4.20 and 
4.21. 
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Figure 4.19 Polyclonal phage ELISA screening for anti-diclazuril scFv displayed on 
phage, following four rounds of the repeated panning procedure. Phage pools 
obtained after each round of panning were tested for binding to ‘diclazuril’-HSA 
conjugate by ELISA. BTG and HSA were also coated on a Nunc MaxiSorp ELISA 
plate as negative controls. The phage pool from round 4 was added to the BTG/HSA 
wells to determine if the phage were non-specifically binding to the conjugate 
proteins. The scFv-displaying phage were detected using 500 ng/mL of a HRP-
conjugated anti-M13 antibody and the absorbance was read at 450 nm using a Tecan 
Safire™ plate reader following a 20 minute incubation with TMB substrate. No 
variation in absorbance was observed over any of the biopanning rounds. 
 
The monoclonal soluble-phage ELISA from the repeated biopanning selection 
confirmed that no expression of diclazuril-specific scFv had occurred (Figures 4.20 
and 4.21). No clones exhibited significant binding to the ‘diclazuril’-conjugate after 
Phage outputs rounds 
1-4 
Specifically binding to 
immobilised diclazuril 
BTG/HSA 
Phage non-specifically 
binding to immobilised 
BTG/HSA  
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the repeated bio-panning selection. The absorbance of the monoclonal ELISAs did not 
reach more than approximately 0.23 at 450nm, which would generally be considered 
as background in most assays under these conditions. 
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Figure 4.20 Monoclonal ELISA to select for anti-diclazuril scFvs from randomly 
selected clones in round three of the repeated biopanning selection procedure. The 
clones were solubly expressed in Top10F cells. MaxiSorp 96-well ELISA plates were 
coated with 1 μg/mL of ‘diclazuril’-HSA and blocked with an appropriate blocking 
agent. ScFv were detected using a HRP-labelled anti-HA antibody.  
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Figure 4.21 Monoclonal ELISA to select for anti-diclazuril scFvs from randomly 
selected clones in round four of the repeated biopanning selection procedure. The 
clones were solubly expressed in Top10F cells. Nunc MaxiSorp 96-well ELISA plates 
were coated with 1 μg/mL of ‘diclazuril’-HSA and blocked with an appropriate 
blocking agent. ScFv were detected using a HRP-labelled anti-HA antibody.  
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4.3 Discussion and Conclusion 
This chapter focuses on the development of a recombinant antibody library to isolate 
diclazuril-specific scFvs, for the subsequent incorporation into a validated diclazuril-
detection assay. The first step involved evoking an immune response to diclazuril in a 
chicken. A chicken was administered with a diclazuril-derived immunogen 
(‘diclazuril’-HSA) to stimulate the production of antibodies towards diclazuril. 
However, after several subsequent boosts, the avian serum was analysed for 
diclazuril-binding antibodies but no response was observed. It should be noted that 
the chicken was responding to a halofuginone immunogen that was administered at 
the same time as the ‘diclazuril’ immunogen, hence the problem was believed to be 
with the ‘diclazuril’ conjugate. A direct ELISA was performed to determine whether 
the ‘diclazuril’ entity was still present on the conjugate, or if the ‘diclazuril’-HSA 
conjugate was unstable. A commercial diclazuril-binding antibody (Randox 
Laboratories) was used to detect ‘diclazuril’ on the conjugates. The results indicated 
that the ‘diclazuril’ entity was still present on the conjugate, and that the conjugate 
was working adequately. 
Three mice were immunised with the ‘diclazuril’-HSA conjugate and a full 
immunisation schedule followed. After five subsequent boosts, sera isolated from tail 
bleeds of the mice was analysed by ELISA for the presence of diclazuril-binding 
antibodies. The presence of an adequate titre of anti-diclazuril antibodies was 
confirmed and the mice were sacrificed. RNA isolated from the spleens of the mice 
was converted to cDNA and the scFv library was constructed using PCR assembly 
methods. Following extensive optimisation attempts the scFv was successfully 
assembled. However, the level of expression of this full-length scFv product was very 
poor. Hence, it was decided to prepare fresh cDNA once again. Using the re-
synthesised cDNA preparation, the full length scFv product was re-assembled 
following further optimisation steps. This was produced on a large-scale and ligated 
into the pComb3XSS vector for the display of diclazuril-specific antibodies on the 
surface of phage. Enrichment of the library was performed by affinity selection 
against a ‘diclazuril’-BTG conjugate. The polyclonal ELISA after biopanning 
indicated the presence of ‘diclazuril’-specific phage in the final round of panning. 
This round was solubly expressed and it was discovered that no diclazuril-binding 
scFv were present in the library. It was decided that the library would be screened 
once more, using less stringent conditions. This method would allow antibodies with 
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very low affinities for diclazuril the opportunity to be enriched during the selection 
process. This second attempt was also unsuccessful in isolating anti-diclazuril scFvs.  
The amplification problems that arose during the construction of the library led to the 
opinion that inefficient variable gene assembly could potentially be responsible for 
the production of a poor quality scFv library. During murine immunoglobulin gene 
assembly the heavy chain is generated by a combination of one of several hundred VH 
genes with one of about thirty D segments and one of six J segments (Barbas et al., 
2004). Due to the copious amounts of variable genes involved, the generation of a 
murine antibody repertoire requires many V-specific oligonucleotide primers (Barbas 
et al., 2004). This in turn, can require extensive optimisation to amplify the various 
heavy chain sequences and capture a good representation of the repertoire (Barbas et 
al., 2004). The incorporation of all the appropriate heavy and light chain variable 
regions into the library using the Barbas series of primers (Barbas et al., 2004) would 
involve amplification using a total of 166 separate primer combinations. To 
circumvent this copious workload, a ‘master-mix’ of primers was used. However, the 
use of this master mix has the potential to cause a loss of diversity from the immune 
repertoire. Certain primer combinations may amplify efficiently, whereas, other 
combinations may need thorough optimisation. This occurrence may lead to bias 
towards abundant genes over more conserved genes, which may be integral to the 
development of a highly specific scFv library. Furthermore, if the overlap PCR 
product of the variable heavy and variable light chains is not highly efficient, 
sequence frame shifts may occur resulting in poor quality of the library 
(Koohapitagtam et al., 2010). These factors may have contributed to the production of 
an inferior scFv library, with minimal specificity for diclazuril. 
 
4.4 Future Work 
Hayhurst and colleagues (2003) previously noted the disadvantages of using murine 
scFvs. These include poor expression levels with low soluble product, cell culture 
arrest and lysis, misfolding of expressed antibody and protein aggregation. It is 
recommended that if the construction of a recombinant antibody library for diclazuril 
is required, immunisations should be carried out using commercial conjugates and 
avian immune models. The concern with conjugates produced ‘in-house’ is that no 
definitive method is in place for their characterisation. Once the exact quality of the 
conjugate is defined, chicken immunisations can proceed for the development of a 
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recombinant antibody for diclazuril. (The advantages of avian models are discussed in 
greater detail in Chapter 3.)  A commercial anti-diclazuril antibody was obtained from 
Randox Ltd., which was incorporated into a multi-analyte detection assay alongside 
an anti-halofuginone and an anti-toltrazuril antibody described in detail in Section 
5.8.3. Future library development for the construction and isolation of an anti-
diclazuril scFv would prove highly advantageous in a range of applications for the 
detection of diclazuril. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Polyclonal antibody-based assays for the  
detection of toltrazuril 
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Chapter outline 
The aim of this work was to develop a highly sensitive immunoassay for the detection 
of the anti-protozoan drug, toltrazuril. This chapter describes the generation of 
toltrazuril-specific polyclonal antibodies and optimisation of their subsequent use in 
an ELISA. Trifluoraminoether (TFME), an antigenic mimic for toltrazuril, was 
coupled to bovine serum albumin (BSA) and used to immunise rabbits, for the 
production of polyclonal antibodies. Concurrently, a commercially obtained 
toltrazuril-BSA conjugate was also used for immunisation. Polyclonal antibodies 
specific to toltrazuril were purified from the rabbit sera and employed in an 
immunoassay for the detection of toltrazuril. The performance of the antibody 
preparation was assessed by competitive ELISA, and a validated assay was 
developed. The antibody was subsequently incorporated into Biacore-based and 
lateral flow-based assay formats. The efficiency of all three methods was directly 
compared. The development of a multi-analyte lateral-flow detection method for the 
simultaneous detection of halofuginone, diclazuril, and toltrazuril is also described. 
  
5.1 Introduction 
The quality of an immunoassay is primarily dependant on the quality of the 
incorporated antibody. Polyclonal antibody production was the method of choice for 
the generation of toltrazuril-specific antibodies. In contrast to the expense and 
expertise required for traditional hybridoma and recombinant antibody production, 
polyclonal antibodies can be raised quickly and at relatively low cost. Animals such 
as rabbits, guinea pigs, goats, sheep, donkeys and fowl are frequently used for the 
generation of polyclonal antisera (Hanly et al., 1995).  
One attractive feature of the immune system of rabbits, for the generation of 
antibodies, is the utilisation of both gene conversion and somatic hypermutation to 
diversify rearranged heavy and light chain genes. The antibody diversity generated by 
VHDJH rearrangements in rabbits is more limited than in mice and humans. This is 
due to the fact that of about 50 functional VH gene segments, only one, VH1, is 
predominantly used. In contrast to the limited VHDJH rearrangements, VκJκ 
rearrangements in rabbits are much more diverse and, thus, the resulting rearranged 
kappa light chain genes may compensate for the limited diversity of rearranged heavy 
chain genes (Popkov et al., 2003). Rabbits also have two kappa light chain isotypes, 
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K1 and K2, compared to only one in mice or humans. Further diversity to the immune 
repertoire may also be contributed from the kappa light chain regions due to the 
unusual germline VK-encoded variability in the length of the complementarity-
determining region 3. Hence, the kappa light chain appears to be a major contributor 
towards the generation of the antibody diversity in the rabbit immune repertoire 
(Popkov et al., 2003).  
The first steps in polyclonal antibody production for haptens are to select the target 
molecule, to identify the appropriate functional groups for conjugation to a carrier 
protein, which can ensure antibody recognition of key structural elements, and then to 
design the hapten-protein conjugation strategy for suitable immunisation. Previously, 
Connolly and colleagues (Connolly et al., 2002) identified an antigenic mimic which 
shared a common substructure for both toltrazuril and its metabolite, ponazuril. Using 
ChemOffice™ software they were able to search the database for drugs that contain a 
similar sub-structure to ponazuril. Trifluoraminoether was identified as having 
structural elements common to toltrazuril and ponazuril structures. In addition, it 
possessed a free amine group suitable for conjugation to a carrier protein. After 
immunising six rabbits with this antigenic mimic, the most sensitive polyclonal 
antibody produced was identified and characterised. Following 13 immunisations of 
the rabbit designated ‘R609’ with a TFME conjugate, 86% displacement of antibody 
occurred in a competitive ELISA. This occurred when the antibody was incubated 
with 50 ng/mL of ponazuril. The IC50 of this ‘R609’ antibody was 18 ng/mL. The 
sensitivity of these toltrazuril-specific antibodies encouraged the production of 
toltrazuril-specific antibodies in the same manner. 
The TFME hapten, with a molecular weight of only 299.31 Da, is too small to induce 
an immune response and, therefore, requires conjugation to a carrier protein to render 
it immunogenic. TFME was conjugated to BSA via diazo-coupling (Figure 5.0).  
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Reaction mechanism for the preparation of the diazonium salt of TFAE-NH2 
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Figure 5.0 Reaction mechanism for the preparation of trifluoraminoether for 
subsequent conjugation to a carrier protein (Section 2.14.1). Trifluoraminoether in 
sulphuric acid (H+) is treated with sodium nitrite, to form a diazotized derivative. This 
derivative can then be used for conjugation to carrier proteins (Szele and Zollinger, 
1983). Mechanism was modified from Wieder, (clem.mscd.edu/~wiederm/oc2ppt 
/aminesphenols.ppt, 2004).  
 
Trifluoroaminoether 
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A commercial toltrazuril-BSA conjugate was obtained from Randox Laboratories. 
Researchers at Randox had discovered a method that allowed the conjugation of 
toltrazuril directly to a carrier protein. This was performed by linking the carrier 
protein to one of the nitrogen rings on the right-hand side of toltrazuril, away from the 
trifluoromethyl group. This conjugate was purchased and subsequently used for 
immunisations.  
Rabbit immunisations were performed externally by the CER Groupe (Belgium). The 
specific antibody titre of the serum received from CER Groupe was estimated by 
direct ELISA.  
 
5.2 Results 
5.2.1 Serum titres of New Zealand white rabbits (Numbers 71-80)  
Following an extensive immunisation regime, an antibody serum titre was performed 
from the final bleeds obtained from the five TFME-BSA immunised rabbits and the 
five toltrazuril-BSA immunised rabbits. As illustrated in Figure 5.1, serum from each 
of the immunised rabbits was diluted (1/50 to 1/156,250) in PBS containing 1% (w/v) 
BSA and analysed for binding to the toltrazuril-BSA conjugate. Bound antibody was 
detected by the addition of a HRP-labelled anti-rabbit IgG secondary antibody. Except 
for three rabbits, antibodies from all of the other polyclonal sera displayed binding to 
the immobilised toltrazuril conjugate. 
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Figure 5.1 Antibody titre of ten rabbits immunised with TLZ-BSA (71-75) and TFME-
BSA (76-80) conjugates. The antibody response for toltrazuril from the sera was 
determined by performing a direct ELISA on Nunc MaxiSorp plates coated with TLZ-
BSA. The immunoplates were blocked with Milk Marvel and serial dilutions of the 
serum from each rabbit were added to the plate. Bound polyclonal antibody was 
detected using a HRP-labelled anti-rabbit IgG secondary antibody. 
 
5.2.2 Competitive ELISA using serum from toltrazuril/trifluoraminoether 
immunised rabbits 
A competitive ELISA was performed with ponazuril concentrations of 10 µg/mL, 2 
µg/mL, 400 ng/mL, 80 ng/mL, 16 ng/mL and 0 ng/mL. It can be observed in Figure 
5.2 that only three polyclonal sera batches, namely 72, 73 and 75, displayed binding 
to free ponazuril. These three sera batches were taken from toltrazuril-BSA 
immunised rabbits 
Sera from rabbits 
immunised with Toltrazuril-
BSA (71-75) and TFME-
BSA (76-80) 
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Competitive ELISA for 7 serum samples from TLZ-BSA and TFME-
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Figure 5.2 Competitive ELISA analysing rabbit sera for toltrazuril-specific 
antibodies. The sera from 7 rabbits, which showed specific binding to the toltrazuril-
BSA conjugate in a direct ELISA, were screened in a competitive assay format. One 
µg/mL TLZ-BSA was coated on the surface of a Nunc MaxiSorp ELISA plate.  The 
sera were incubated with final concentrations of ponazuril at 10 µg/mL, 2 µg/mL, 400 
ng/mL, 80 ng/mL, 16 ng/mL and zero ng/mL.  The dilution of sera used in the 
competitive ELISA was estimated from the direct ELISA (Figure 5.1). Rabbit sera 
‘71’ and ‘75’ were used at a final 1/250 dilution, sera ‘72’ and ‘73’ at a 1/1,000 
dilution and sera ‘ 76’, ‘78’ and ‘79’ at a 1/5,000 dilution. The results are shown as 
A/A0, where the absorbance values of the evaluated samples (A), are normalised by 
expressing them as a function of the blank standard (A0). 
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5.2.3 Competitive ELISA analysis for toltrazuril detection 
Another competitive ELISA was performed using a wider concentration range of 
ponazuril, using the three sera samples exhibiting toltrazuril-binding. These sera were 
isolated from rabbits designated ‘72’, ‘73’ and ‘75’ (Figure 5.3). The three sera 
samples were pooled and purified by Protein G affinity chromatography. 
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Figure 5.3 Competitive ELISA using toltrazuril-specific polyclonal sera. TLZ-BSA 
was coated on a Nunc MaxiSorp ELISA plate. Three different serum batches, 
exhibiting displacement by free ponazuril (as determined in Figure 5.2), were 
analysed in a broad range competitive assay. Serum ‘75’ was used at a final 1/250 
dilution, and ‘72’ and ‘73’ at a 1/1,000 dilution. The antibodies were incubated with 
final concentrations of ponazuril at 10 µg/mL, 3.3 µg/mL, 1.1 µg/mL, 370 ng/mL, 123 
ng/mL, 41 ng/mL, 13.7 ng/mL, 4.5 ng/mL, 1.5 ng/mL and 0 ng/mL. The results are 
shown as A/A0, where the absorbance values of the evaluated samples (A), are 
normalised by expressing them as a function of the blank standard (A0). 
Normalised absorbance of three 
replicate competitive assays, for 
sera 72, 73 and 75 
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5.2.4 Purification of polyclonal antibodies from rabbit sera by Protein G affinity 
chromatography 
Sera from rabbits designated ‘72’, ‘73’ and ‘75’ were pooled. All three batches 
isolated from the rabbits were competitive with free ponazuril. Antibodies were 
purified by immunoaffinity chromatography using protein G-sepharose.  Protein G 
(SpG) from Streptococci groups C and G is a surface IgG binding protein with 
specific affinity for the Fc region. However, it also associates with the constant heavy 
chain (CH1) domain of the antibody binding fragment (Fab) portion through a β-
zipper interaction (Roque et al., 2004).  All eluted fractions, obtained from the Protein 
G column, were analysed by SDS-PAGE. Eluted fractions were approximately 3.2 
mg/mL following concentration. 
 
5.2.5 Characterisation of purified polyclonal antibodies by SDS-PAGE and 
Western Blot analysis 
The level of purity of the antibodies was assessed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). Figure 5.4 shows the resulting gel 
and the increase in the level of purity from the crude serum to the affinity-purified 
fractions. To confirm the presence of rabbit IgG antibody molecules western blotting 
was performed on an SDS gel of purified antibody (Figure 5.5). 
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Figure 5.4 SDS-PAGE analyses on the fractions obtained during protein G affinity 
chromatography purification of polyclonal antibody fractions, from toltrazuril-
specific rabbit serum. Lanes 1 and 7 = Colour Burst molecular weight markers 
(Fermentas); Lane 2 = Serum samples diluted 10-fold in PBS; Lane 3 = ‘Flow-
through’  mixture of 1 and 2 diluted 10-fold after passage of serum through a  protein 
G column; Lane 4 = Wash ‘A’; Lane 5 = Wash ‘B’; Lane 6 = Eluted purified 
antibody pooled fractions used undiluted. Two distinct bands are visible at 
approximately 50 kDa and 25 kDa in the purified fractions, representing the heavy 
and light chains, respectively. 
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Figure 5.5 Western blot analysis of the purified anti-toltrazuril antibodies. Lane 1 = 
Purified anti-toltrazuril polyclonal antibody; Lane 2 = HFG-specific avian scFv used 
as a control and Lane 3 = High Molecular Weight Marker (Sigma). HRP-labelled 
anti-rabbit IgG was used to probe for rabbit antibodies. Two distinct bands are 
visible in Lane 1 at approximately 50 kDa and 25 kDa. These bands indicate the 
heavy and light chains. 
 
5.3 Optimisation of an ELISA for the detection of toltrazuril using the purified 
anti-toltrazuril polyclonal antibody 
Following purification of the polyclonal antibody preparation, its use in a competitive 
immunoassay for the detection of toltrazuril was investigated. In order to maximise 
the performance of the assay, several parameters were varied to determine the optimal 
conditions. These included the coating concentration of the conjugate, the buffer used 
for coating and the concentration of antibody. Once these parameters were 
determined, intra/inter-day assays were performed to establish the reproducibility of 
the assay. 
 
5.3.1 Selection of conjugate coating buffer for the competitive ELISA for 
toltrazuril   
To investigate the optimal pH for coating the TLZ-BSA conjugate onto the Nunc 
MaxiSorp plates, five different coating buffers were employed at five different pH 
levels. The buffers investigated were: 0.1 M acetate buffer, pH 4.8;  0.01 M TBS 
buffer, pH 7.4; 0.01 M TBS buffer, pH 4.2;  0.1 M carbonate buffer, pH 10.3 and 0.01 
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M PBS, pH 7.4. The results are illustrated in Figure 5.6. The results show that the 
amount of antigen bound to the plate was greatest when using PBS at a pH of 7.4, 
TBS at a pH of 7.4, or carbonate buffer at a pH of 10.3. PBS at a pH of 7.4 was 
chosen as the conjugate coating buffer for use in subsequent assays. 
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Figure 5.6 Selection of optimal coating buffer for use in ELISA for detection of 
toltrazuril. One µg/mL of toltrazuril-BSA conjugate was used. Coating buffers tested 
were; acetate buffer, pH 4.8; TBS buffer, pH 7.4; carbonate buffer, pH 10.3; PBS, pH 
7.4 and TBS buffer, pH 4.2. The anti-toltrazuril antibody preparation was serially 
diluted in buffer and added to the coated/blocked wells. Bound polyclonal antibody 
was then detected using HRP-labelled anti-rabbit IgG secondary antibody. 
 
5.3.2 Checkerboard ELISA for the determination of the optimum polyclonal 
antibody dilution and optimum coating concentration for toltrazuril conjugates 
 It was essential to optimise both the coating concentration of the conjugate and the 
optimal dilution of antibody in a competitive ELISA.  Nunc MaxiSorp ELISA plates 
Conjugate 
coating buffer 
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were coated with varying concentrations of the TLZ-BSA conjugate in the optimal 
conjugate coating buffer as previously established. To determine the conjugate 
concentrations which would give the best assay sensitivity, a checkerboard ELISA 
was performed with varying dilutions of the affinity-purified antibodies. The results 
shown in Figure 5.7 indicate that an optimum coating concentration of 2 µg/mL TLZ-
BSA gave the highest absorbance using the most economical conjugate concentration. 
The optimal antibody dilution chosen, was a 1/3,000 dilution. 
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Figure 5.7 Checkerboard ELISA for the determination of the optimal conjugate 
coating concentration and polyclonal antibody dilution for use in a competitive 
ELISA. TLZ-BSA concentrations of 8, 4, 2 and 1 µg/mL were used in a direct ELISA 
with varying dilutions of antibody ranging from 1/25 to 1/ 48,828,125. A 2 µg/mL 
TLZ-BSA concentration and a 1/3,000 dilution of the antibody preparation were 
chosen for use in a competitive assay format. 
 
TLZ-BSA coating 
concentration 
 μg/mL 
 μg/mL 
 μg/mL 
 μg/mL 
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5.3.3 Intra and inter-assay variability studies of the competitive ELISA for 
toltrazuril  
Using the optimised parameters established, a competitive assay (free ponazuril in 
solution competing against immobilised conjugate for binding to the antibody), was 
performed in PBS to determine the range of detection of the ELISA. Standards of 
ponazuril were prepared in 0.01 M PBS, pH 7.4, and were diluted with equal volumes 
of the antibody at a 1/3,000 (final) dilution. The final concentrations of ponazuril 
ranged from 5 μg/mL down to 254 pg/mL. This antibody-ponazuril preparation was 
added to an immunoplate coated with TLZ-BSA in 0.01M PBS, pH 7.4, and blocked 
with 5% (w/v) Milk Marvel. HRP-labelled goat-anti-rabbit IgG was then used to 
detect toltrazuril-bound antibody. The assay format is shown in Figure 5.8 below. 
 
 
 
 
 
Figure 5.8 Assay format used in the competitive ELISA for the detection of toltrazuril. 
TLZ-BSA conjugate was coated on the wells of the plate. Varying concentrations of 
free ponazuril (the primary metabolite of toltrazuril) were incubated with the anti-
toltrazuril antibody preparation. This free antigen-antibody mix was added to the 
toltrazuril-coated immunoplate. The free ponazuril in solution competes with the 
immobilised toltrazuril conjugate for binding to the toltrazuril antibodies. Bound 
antibodies are detected following the addition of a HRP-labelled anti-rabbit IgG. 
Anti-toltrazuril antibody added 
to immunoplate with ponazuril 
Anti-toltrazuril polyclonal antibody 
ponazuril 
Legend: 
 
  = HRP-labelled anti-rabbit IgG   
 
= Colour Development after addition of substrate 
   = Toltrazuril-BSA conjugate    
 
  = Anti-toltrazuril polyclonal antibody preparation                = Free ponazuril    
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Repeatability of an assay is defined as the precision of repeated measurements within 
the same analytical run under the same operating conditions, over a short period of 
time. This is also known as the intra day-assay precision (Mire-Sluis et al., 2004). The 
intra-assay repeatability was calculated by comparing the variation between six 
measurements within the same assay on the same day. The reproducibility of the 
assay was determined by comparing triplicate measurements of the levels of antigen 
within three separate assays. This is also known as the inter-assay precision (Mire-
Sluis et al., 2004). The precision of an analytical method is usually described by 
coefficients of variation (CV) between and within assays (Forkman, 2005). The 
coefficients of variation (CV) for an assay are defined as the standard deviation 
divided by the mean (Forkman, 2005). Hence, to calculate the precision of an assay 
the formula given below is used: 
 
  Precision (%) = CV (%) = (Standard Deviation ÷ Mean) X 100 
            
This formula was employed to determine the precision of the competitive ELISA for 
toltrazuril detection. All calculated CV values for the inter-assay study are shown in 
Table 5.0. The highest intra-day CV was recorded at 17.7%. The highest inter-day 
CVs were calculated at 19%.  
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Table 5.0 Inter-assay co-efficient of variation (CVs), for the detection of toltrazuril in 
PBS, in a competitive ELISA format. Each standard was analysed in triplicate over 
three separate days and the CVs were calculated. 
Ponazuril Conc. 
(pg/mL) 
Inter-day 
(% C.V) 
A/A0  
250,000 10.8 0.1  
125,000 19.0 0.2 
62,500 5.0 0.3 
31,250 11.2 0.3  
15,625 2.9 0.4  
7812 3.4 0.5  
3906 7.7 0.6  
1953 3.6 0.7  
976 7.1 0.7 
488 12.0 1.0  
 
Calibration curves were generated for both the inter/intra-day-assays. Using 
BIAevaluation 4.0.1 software, a four-parameter equation was fitted to the data to 
generate a calibration curve. Figure 5.9 illustrates the calibration curve established 
for the inter-day assay using the anti-toltrazuril polyclonal antibody and free ponazuril 
in concentrations ranging from 500,000 pg/mL down to 254 pg/mL in PBS. Ponazuril 
standards were prepared singly and analysed in triplicate. The mean absorbance (A) 
obtained for each standard between the assays was divided by the absorbance value 
determined when no competitor (free ponazuril) was present (A0). Normalised 
absorbance values (A/A0) were plotted against the logarithm of the ponazuril 
concentration. The limit of detection of this assay, when performed in PBS, was 
calculated as approximately 600 pg/mL, when extrapolated from the calibration curve. 
The red dashed line shown in Figure 5.9 indicates the lowest concentration of 
ponazuril that the antibody can detect. 
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Figure 5.9 Calibration curve for the determination of free ponazuril in solution. 
Ponazuril standards used in the assay were 500,000, 166,667, 555,555, 185,185, 
61,728, 20,576, 6,858, 2,286, 762 and 254 pg/mL.  A plate was coated with 2 µg/mL 
toltrazuril-BSA conjugate and blocked with 5% (w/v) Milk Marvel. The ponazuril 
standards were incubated with the anti-toltrazuril antibody preparation and added to 
the immunoplate. Bound anti-toltrazuril antibody was detected using a HRP-labelled 
goat-anti-rabbit IgG secondary antibody. The data is the result of triplicate 
measurements in three different assays performed over a three day period. 
 
5.3.3.1 Development of an ELISA for the detection of toltrazuril in egg samples 
Organic eggs were spiked with known concentrations of ponazuril ranging from 488 
pg/mL to 2.5 μg/mL. Following the extraction procedure described in Section 2.12, 
the extracted residues were incubated with an equal volume of anti-toltrazuril 
polyclonal antibody on a toltrazuril-BSA-coated ELISA plate. Bound toltrazuril 
antibody was detected following the addition of a HRP-labelled anti-rabbit IgG. The 
Ponazuril concentration (pg/mL) 
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overlaid graphs in Figure 5.10 illustrate the effect that the egg matrix had on the 
calibration curve when directly compared to the curve prepared in PBS. The decrease 
in sensitivity of the assay can be observed by a shift in the calibration curve when the 
assay is performed in extracted egg samples. However, this loss of sensitivity is not 
statistically significant, as when the overall extraction efficiency is calculated, average 
losses of 14 % were incurred. This loss level is below the 20 % loss allowable for an 
efficient extraction procedure by E.U standards. Table 5.1 lists the ponazuril 
concentrations used in the inter-day assay, and the corresponding variability and 
efficiency data calculated for each standard in the assay.  The ‘back calculated 
concentrations’ are extrapolated from the calibration curve for each respective 
absorbance value, determined for the different ponazuril concentrations. This ‘back 
calculated concentration’ is subsequently expressed as a percentage of the actual 
ponazuril concentration to determine the ‘estimated recovery’. Finally the ‘actual 
recovery’ is calculated by expressing the absorbance values obtained from the egg-
extracted calibration curve as a percentage of the non-extracted PBS curve.  
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Table 5.1 Inter-assay co-efficient of variation (CVs) for the detection of free 
ponazuril, from spiked egg samples, using the purified anti-toltrazuril antibody in a 
competitive ELISA format. Each standard was analysed in triplicate over three 
separate days and the CVs were calculated.  
 
Ponazuril 
Conc. 
(pg/mL) 
Inter-
day 
(% 
C.V) 
A/A0 ± S.D Back 
Calculated 
Concentration 
(pg/mL) 
Estimated 
Recovery  
(%) 
Actual 
Recovery 
(%) 
5,000,000 5.9 0.3 3,826,471 77 45 
1,666,667 2.1 0.3  2,193,832 131 69 
555,555 3.8 0.5  559,487 100 92 
185,185 3.7 0.6  180,379 97 91 
61,728 3.1 0.8  55,055 89 91 
20,576 1.9 0.9  20,077 98 92 
6,858 0.9 0.9  8,560 125 97 
2,286 1.4 1.0  4,033 176 96 
762 1.3 1.03 183 24 91 
254 1.3 1.0 126 50 98 
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Figure 5.10 Inter-day calibration curves comparing the determination of free 
ponazuril in both PBS and extracted egg samples. Ponazuril standards used were 
250,000, 125,000, 62,500, 31,250, 156,25, 7812, 3906, 1953, 976 and 488 pg/mL. A 
plate was coated with 2 µg/mL toltrazuril-BSA conjugate and blocked with 5% (w/v) 
Milk Marvel. The ponazuril standards were either extracted from spiked egg samples 
or spiked directly into PBS and incubated with the anti-toltrazuril antibody 
preparation (at the optimal working dilution). Bound anti-toltrazuril antibody was 
detected using a HRP-labelled anti-rabbit IgG secondary antibody. This data is the 
result of triplicate measurements in three different assays performed over a three day 
period. The absorbance readings were normalised whereby the absorbance for each 
ponazuril concentration incubated with antibody (A) was divided by the maximum 
absorbance for each selected antibody without antigen (A0). 
 
 
 
Assay Matrix 
Ponazuril concentration (pg/mL) 
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5.3.4 Determination of analytical limits 
The limit of detection (LOD) is the smallest concentration of an analyte that produces 
a signal which can be significantly distinguished from zero for a given sample matrix 
(Armbruster et al., 1994). This value was determined by selecting the mean 
normalised absorbance minus three standard deviations for the blank standard. When 
extrapolated from Figure 5.10 this was found to be approximately 900 pg/mL. The 
LOD can also be experimentally verified using the precision assay. This is a more 
accurate method to determine the LOD within a smaller range of concentrations. This 
is also known as the CCβ or the detection capability. It involves determining the 
lowest concentration which can be reliably differentiated with 95% confidence from 
the blank standard.  The CCβ determined using this precision assay was confirmed to 
be 900 pg/mL. This was established by analysing 20 positive samples of 
concentrations flanking each side of this concentration.  Twenty samples of 1,200 
pg/mL, 900 pg/mL and 700 pg/mL were assayed in a competitive ELISA format, 
alongside 20 negative blank samples to investigate the accuracy of the assay. It can be 
observed in Figure 5.11 that 900 pg/mL could be distinguished from the blank 
replicates in 100% of the samples. In contrast, 700pg/mL could only be distinguished 
from the blank 55% of the time (11/20). This assay sensitivity is far below the lowest 
allowable E.U. MRL for toltrazuril of 100 µg/kg (corresponding to approximately 100 
ng/mL). Hence, this assay does not need to be modified further to improve sensitivity. 
The assay could now be successfully applied for the detection of toltrazuril in ‘real’ 
food samples. 
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Figure 5.11 Precision assay to experimentally verify the detection capability of the 
toltrazuril ELISA. Twenty replicates of 1,200 pg/mL, 900 pg/mL, and 700 pg/mL 
ponazuril were analysed with twenty blank samples to determine the lowest 
concentration of analyte that could be detected with 95% confidence. This was 
performed in a competitive ELISA format using anti-toltrazuril polyclonal antibodies. 
Bound anti-toltrazuril antibody was detected using a HRP-labelled anti-rabbit IgG 
secondary antibody. 
 
 
 
 
 
 
 
 
 
Free ponazuril 
concentration 
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5.4 Development of a polyclonal antibody-based Biacore assay for the detection 
of toltrazuril 
Using the polyclonal antibody previously described, a surface plasmon resonance-
based assay, using the Biacore 3000TM system, was optimised to detect toltrazuril. 
 
5.4.1 Preconcentration studies for the immobilisation of toltrazuril-BSA onto the 
CM5 sensor chip surface 
Maximizing the electrostatic attractive force between the proteins and the carboxyl 
surface of a CM5 Biacore chip leads to an accumulation of the proteins close to the 
surface. This is also known as preconcentration (Bonroy et al., 2006). 
Preconcentration studies were performed to determine the optimum pH at which the 
electrostatic interactions between the toltrazuril-BSA and a CM5 sensor chip surface 
are most favourable for maximum binding to occur. A broad pH range was 
investigated using buffers with different buffering capacities. The conjugate was 
passed over the activated chip surface in different buffers with pH below the 
isoelectric point (pI) of the protein. Under these conditions, the conjugate acquires a 
positive charge and is effectively preconcentrated onto the negatively charged 
carboxymethyl dextran matrix (Jason-Moller et al., 2006). Figure 5.12 demonstrates 
that the amount of conjugate electrostatically absorbed onto the CM dextran surface is 
dependant on the pH of the buffer. The pH allowing the optimum amount of 
conjugate to be immobilised on the surface was 4.0. This buffer was selected for the 
immobilisation of the conjugate onto the CM5 sensor chip. 
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Figure 5.13 The toltrazuril-BSA conjugate in 10mM solutions of sodium acetate, at 
pH levels of 4.0, 4.2, 4.4, 4.6, and 4.8, was passed over the surface of a CM5 dextran 
chip at a flowrate of 10 μl/minute. The optimal pH for the immobilisation of the 
toltrazuril-BSA conjugate to the CM5 dextran surface was pH 4.0 with the highest 
levels of apparent binding observed. 
 
5.4.2 Production of a CM5 sensor chip surface with directly immobilised 
toltrazuril-BSA  
Toltrazuril-BSA was directly immobilised onto the surface of a CM5 chip, as 
described in Section 2.11.4, by coupling free primary amine groups, such as lysine 
residues, on the conjugate. This immobilisation process can be observed in Figure 
5.14. The carboxymethyl groups on the chip are activated by passing a mixture of 
EDC/NHS over the surface. In the presence of NHS, EDC converts carboxyl groups 
to amine-reactive sulfo-NHS esters. The generated NHS esters react with nucleophiles 
to release the NHS or sulfo-NHS group and to create stable amide and imide bonds 
10mM sodium 
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with primary or secondary amines, such as the free N-terminus and groups in lysine 
side chains of proteins (BSA in this case) (Kalkhof and Sinz, 2008). 
In the last step, the remaining esters are transformed into amides by reaction with 
ethanolamine, essentially ‘capping’ any unreacted sites. A final level of 2,203.9 RU of 
covalently attached toltrazuril-BSA was achieved. 
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Figure 5.14 Sensorgram illustrating the direct coupling of toltrazuril-BSA to a CM5 
sensor chip surface. The surface was activated with an EDC/NHS solution, and the 
toltrazuril-BSA was passed over the activated carboxyl surface. Deactivation of any 
unbound or free functional ester groups was achieved by treating the chip surface 
with ethanolamine-HCl, resulting in the capping of any reactive groups. The surface 
was then regenerated with a solution of NaOH. A final level of 2,204 RU of covalently 
attached toltrazuril-BSA was achieved as illustrated by the red arrow. 
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5.4.3 Binding studies on the directly immobilised toltrazuril-BSA surface. 
Different concentrations of polyclonal anti-toltrazuril antibody ranging from 20 to 100 
μg/mL were prepared in egg matrix (as described in Section 2.12) and tested for 
binding to the surface of the toltrazuril-BSA-immobilised chip. These solutions were 
each injected over the chip for 2 minutes at 10 µL/minute. The specific binding was 
recorded, and the optimal antibody concentration was chosen by comparing response 
units with antibody concentration. It can be observed in Figure 5.15 that the antibody 
concentration of 100 μg/mL was the optimal concentration of antibody for use in 
subsequent assays, with the highest RU observed when analysed for binding in egg 
matrix. This 250 RU level is high enough to be able to distinguish small decreases in 
binding when a competitor is present. 
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Figure 5.15 Overlay sensorgram plot illustrating the binding of the polyclonal anti-
toltrazuril antibody to the immobilised toltrazuril-BSA surface in an egg matrix. 
Concentrations of 20, 40, 60, 80 and 100 μg/mL of anti-toltrazuril antibody were 
passed over the surface of the toltrazuril-immobilised CM5 sensor chip, for 2 minutes 
at a flowrate of 10 µL/minute and specific binding was recorded. 
 
5.5 Preliminary analysis of a Biacore inhibition assay format for ponazuril-
binding in PBS 
A preliminary competitive assay was carried out in PBS to determine the range of 
toltrazuril-detection of the polyclonal anti-toltrazuril antibody in a Biacore 
competitive assay format. Concentrations of ponazuril from 254 pg/mL to 5 μg/mL 
were mixed with an equal volume of antibody (100 μg/mL) and passed over the 
toltrazuril-BSA immobilised chip-surface. Inter- and intra-assay variation studies (as 
outlined previously in Section 5.3.3) were performed with each standard injected in 
Antibody 
concentration 
(μg/mL) 
Time (s) 
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triplicate at a flow-rate of 10 µL/minute for 2 minutes. The amount of response units 
observed was recorded after each injection. To assess the assay precision, CV values 
for each standard were also determined. These are summarized in Table 5.2. The 
mean response obtained at each ponazuril concentration (R) was divided by the 
response determined in the presence of zero drug (R0). The normalised responses 
(R/R0) were plotted against the logarithm of ponazuril concentration using 
BIAevaluation 4.0.1 software and a four-parameter equation fitted to the data. Figure 
5.16 shows the inter-assay (mean results of three separate assays) calibration curve 
using the anti-toltrazuril-polyclonal antibody. The LOD (as outlined in Section 5.3.4) 
of the assay was found to be 890 pg/mL, when extrapolated from the calibration 
curve. The red dashed line shown in Figure 5.16 indicates the lowest distinguishable 
concentration of ponazuril the antibody can detect in the Biacore assay format. 
However, for this assay to be a ‘validated’ toltrazuril detection assay, it has to be 
performed in an egg matrix. 
 
Table 5.2 Inter-assay co-efficient of variation (CVs) for the detection of free 
ponazuril in PBS using the purified anti-toltrazuril antibody in a Biacore assay 
format. Each standard was analysed in triplicate over three separate days and the 
CVs calculated. 
Ponazuril 
Conc. 
(pg/mL) 
Inter-day 
(% C.V) 
R/R0  Back 
Calculated 
Concentration 
(pg/mL) 
% Recovery 
5,000,000 13 26 5,762,608 115 
1,666,667 14 37 1,737,825 104 
555,555 10 58 504,765 91 
185,185 3 86 178,085 96 
61,728 5 119 65,213 106 
20,576 6 155 21,660 105 
6,858 5 184 7,091 103 
2,286 3 208 1,517 66 
762 1 216 590 77 
254 1 216 595 234 
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Figure 5.16 Calibration curves for the detection of ponazuril in PBS.  Three 
replicates of each standard were analysed in three separate assays. Toltrazuril-BSA 
was directly immobilised onto the surface of a CM5 sensor-chip. The binding 
response at each ponazuril concentration was divided by the antibody response in the 
absence of free ponazuril, to give the normalised response. The detection limit of the 
assay was determined to be approximately 890 pg/mL, as extrapolated from the 
calibration curve, and indicated by the red dashed line. 
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5.5.1 Stability of the immobilised toltrazuril-BSA surface after multiple 
sample/regeneration cycles. 
Repeated use of the immobilised-sensor chip surface is a key aspect of a successful 
biosensor immunoassay.  The sensor chip surface requires re-conditioning after each 
sample analysis, hence, it is imperative that the antigen-reactivity and conformation 
remains unaltered (Mason et al., 2003). To study the integrity of the biosensor 
surface, the baseline stability was monitored following 50 consecutive 
binding/regeneration cycles. Egg matrix was extracted as previously outlined in 
Section 2.12. Antibody (100 μg/mL) was added to the egg matrix and passed over the 
surface of the toltrazuril-BSA-immobilised chip, at a flow rate of 10 µL/minute for 2 
minutes. The chip surface was regenerated with two 30-second pulses of 100 mM 
NaOH. Following fifty consecutive binding/regeneration cycles, no significant 
decrease in the baseline stability occurred (Figure 5.17) with only a 3.6 % variation in 
binding response over all 50 cycles. 
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Figure 5.17 Typical regeneration profile for a CM5 chip immobilised with toltrazuril-
BSA. For 50 consecutive binding-regeneration cycles, a 2 minute pulse was 
performed, passing purified polyclonal antibody, in egg extract, over the chip surface. 
Antibody, at a concentration of 100 μg/mL, was used and the surface regenerated 
with two 30 second pulses of 100 mM NaOH after binding. The binding response 
stayed constant after 50 cycles with a 3.6 % variation in binding response, indicating 
high stability and reproducibility. 
 
5.6 Analysis of Biacore-based toltrazuril-detection assay performed in egg 
matrices. 
Egg samples were spiked with known concentrations of ponazuril ranging from 5 
µg/mL to 254 pg/mL and subsequently extracted. These standards were mixed with an 
equal volume of antibody at the final optimal concentration of 100 μg/mL and passed 
over the toltrazuril-BSA immobilised chip-surface. Samples were incubated for 30 
minutes at room temperature before they were each injected over the toltrazuril-BSA 
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immobilised surface. Each standard was injected in triplicate at a flow-rate of 10 
µL/minute for 2 minutes. The quantity of response units observed was recorded after 
each injection.  Inter- and Intra-assay variation studies were performed and CV values 
for each standard were determined (Table 5.3). The normalised responses were 
calculated and a four-parameter equation was fitted to the data curve. Figure 5.18 
shows the inter-assay mean calibration curve in extracted egg matrix using the 
toltrazuril-polyclonal antibody. The red dashed line in Figure 5.18 indicates the 
lowest level of ponazuril detectable in this matrix. The LOD of the assay in egg 
samples was found to be approximately 1,920 pg/mL as extrapolated from the 
calibration curve.   
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Figure 5.18 Calibration curves for the detection of ponazuril in extracted egg 
samples. Replicates (3) of each standard were analysed in three separate assays. The 
binding response at each ponazuril concentration was divided by the antibody 
response in the absence of free ponazuril, to give the normalised response. The LOD 
was determined to be 1,920 pg/mL. The results are shown as R/R0, where the 
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response units of the evaluated samples (R), are normalised by expressing them as a 
function of the blank standard (R0). 
 
5.6.1 Evaluation of extraction efficiency from egg samples 
Eggs from organically treated hens were spiked with ponazuril post-extraction (i.e 
following recovery of residues from the egg matrix) and compared to standards spiked 
in eggs prior to extraction, to assess the efficiency of the procedure. Figure 5.19 
shows that the average extraction efficiency from the eggs was quite high at 93 %. 
The actual recoveries, outlined in Table 5.3, correspond to the percentage of the total 
ponazuril concentration efficiently extracted from each of the spiked standards. 
Recoveries can also be estimated from the calibration curve for each standard.  Using 
this method, the mean percentage recovery was calculated as 139%, as shown in the 
recoveries listed in Table 5.3. This ‘estimated’ recovery from the calibration curve 
suggests that a higher amount of ponazuril was present in the samples than that which 
was actually spiked, as the value is greater than 100%. The reason the curve indicates 
the presence of higher concentrations of ponazuril, is that fewer antibodies are 
binding to the surface of the chip, which indicates that more free drug is displacing 
the antibody than is actually present. However, as can be observed from Table 5.2, 
when the samples are analysed is PBS, the average recovery calculated from the 
calibration curve is at 110%. This indicates only a 10% overall deviation from the 
actual concentrations. Taking into account the 7% loss observed during extraction, 
when analysis is performed in standards extracted from egg matrix, there is a 32% 
deviation from the apparent concentrations. This is assumed to be due to matrix 
effects from the extracted egg samples interfering with the assay.  
When comparing the calibration curve of the spiked ponazuril in extracted egg 
samples (Figure 5.19) to the calibration curve in PBS, it can be observed that a 2.2-
fold loss in sensitivity of the assay can be attributed to matrix interference and losses 
incurred during the extraction procedure. Indyk and Filonzi (2004) observed that it is 
common practice to generate calibration curves for the detection of contaminants in 
analyte-free matrix. This can be observed in Figure 5.19, whereby a calibration curve 
performed on egg samples spiked with ponazuril post extraction is directly compared 
to the calibration curve in PBS. The influence of the matrix and the extraction effects 
can also be seen in Figure 5.19. 
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Table 5.3 Inter-assay co-efficient of variation (CVs) for the detection of free 
ponazuril in PBS, using the purified anti-toltrazuril antibody, in a Biacore assay 
format. Each standard was analysed in triplicate over three separate days and the 
CVs calculated.  
Ponazuril 
Conc. 
(pg/mL) 
Inter-
day 
(% 
C.V) 
R/R0  Back 
Calculated 
Concentration 
(pg/mL) 
Estimated 
Recovery  
(%) 
Actual 
Recovery 
(%) 
5,000,000 18 34 7,129,648 143 99 
1,666,667 6 46 1,899,391 114 100 
555,555 7 77 421,740 76 99 
185,185 2 104 188,097 102 93 
61,728 5 137 79,537 129 89 
20,576 1 187 15,718 76 93 
6,858 2 204 5,800 85 85 
2,286 2 216 1,261 55 90 
762 2 217 428 56 89 
254 2 216 162 63 88 
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Figure 5.19 Comparison of the inter-assay calibration curves for the detection of 
ponazuril in PBS, extracted egg spiked with concentrations of ponazuril prior to 
extraction, and extracted egg spiked with concentrations of ponazuril post-extraction. 
The influence the matrix has on the sensitivity of the assay can be observed by the 
shift of the curve between the ‘green’ PBS calibration curve, and the ‘red’ egg matrix 
calibration curve. The efficiency of the extraction procedure is shown by comparing 
both the pre-spiked ‘blue’ and post-spiked ‘red’ calibration curves. 
 
In order to experimentally verify the detection capability (CCβ) of the Biacore assay 
from extracted egg samples, a precision assay was performed. Twenty samples of              
concentrations, 2,000, 1,900, 1,500, 1,000, 500, and 0 pg/mL were spiked into egg 
samples and extracted, as previously described in Section 2.12. Each of the samples 
was incubated with an equal volume of (100 μg/mL) anti-toltrazuril polyclonal 
antibody and passed over the surface the toltrazuril-BSA-immobilised CM5 chip. The 
response units observed were recorded for each replicate. It can be deduced from 
Assay matrix 
Extracted egg spiked pre-
extraction 
Extracted egg spiked post-
extraction 
 
PBS 
Ponazuril concentration (pg/mL) 
100         1,000    10,000          100,000      1,000,000      10,000,000 
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Figure 5.20 that 1,500 pg/mL of ponazuril can be successfully distinguished from 
blank samples. This concentration of 1,500 pg/mL of ponazuril represents the lowest 
concentration of analyte capable of being detected with a 95% confidence level using 
the anti-toltrazuril antibody in a Biacore-based assay format. 
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Figure 5.20 Precision assays to experimentally verify the functional limit of detection 
of toltrazuril in a Biacore assay format. Twenty replicates of 2,000, 1,900, 1,500, 
1,000, 500 and 0 pg/mL of ponazuril were analysed with twenty blank samples to 
determine the lowest concentration of analyte that can be detected with 95% 
confidence level. This was performed in a competitive Biacore format using the anti-
toltrazuril polyclonal antibody. Bound anti-toltrazuril antibody was recorded in 
response units (RU). 
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concentration 
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5.7 Development of a lateral-flow based immunoassay using the anti-toltrazuril 
polyclonal antibody for the detection of toltrazuril 
In an effort to reduce the assay time for the detection of ponazuril and circumvent the 
time-consuming washing and incubation steps of the ELISA-based approach, a 
lateral-flow immunoassay was developed for the rapid detection of ponazuril using 
the anti-toltrazuril polyclonal antibody. This method also has several field advantages 
when comparing to ELISA and Biacore-based methods, in that no specially trained 
personnel are required to perform the assay and the assay can be easily performed 
outside of the laboratory. 
 Lateral-flow immunoassays (LFIAs) have been employed for the detection of several 
medicinal veterinary contaminants, including nicarbazin in poultry feed (Campbell et 
al., 2007) and sulfonamides in eggs and chicken muscle (Kandimalla et al., 2007; 
Guo et al., 2010).  
In lateral flow devices, the principal element is the movement of a liquid sample, or 
an extract containing the analyte of interest, along a strip of polymeric material where 
it can interact with immobilised molecules (Posthuma-Trumpie et al., 2009). A typical 
lateral flow format (Figure 5.21) consists of a surface layer to carry the sample from 
the sample application pad through the conjugate release pad, along the strip and the 
detection zone up to the absorbent pad (Posthuma-Trumpie et al., 2009). The chosen 
format for a lateral flow immunoassay depends on the analyte being detected. For the 
detection of toltrazuril, the format is restricted to a competitive assay due to the small 
size and the lack of more than one epitope on the hapten. The optimal assay format 
for use with small haptens would contain either a labelled-antigen or labelled-
antibody, whereby sample analyte competes with immobilised or labelled antigen for 
binding to the antibody. Generally, labels used in lateral-flow are made of coloured or 
fluorescent labels or, more recently, nanoparticles with sizes of 15–800 nm, allowing 
an unobstructed flow through the membrane (Posthuma-Trumpie et al., 2009). 
Following preliminary studies and assay optimisation using a HRP-labelled secondary 
antibody and a colorimetric substrate, the assay was performed with coloured 
polystyrene beads. 
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Figure 5.21. Schematic of a potential lateral flow assay for the detection of a hapten, 
e.g. toltrazuril. Using anti-toltrazuril-coated-coloured latex microspheres, 
visualisation of bound antibody occurs at the ‘test’-Toltrazuril-BSA conjugate-coated 
line, or the ‘control’- anti-rabbit IgG-coated line. Sample travels through the 
nitrocellulose membrane with the assistance of an absorbent ‘wicking pad’ positioned 
at the top of the membrane. 
 
5.7.1 Determination of the range of detection of toltrazuril in PBS using a LFIA 
inhibition assay format 
Initially a preliminary lateral-flow assay was performed for toltrazuril detection to 
determine the optimal concentration of toltrazuril-BSA for use in the assay. A strip of 
Hi-Flow plus nitrocellulose membrane was cut to specific dimensions (4cm x 1cm). 
Anti-rabbit IgG was used as a control line. Varying concentrations of toltrazuril-BSA 
were sprayed as the test lines. The buffers used for spotting samples onto the test 
strips and running the assay were; 50 mM sodium phosphate, pH 7.5/ 1% (w/v) 
trehalose, and 50mM sodium phosphate, pH 7.5/0.5% (v/v) Tween20. Anti-toltrazuril 
antibody was diluted in running buffer and allowed to travel up the strip by capillary 
action. The antibody concentration for use in the assay was estimated from previous 
ELISA results. The strip was washed by the addition of running buffer and HRP-
labelled anti-rabbit IgG was used to probe for bound toltrazuril-antibody. Following 
the addition of the chromogenic substrate, TMB, a colour develops at the test line, 
where anti-toltrazuril antibody is bound. The completed assay can be observed in 
Figure 5.22. A slight colour is observed in the test line in A (Blank), which may be 
attributed to non-specific binding of the antibodies when travelling up the membrane 
Control line: anti-
rabbit antibodies 
‘Control line’ 
Toltrazuril-BSA 
conjugate: 
‘Test line’ 
Wicking Pad 
Anti-toltrazuril antibody-coated 
with coloured latex microspheres 
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as no conjugate was sprayed onto the strip. Kaur et al. (2007) previously noted that 
because of the hydrophobicity of the nitrocellulose membrane, non-specific 
interaction of a hydrophobic analyte with the membrane can generate significant non-
specific signals. To circumvent this, 0.1% (w/v) Milk Marvel was included in all 
subsequent assays. In Figure 5.22 the intensity of the test line is only visible between 
the concentrations of 10 μg/mL and 100 μg/mL of ponazuril. From this, 50 μg/mL of 
toltrazuril-BSA was chosen as the optimal test-line spotting concentration for all 
further assays. Validation of the assay was performed through inter-assay studies with 
‘real’ samples. This would enable the detection limit of the assay to be verified. 
 
 
Figure 5.22 TMB-developed nitrocellulose membrane strips from the toltrazuril-
lateral-flow detection assay. Anti-rabbit IgG was used as the control line and 
toltrazuril-BSA as the test line, at concentrations of 0, 5, 10, 20, 50 and 100 μg/mL. 
Anti-toltrazuril antibody was allowed to travel up the strip. Bound antibody was 
detected following the addition of a HRP-labelled anti-rabbit IgG. Toltrazuril-BSA 
concentrations A-F listed above are as follows; A= 0 μg/mL; B= 5 μg/mL; C= 10 
μg/mL; D= 20 μg/mL; E= 50 μg/mL and F= 100 μg/mL. 
 
5.7.2 Analysis of lateral-flow based assay for the detection of toltrazuril in an egg 
matrix. 
In order to validate the lateral-flow assay and determine the detection capability 
(CCβ) for toltrazuril, a validated assay was prepared and tested in egg samples. Egg 
samples were spiked with 100, 80, 40, 20, 10, 5 and 0 ng/mL of ponazuril and 
subsequently extracted as previously outlined in Section 2.12. It was initially believed 
that methanol in the extraction buffer would interfere with the nitrocellulose 
membrane. However, 5% (v/v) methanol had no apparent effect on the nitrocellulose. 
It was previously determined by Wang and colleagues (2005) that standard 
nitrocellulose can tolerate up to ten percent methanol without damage.  
A B C D E        F 
        Control line 
 
 
    
    Test line 
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Inter-assay studies were performed in triplicate over three days. A schematic of the 
lateral flow immunoassay set-up can be observed in Figure 5.23.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 Schematic of a lateral flow immunoassay for the detection of toltrazuril 
using HRP-labelled anti-rabbit IgG secondary antibody and TMB substrate for 
visualisation of binding. Step 1: Toltrazuril-BSA conjugate is sprayed onto a 
nitrocellulose membrane as the ‘test-line’, anti-rabbit antibody was sprayed onto the 
nitrocellulose as the ‘control line’. Toltrazuril-specific antibody was incubated with 
free toltrazuril and the mixture was allowed to travel up the length of the 
nitrocellulose membrane. Step 2: Free ponazuril in the sample will occupy the 
 
Step 4 
Step 1 
Step 2 
 Key:    Anti-toltrazuril antibody,    Free toltrazuril,   Toltrazuril-BSA 
  conjugate,  Anti-rabbit polyclonal antibody, 
 
 HRP-labelled anti-rabbit Ig antibody 
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binding sites of the antibody leaving it unable to react with the toltrazuril on the 
nitrocellulose; hence the amount of ponazuril in the sample is inversely proportional 
to the amount of binding that should be visible. Step 3: Toltrazuril-specific antibody 
bound on the nitrocellulose membrane is detected by the addition of a HRP-labelled 
anti-rabbit IgG secondary antibody. Step 4: TMB substrate is then added to the strip 
which reacts with the HRP-conjugated anti-rabbit IgG antibody, thereby allowing 
visualisation of bound antibody at both the test and control lines. 
 
Goat-Anti-rabbit IgG was sprayed on the nitrocellulose membrane denoting the 
‘control’ line and toltrazuril-BSA was sprayed as the test line. Anti-toltrazuril 
antibody was incubated with equal volumes of each of the spiked egg samples. Each 
of the mixtures was allowed to travel up specified strips of nitrocellulose. Any 
toltrazuril-specific antibodies that were not displaced by free ponazuril would bind to 
the test line, and the free drug-antibody complex would bind to the control line. The 
membrane was washed 3 times with running buffer prior to probing the strip with 
HRP-labelled anti-rabbit IgG antibody. Following this, the washing cycle was 
repeated and TMB was allowed to migrate up the strip to visualize the presence of 
bound-HRP-labelled anti-rabbit IgG antibody. The three inter-assay LFIAs can be 
observed in Figure 5.24. Detection of ponazuril is clearly evident down to a 
concentration of approximately 40 ng/mL across all of the inter-assay results. 
However, as this assay is purely qualitative, a positive result can only be confirmed 
with 100% confidence by the complete absence of a test line. Hence, it can only be 
stated that the LFIA has a detection capability of 100 ng/mL, as this is the only 
ponazuril concentration whereby a positive test-line is eliminated, due to the high 
concentration of ponazuril occupying the antibody binding sites and inhibiting 
binding on the surface of the nitrocellulose. 
 The detection capability of the previous lateral flow assays was determined solely by 
judging visually the control intensity of bands generated (Wang et al., 2005). When 
excess ponazuril is present, the ponazuril occupies any free antibody binding sites and 
inhibits the accumulation of the antibody at the toltrazuril-BSA test line. This 
ponazuril concentration was determined from the inter-assay LFIAs to be 100 ng/mL. 
Any ponazuril concentration lower than 100 ng/mL would only occupy a certain 
limited amount of binding sites on the anti-toltrazuril antibodies, leaving other 
binding sites free to bind to the ‘test line’. This results in a visible coloured band after 
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the addition of the HRP-labelled anti-rabbit IgG and TMB substrate. It can be 
concluded that the detection capability of the anti-toltrazuril polyclonal antibody in an 
LFIA is 100 ng/mL of ponazuril. If a hand-held reader was available to determine the 
exact colour intensity of the bands, a more quantitative method of determining the 
analytical range of the assay would be achievable. However, as no such instrument 
was available, a visual evaluation of the detection limits of the assay had to suffice. 
 
 
 
 
Figure 5.24 Inter-assay LFIAs for the detection of ponazuril from spiked egg samples 
using the anti-toltrazuril polyclonal antibody. Anti-rabbit IgG was used as a control 
line and toltrazuril-BSA conjugate was used as the test line. Ponazuril concentrations 
of 0, 5, 10, 20, 40, 80, 100 ng/mL were spiked into egg samples prior to extraction. An 
equal volume of 10 μg/mL of anti-toltrazuril antibody was mixed with the ponazuril 
samples following extraction. The free ponazuril-toltrazuril antibody mix was applied 
to the bottom of the nitrocellulose strip and allowed to travel up to the detection 
zones.  Bound antibody was detected by probing with HRP-labelled anti-rabbit IgG 
antibody. Following the addition of TMB substrate, a colour develops at the 
control/test lines. Ponazuril concentrations A-G listed above are as follows; A= 100 
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   Test line 
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ng/mL; B= 80 ng/mL; C= 40 ng/mL; D= 20 ng/mL; E= 10 ng/mL; F= 5 ng/mL and 
G= 0 ng/mL. 
 
5.8 Generation of a multi-analyte assay for the detection of halofuginone, 
toltrazuril and diclazuril 
Effective assays for the rapid detection of multiple contaminants are in great demand 
for food quality monitoring. 
In order to generate a quick and efficient assay, amenable to the simultaneous 
detection of halofuginone, toltrazuril and diclazuril, a lateral-flow based platform was 
developed. This one-step, qualitative, lateral flow-immunoassay offers several 
advantages over other multi-analyte detection systems, including a simple yes/no 
response which can be interpreted visually and reduce time and cost per analysis.  The 
simple assay protocol also means that the final assay procedure can be completed in 
less than 5 minutes. 
When applied to spiked egg samples, the assay gives accurate and reproducible results 
for detecting all three anti-protozoan drug residues. Hence, this assay is a highly 
attractive ‘on-site’ screening technique for the simultaneous detection of anti-
protozoan drug residues. 
 
5.8.1 Covalent coupling of anti-toltrazuril/halofuginone/diclazuril antibodies to 
polybead-coloured carboxylated polystyrene microspheres, for use in lateral-flow 
immunoassays 
In order to visualise antibody binding on the nitrocellulose membrane and facilitate a 
one-step assay, coloured carboxylated polystyrene microspheres were coupled to the 
antibodies. The beads are 0.2 μm in diameter, which allows them to easily traverse 
through the nitrocellulose membrane. In this format, the assay time is accelerated as 
there is no requirement for the addition of substrate. The protocol used for covalent 
coupling is outlined in Section 2.15.3.2. The coupling was performed overnight using 
carbodiimide hydrochloride (EDC). Any remaining unreacted carbodiimide sites were 
blocked by the addition of ethanolamine. To determine whether the antibodies were 
coupled to the polystyrene microparticles, and ensure functionality of the assay in this 
format, preliminary lateral-flow test assays were performed. 
Individual secondary antibodies specific to each of the anti-halofuginone/diclazuril 
and toltrazuril primary antibodies, were employed to capture the primary antibody-
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carboxylated microsphere complexes. Anti-HA mAb was used to capture the anti-
halofuginone-microsphere complex, goat-anti-rabbit IgG to capture the anti-toltrazuril 
complex and rabbit-anti-goat IgG to capture the anti-diclazuril complex.  Each of the 
secondary antibodies was sprayed on separate nitrocellulose strips and each of the 
antibody-microsphere beads were sprayed along the bottom of the strip. The antibody-
microsphere mixture was then sprayed on the bottom of each of the corresponding 
‘secondary antibody-embedded’ strips i.e. the anti-toltrazuril antibody-microsphere 
complex was sprayed on the strip embedded with anti-rabbit IgG. The strips were then 
dipped in a borate buffer (the same as the storage buffer used for the microsphere 
complexes) with 0.05% (v/v) Tween, which is a routinely used buffer in lateral-flow 
assays. The buffer could be observed travelling up the strip via capillary action. 
However, no movement of the green microspheres could be observed up the strip. In 
order to overcome this, several components of the assay procedure were optimised 
focusing on the spotting and running buffers utilised in the assay. 
 
5.8.1.1 Running and spotting buffer optimisation for use in a multi-analyte 
lateral-flow assay 
Prior to optimising the final multi-analyte assay, each of the antibody-microsphere 
complexes were sprayed on separate strips with each corresponding conjugate 
embedded on the strip. To facilitate the flow of the antibody-microsphere up the 
membrane, several different spotting and running buffers were used. The buffers 
studied for spotting of the antibody complex onto the membrane were; 2 mM borate 
buffer, pH 7.0, (0.1% (w/v) BSA, 0.05% (v/v) Tween, 0.01% (v/v) Triton X), 50 mM 
sodium phosphate, pH 7.5, with 1% (w/v) trehalose and 15 mM sodium citrate, pH 
7.0, with 0.01% (v/v) Triton X. These three spotting buffers were then used in 
conjunction with three different running buffers (2 mM borate buffer, pH 7.0, with 
0.05% (v/v) Tween, 50 mM sodium phosphate, pH 7.5, with 0.05% (v/v) Tween and 
15 mM sodium citrate, pH 7.0, with 0.05% (v/v) Tween), to determine which buffer 
combination gave the greatest resolution of the antibody-microsphere complex 
through the membrane, and the least amount of non-specific interactions. The results 
of this are not shown because only one buffer combination induced any movement of 
the antibody-bead complex up the membrane. When 15 mM sodium citrate, pH 7.0, 
with 0.01% (v/v) Triton X was employed alongside the 15 mM sodium citrate, pH 
7.0, with 0.05% (v/v) Tween running buffer, partial movement of the antibody 
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complex was observed. Similarly, Carter et al., (2007) found that microsphere 
aggregation was reduced when using this running buffer. However, at least half of the 
antibody complex did not travel through the membrane. Hence, the problem did not 
appear to be in using the optimal buffer combinations, but in the actual antibody-
microsphere complexes themselves. The complexes were characterised by dynamic 
light scattering to determine if coupling occurred successfully and also to identify if 
any particle aggregation had occurred.  
 
5.8.1.2 Dynamic Light scattering analysis of anti-halofuginone, anti-toltrazuril, 
and anti-diclazuril-microsphere covalently bound complexes. 
To further characterise the antibody-bead complexes and to determine the exact size 
of the covalently coupled particles, dynamic light scattering (DLS) was used. 
Dynamic light scattering is a non-invasive technique that can easily detect the 
presence of small aggregates. Hence, this technique would help to elucidate the issue 
with the hindered mobility of the complexes. The DLS analysis was performed as 
described in Section 2.15.3.6. Each analysis was performed in triplicate, with data 
generated using the Delsa Nano UI 2.21 software. From this data, polydispersity was 
calculated. This is used to describe the width of the particle size distribution 
(Arzenšek, 2010). The higher the polydispersity index (PDI), the greater the size 
variation of the particles. When the beads were analysed on their own (Figure 5.25), 
the average size was found to be approximately 172 nm. The monodispersity of the 
solution is evident by having a PDI of lower than 0.1 (Nobbmann et al., 2007). The 
PDI for the polystyrene beads alone was calculated as 0.033 indicating a highly 
homogeneous solution. The anti-diclazuril-bead complexes were analysed in triplicate 
and the average diameter (nm) was plotted as a function of the differential intensity 
(%) as shown in Figure 5.26 .The z-average size (hydrodynamic diameter) can be 
observed at 5,670 nm with a PDI of 0.628. This PDI is quite high, indicating that the 
solution is not very homogenous. The sizes of the polystyrene beads are 
approximately 200 nm, and the conjugated antibody has no greater size than 
approximately 20 nm, implying that a large degree of aggregation of the particles was 
occurring. This can also be observed in Figures 5.27 and 5.28 for the anti-
toltrazuril/anti-halofuginone-bead complexes, respectively. The anti-toltrazuril bead 
complex has an average hydrodynamic diameter of 5,433 nm with a PDI of 0.599 
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(Figure 5.27). The anti-halofuginone bead complex has an average diameter of 7,291 
nm with a PDI of 0.859 (Figure 5.28).  
The Hi-Flow 135 membrane (Millipore) used in the lateral flow assay has an average 
capillary flowrate of 135 seconds/4cm of strip. However, this flowrate is significantly 
slower when using particles greater than 3 μm according to the manufacturer’s 
specifications. Figures 5.26-5.28 indicate that particle aggregates are at their highest 
between sizes of 1.6 – 25 μm. This increased amount of aggregation appears to be the 
contributing factor to the diminished mobility of the complexes. Lucas et al. (2006) 
reported how they found that highly carboxylated microspheres, such as those used in 
this assay, have a very strong electronegative polarity, providing polar repulsion 
betweens the particles, subsequently preventing aggregation. Therefore, it is believed 
that aggregation is being caused by the coupling method employed. Aggregates 
caused by chemical bonding are quite stable and not susceptible to breaking up under 
shear force (Pease et al., 2008). Hence, an alternative method for the conjugation of 
the antibodies onto the beads was sought. 
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Figure 5.25 Size distribution profile of the green polystyrene carboxylated beads used 
for conjugation to the anti-diclazuril, anti-halofuginone and anti-toltrazuril 
antibodies. Data was obtained from DLS analysis of three different samples. 
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Figure 5.26 Size distribution profile by DLS analysis of the anti-diclazuril antibodies 
conjugated to carboxylated polystyrene beads via covalent coupling. The average 
diameter of the particles in the solution was 5,760 nm, with particles ranging in size 
from 1,178 nm to 29,985 nm. The distribution profile shows many differential 
intensity peaks indicating a heterogeneous population in solution. The data was 
analysed using the Delsa Nano UI 2.21 software. 
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Figure 5.27 Size distribution profile by DLS analysis of the anti-toltrazuril antibodies 
conjugated to carboxylated polystyrene beads via covalent coupling. The average 
diameter of the particles in the solution was 5,433 nm, with particles ranging from 
1,261 nm to 27,291 nm. The data was analysed using the Delsa Nano UI 2.21 
software. 
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Figure 5.28 Size distribution profile by DLS analysis of the anti-halofuginone 
antibodies conjugated to carboxylated polystyrene beads via covalent coupling. The 
average diameter of the particles in the solution was 7,291 nm, with particles ranging 
in size from 1,346 nm to 42,565 nm. The data was analysed using the Delsa Nano UI 
2.21 software. 
 
5.8.2 Passive adsorbtion of the anti-diclazuril, anti-halofuginone and anti-
toltrazuril antibodies to green carboxylated microspheres. 
A substantial degree of aggregation occurred when the antibodies were coupled to the 
microspheres via chemical coupling. Antibodies can be bound to microspheres 
passively through hydrophobic interactions, hydrogen bonding or electrostatic 
interactions (Lucas, et al., 2006). Passive adsorption was used to conjugate the 
microspheres to the antibody with the expectation that fewer aggregates would 
develop when compared to covalent coupling. Passive adsorption was carried out as 
described in Section 2.15.3.5. To determine if the antibodies were coupled to the 
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polystyrene microparticles, and ensure functionality of the assay in this format, 
preliminary lateral-flow test assays were performed. Lateral flow strips were coated 
with specific secondary antibodies, corresponding to each of the anti-halofuginone, 
anti-diclazuril and anti-toltrazuril antibodies, as described previously to test for 
successful conjugation (Section 5.8.1). The antibody-microsphere complexes were 
sprayed onto the end of each of the strips, and allowed to travel upwards, following 
contact of the end of the strip with running buffer. The antibody-microsphere complex 
travelled the length of the strip towards the test-line to interact with the corresponding 
secondary antibodies (i.e. anti-rabbit IgG for the anti-toltrazuril-microsphere complex, 
anti-goat IgG for the anti-diclazuril-microsphere complex, and anti-HA mAb for the 
anti-halofuginone-microsphere complex). 
Using the passive adsorption coupling method, it was apparent that the antibody-bead 
complexes could easily traverse up the membrane indicating no significant 
aggregation had occurred. The antibodies appeared to be successfully coupled to the 
beads, as green lines were clearly visible at each of the test lines. This binding was 
characterised further by performing competitive titration lateral-flow assays, with 
each of the anti-protozoan drugs in the free form (See Section 5.8.2.2). 
 
5.8.2.1 Dynamic light scattering analysis of anti-halofuginone, anti-toltrazuril, 
and anti-diclazuril-microsphere, passively adsorbed bound complexes 
Following passive adsorption coupling, characterisation of the antibody-microsphere 
complexes was performed using DLS analysis. It is apparent from Figures 5.29- 5.31 
that a different size distribution profile is obtained when compared to chemical 
coupling. Figure 5.29 shows the size distribution profile for the anti-diclazuril-bead 
complexes, with an average particle size of 490 nm. This average particle size implies 
that coupling has occurred efficiently as the size is larger than the 172 nm average for 
uncoupled beads. It also suggests that a small degree of aggregation was still occuring 
amongst the particles, with the largest aggregate particle size determined as 1,758 nm. 
This is also the case for the anti-toltrazuril-bead complexes as shown in Figure 5.30 
where the average particle size is 403 nm, with the largest aggregated particle size 
reaching 1,191 nm. Figure 5.31 shows the size distribution profile for the anti-
halofuginone-bead complex. These complexes have a higher average diameter of 505 
nm. A higher overall complex size was also observed at 2,093 nm, when compared to 
the other two full size IgG antibodies. This may be because scFv dimerise more 
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readily than IgG, causing a greater degree of aggregation than IgG. Table 5.4 
compares the polydispersity index and average diameter of the antibody-microsphere 
complexes with the two different coupling methods. The percentage aggregation 
shown was calculated as a function of the maximum diameter of particle size 
observed. The maximum particle size was denoted with 100% aggregation, which 
occurred when the anti-halofuginone scFv was used. It can also be noted, that when 
coupling was performed using covalent methods, at least 12 times more aggregation 
occurred when compared to the passively adsorbed coupling. 
 
Table 5.4 Comparison of the polydispersity index and particle size between 
antibodies conjugated to carboxylated microspheres via both covalent and adsorption 
coupling methods. 
Sample analysed by Dynamic 
Light Scattering Analysis (All 
results are average of triplicate 
assays) 
Polydispersity 
Index 
Diameter 
50% (nm) 
Diameter 
100% 
(nm) 
Percentage 
Aggregation 
(%) 
Polybead carboxylate beads 
 0.2 μm 
0.033 173 225 0.5 
Covalently coupled 
anti-diclazuril Ab-beads 
0.628 5670 29,985 70.4 
Covalently coupled 
anti-toltrazuril Ab-beads 
0.599 5433 27,291 64.1 
Covalently coupled 
anti-halofuginone Ab-beads 
0.859 7291 42,565 100 
Passively adsorbed 
Anti-diclazuril Ab-beads 
0.201 490 1,758 4.1 
Passively adsorbed 
Anti- toltrazuril Ab-beads 
0.195 403 1,191 2.8 
Passively adsorbed 
anti-halofuginone Ab-beads 
0.225 505 2,093 4.9 
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Figure 5.29 Size distribution profile by DLS analysis of the anti-diclazuril antibodies 
conjugated to carboxylated polystyrene beads via passive adsorption. The average 
diameter of the particles in the solution was 490 nm, with particles ranging in size 
from 168 nm to 1,758 nm. The data was analysed using the Delsa Nano UI 2.21 
software. 
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Figure 5.30 Size distribution profile by DLS analysis of the anti-toltrazuril antibodies 
conjugated to carboxylated polystyrene beads via passive adsorption. The average 
diameter of the particles in the solution was 403 nm, with particles ranging in size 
from 145 nm to 1,191 nm. The data was analysed using the Delsa Nano UI 2.21 
software. 
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Figure 5.31 Size distribution profile by DLS analysis of the anti-halofuginone 
antibodies conjugated to carboxylated polystyrene beads via passive adsorption. The 
average diameter of the particles in the solution was 505 nm, with particles ranging 
in size from 150 nm to 2093 nm. The data was analysed using the Delsa Nano UI 2.21 
software. 
 
 
 
 
 
 
 
 
 
 229 
5.8.2.2 Characterisation of anti-halofuginone, anti-diclazuril and anti-toltrazuril 
Ab-microsphere complexes via a competitive lateral flow immunoassay to 
determine the detection range of each antibody-coated microsphere complex 
from extracted egg residues 
The competitive lateral-flow immunoassay was performed as described in Section 
2.15.3.7. Varying concentrations of free antiprotozoan drugs were spiked into the 
running buffer for each separate LFIA strip. The free drug competes with the 
conjugate drug embedded on the LFIA at the test-zone. A positive result would yield 
no visible test-line. The amount of colour present at the test line is inversely 
proportional to the amount of free drug present. A broad range of each free drug was 
used to observe full saturation of antibody at the test line to complete competition of 
binding at the test line. The concentrations of halofuginone, diclazuril and toltrazuril 
extracted from egg samples were; 10 μg, 1 μg, 100 ng, 10 ng, 1 ng and 0  ng/mL in 
the optimal running buffer (15mM sodium citrate, pH 7.0, with 0.05% (v/v) Tween 
and 5 % (v/v) methanol for resuspending the extracted residues) from Section 5.8.1.2. 
It can be observed from Figure 5.32, that the detection limit of the anti-toltrazuril-
bead complex in the LFIA is at approximately 100 ng/mL. The anti-diclazuril-
microsphere complex showed a similar result with a detection limit of 100 ng/mL 
also. The halofuginone scFv-bound microsphere has a lower limit of detection for 
halofuginone at approximately 10 ng/mL. This assay was performed in triplicate. 
Once the limit of detection of each antibody-complex was clearly established, a multi-
analyte assay was performed in extracted egg samples. 
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Figure 5.32 Lateral-flow immunoassays for the determination for the limit of 
detection of the anti-halofuginone, anti-toltrazuril and anti-diclazuril Ab-microsphere 
coupled complexes in a competitive assay format. The concentrations of each of the 
free anti-protozoan drugs spiked into each of the running buffers are denoted below 
the lateral flow strips. These concentrations were 10 μg, 1 μg, 100 ng, 10 ng, 1 ng and 
0 ng/mL. No visible line at the test line indicates a high concentration of drug in the 
sample analysed. The limit of detection of the anti-toltrazuril/anti-diclazuril Ab 
complexes appears to be at approximately 100 ng/mL with the anti-halofuginone Ab 
complex detecting slightly lower concentrations at 10 ng/mL. 
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5.8.3 Multi-analyte detection of halofuginone, diclazuril and toltrazuril in a 
competitive lateral flow immunoassay using antibody conjugated coloured 
microspheres. 
In the field of veterinary residue monitoring, numerous anti-protozoan drugs may be 
used at any given time. Hence surveillance of all residues in food can be costly and 
time consuming, if several different assays are required. To circumvent this, and 
ensure a cost-efficient and rapid screening method could be made available for the 
detection of anti-protozoan drug residues, a multi-analyte assay was developed. This 
multi-analyte assay allows the concurrent detection of toltrazuril, halofuginone, and 
diclazuril residues below the MRL’s set for each, in one easy-to-use lateral-flow 
immunoassay. The multi-analyte assay method is outlined in Section 2.15.3.7. This 
method is a proof-of-principle assay for the simultaneous detection of all three anti-
protozoan residues. If the method was to be validated fully 20 samples at each of the 
varying concentrations of the drugs would be spiked and extracted from real matrices 
and analysed in triplicate on separate days, If this assay was going to be 
commercialised, use of mathematical models for competitive lateral-flow assays, such 
as those outlined by Qian and Bau (2004), could be used for the optimisation of the 
parameters of the competitive assay, thus reducing the time for laboratory 
optimisation. A digital scanner may also be used to determine the signal intensity and 
to record the results quantitatively.  To establish if any cross reactivity or non-specific 
binding would occur between the antibodies and all three of the test zones, assays 
were prepared for each of the drugs using the lowest concentration of each of the anti-
protozoan drugs detectable by the antibodies. Each set of assays included one of the 
drugs at the lowest concentration detectable by the corresponding assay, and neither 
of the other drugs. Hence, binding was inhibited at one test zone, but not at the others. 
Figure 5.33 illustrates the binding of the antibodies, when varying concentrations of 
each of the target drugs were assessed, in the lateral-flow immunoassay.  It is apparent 
from the lateral-flow strips that no significant cross-reactivity of the antibody-bead 
complexes can be observed. At the toltrazuril test zone in assay (A) from Figure 5.33 
a coloured line was observed when it was not observed in the other two test-zones. 
This indicates the presence of diclazuril and halofuginone at quantities greater than 
100 ng/mL and 10 ng/mL, respectively. This can also be observed in assays (B) and 
(C) for diclazuril and halofuginone respectively. An apparent test line in (B) in the 
diclazuril test-zone indicates the absence of diclazuril. Similarly, in assay (C) a test 
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line is present at the halofuginone test-zone but not at the other two, indicating no 
halofuginone is present but the other two drugs are present in quantities at or greater 
than the limit of detection. Figure 5.34 illustrates the assay run in the presence of no 
competitors, whereby all three test lines and control line are visible. In Figure 5.35 
the assays were run with only one of the competitors present. Assay (A) shows the 
assay performed with 100 ng/mL of toltrazuril present, (B) shows the assay with 
100ng/mL of diclazuril present and (C) shows the assay with 10 ng/mL of 
halofuginone present. It can be observed that the only test-line not visible is at the 
test-zone corresponding to the specific drug that was present in the sample mix. This 
proves that the multi-analyte assay is functional for simultaneous detection. 
When comparing the lateral flow set-up to other formats for simultaneous detection, 
the lateral-flow multi-analyte detection method appears to be ‘fit-for-purpose’ and 
feasible for high throughput screening in an ‘on-line’ monitoring environment.  
 
 
 
 
Figure 5.33 Multi-analyte lateral-flow immunoassays for the simultaneous detection 
of halofuginone, toltrazuril and diclazuril in a competitive assay format (in triplicate). 
In (A) no toltrazuril was present in the spiked samples, in (B) no diclazuril was 
present in the spiked samples and in (C) no halofuginone was present. It can be 
observed in each of the assays that when no competitor is present, a visible line can 
be observed in the relevant specific test-zone. The required control-line is also evident 
in all of the above assays. 
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Figure 5.34 Multi-analyte lateral-flow immunoassays performed in the presence of no 
anti-protozoan drugs. The control line is clearly visible at the top ot the strip along 
with three lines observed at the toltrazuril, diclazuril and halofuginone test-zones. 
 
 
 
 
 
Figure 5.35 Multi-analyte lateral-flow immunoassay. The assay was performed in the 
presence of only one of the anti-protozoan drugs. The control line is clearly visible at 
the top of each of the strips. Assay set (A) was performed in the presence of 100 
ng/mL of toltrazuril, assay set (B) with 100ng/mL of diclazuril, and assay set (C) with 
10ng/mL of halofuginone. 
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5.9 Discussion and Conclusions 
The production and characterisation of polyclonal antibodies to toltrazuril, and their 
subsequent incorporation into ELISA, Biacore and lateral-flow-based assays for the 
detection of toltrazuril residues was described in this chapter.  Toltrazuril-BSA and 
TFME-BSA conjugates were used for the immunisation of ten rabbits. The presence 
of toltrazuril-specific antibody from sera samples was determined by competitive 
ELISA using the primary toltrazuril metabolite ‘ponazuril’. The toltrazuril-BSA 
conjugate induced a high antibody response to toltrazuril in three of the rabbits. 
Subsequently, the anti-toltrazuril antibodies were purified from the sera by 
immunoaffinity chromatography using Protein G-immobilised sepharose. The 
purification process was assessed by SDS-PAGE and the presence of rabbit IgG 
molecules was confirmed by Western blotting.  
Initially, the polyclonal antibodies were used in a competitive ELISA format for the 
detection of toltrazuril in PBS. The optimal conditions for the assay were investigated 
by analysing different conjugate coating buffers, conjugate concentrations and 
amounts of antibody used. Once these were optimised, the resulting ELISA proved 
reproducible, with inter-assay CVs less than 19%. The assay was then validated by 
performing the inter-assay evaluations in egg-samples. The extraction efficiency was 
determined to be approximately 86%, which is above the mandatory recovery of 80%, 
for a method to be validated by E.U. standards. The LOD of the assay was determined 
to be 900 pg/mL by extrapolation from the inter-assay calibration curve. This 
ponazuril concentration for the LOD was also experimentally verified via a precision 
assay in egg matrix, confirming this detection capability of the assay.  This assay 
sensitivity is significantly below the lowest EU MRL for toltrazuril, of 100 µg/kg, 
corresponding to approximately 100 ng/mL. This sensitivity makes the assay highly 
applicable for the detection of toltrazuril from certain matrices, where loss of residue 
may occur due to lengthy extraction procedures. 
In an attempt to develop the most sensitive assay format for the detection of 
toltrazuril, both Biacore and lateral-flow assay formats were also investigated. A 
Biacore inhibition assay was produced, employing the anti-toltrazuril polyclonal 
antibody,a CM5 Biacore chip immobilised with the toltrazuril-BSA conjugate and 
free ponazuril. Following preliminary analysis a concentration of 100 μg/mL of 
polyclonal antibody to what proved optimal for use in the development of the 
toltrazuril-Biacore assay. A preliminary inhibition assay showed that using the 
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Biacore-based assay format, the anti-toltrazuril polyclonal antibody could detect down 
to 890 pg/mL of ponazuril in a PBS matrix. When the same analysis was performed in 
an egg matrix, the limit of detection of the assay was determined to be approximately 
1920 pg/mL. The average extraction efficiency was calculated as 93%. When a 
precision assay was performed to verify the limit of detection, 1.5 ng/mL of ponazuril 
could be distinguished 100% of the time from the blank samples.  
 Previous studies comparing both ELISA and Biacore formats have often shown the 
advantages of using biosensors (Guidi et al., 2001), particularly in environmental 
monitoring when high throughput sampling is required. The use of Biacore 
technology allows ‘real-time’ measurement, cutting out lengthy incubation stages. It 
requires low amounts of reagents without any special preparation and does not require 
antibody labelling or a second reagent for immunocomplex detection. However, 
greater or similar sensitivities to Biacore assays have also been found when using 
ELISA for monitoring trace residues. Fodey et al. (2007) reported greater sensitivity 
in ELISA over Biacore formats for monitoring chloramphenicol residues when the 
assay was performed in milk extracts. This was not the case when the assay was 
performed in buffer, and therefore the loss of sensitivity in the SPR assay was 
determined to be influenced by the matrix. He et al., (2007), also noted how matrix 
interferences were observed during detection of sudan-dye residues from egg yolk, 
when extraction with acetonitrile was used. Hence, other methods such as extraction 
with n-hexane or toluene, may help in reducing effects caused by the egg matrix. 
  It is apparent from the assay results, when the Biacore detection assay is performed 
in buffer the LOD is actually lower than the LOD of the ELISA. However, according 
to the European Commission Decision 2002/657, for a method to be valid for 
monitoring residues in foodstuffs, analysis should be performed in the contaminated 
matrix. Hence, it can be concluded that for the analysis of toltrazuril residues in real-
food samples, ELISA detection is marginally more sensitive than Biacore detection 
methods. 
In an effort to ensure the assay will be compatible for field applications, the 
development of a dipstick-based lateral flow format was investigated. A simple 
method using anti-rabbit IgG as a control capture antibody and toltrazuril-BSA as a 
test zone was used. The strips were exposed to extracted egg samples spiked with 
varying concentrations of ponazuril. Equal volumes of anti-toltrazuril antibody were 
mixed with the ponazuril samples following extraction. Any anti-toltrazuril antibody 
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bound on the strip was detected following the addition of an HRP conjugated anti-
rabbit IgG antibody. The results were visually determined from the lateral flow-strips, 
and after inter-assay analysis from real samples, it was clear that 100 ng/mL of 
toltrazuril could be distinguished from blank samples. This LOD is relatively poor in 
comparison to that achievable by ELISA and Biacore methods. However, it is still 
capable of detecting levels of toltrazuril at and above the MRL set by the E.U. The 
advantage of this assay is that it is an inexpensive assay suitable for ‘on-site’ high 
throughput screening.  
The significant differences in sensitivity limits between the 900pg/mL LOD for the 
ELISA and the 100ng/mL LOD for the lateral-flow assay for the detection of 
toltrazuril could be justified by several factors. The higher binding capacity of the 
antibodies on polystyrene microtiter plate in comparison to that on nitrocellulose 
membranes and the interaction time of the antibody and the plate in the ELISA assay 
is greater when compared to the minimal interaction time available during the lateral 
flow assay. Also, the use of a sophisticated ELISA reader, for signal detection, 
compared to visually analysing results in the LFIA (Kaur et al., 2007) may also affect 
detection capability. All of these factors contribute to the higher sensitivity recorded 
with ELISA. 
It is understood that there is currently only one reported antibody-based detection 
method for toltrazuril (Connolly et al., 2002). That immunoassay uses a polyclonal 
antibody, produced from rabbits immunised with a trifluoraminoether conjugate. An 
LOD is not reported for this ELISA assay. However, they described an IC50 of 18 
ng/mL, which is slightly less sensitive than the limits reported herein for the ELISA 
and Biacore detection methods. Even though the LFIA is not as sensitive as the 
previously reported method, all three of the immunoassay-based methods reported 
here have advantages over HPLC-based methods for detecting toltrazuril due to their 
rapidity, sensitivity and cost-effectiveness. 
A multiplex assay for the detection of toltrazuril concurrently with other anti-
protoazoan agents, diclazuril and halofuginone was developed. This assay would 
prove very advantageous in the simultaneous monitoring and control of these 
residues, by significantly reducing operator time and costs of analysis. The 
toltrazuril/diclazuril/halofuginone antibodies were immobilised on coloured 
polystyrene beads via chemical coupling.  However, after substantial dynamic light 
scattering analysis, it was apparent that the chemical coupling was inducing 
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aggregation amongst the polystyrene beads which were hindering the antibody-bead 
complexes from passing up the lateral flow-strips. To circumvent this, passive 
adsorption methods were investigated. Passive adsorption of the antibody onto the 
beads was successful and following further analysis using dynamic light scattering, it 
was apparent that little aggregation had occured. Preliminary optimisation assays 
were performed. and, once the range of the assays was established, the multi-analyte 
assay was performed with real samples. It was observed from the LFIA that the LOD 
of the assay in this format was at 10 ng/mL for halofuginone, and at 100 ng/mL for 
both diclazuril and toltrazuril. This LOD of the assay is below the MRL set for both 
halofuginone and toltrazuril. However, the MRL for diclazuril is 1.5 ng/mL, therefore, 
this assay would not be suitable for diclazuril detection in foodstuffs. The antibody 
employed to detect diclazuril was a commercial antibody. This leads to the belief that 
had a recombinant diclazuril antibody been successfully developed, greater assay 
sensitivities would be achievable, and this recombinant antibody would be far more 
suitable for incorporation into this multi-analyte detection assay.  
High-throughput screening for the semi-quantification of residues in food is proving 
to have increasingly more merit in food analysis as shown by Pang et al., (2006). 
More samples can be analysed in a shorter time for a variety of different 
contaminants. The introduction of a two-tier system for residue analysis in food, 
consisting of an initial low-cost screening step, means that a fast, effective assay 
capable of detecting contaminating residues in vast quantities of samples is required. 
The potential health risks imposed from anti-protozoan residues in food, highlight the 
particular importance to provide easy to use, precise, reliable and accurate tests for the 
efficient monitoring of these residues, to ensure food safety throughout the EU. Most 
of the traditional analysis of coccidiostats is applied to the detection of a single 
component, making thorough screening processes expensive and arduous. Multi-
analyte systems like the lateral-flow assay described herein are likely to totally 
transform environmental monitoring for the better in the foreseeable future. This 
multi-analyte assay not only proved that all three anti-protozoan drugs could be 
detected simultaneously from food samples with no cross reactivity of the antibodies 
occurring, but also, that each drug could be quantified independently of the other two.   
Most lateral-flow assays previously reported for monitoring of food contaminants, 
only focus on the detection of one contaminant such as those reported by Laura et al., 
(2011), Zhang et al., (2008) and Wang et al., (2005). Kranthi and colleagues (2009) 
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previously reported the development of a multi-analyte lateral flow strip for the 
determination of different insecticide residues. However, this method did not test the 
residues individually, as only one test line was used, therby making it impossible to 
determine which residue was present or quantify it. Xie et al., (2009) also reported a 
multi-residue detection lateral flow for cephems in milk. However, this method also 
did not allow for the individual detection of the different residues, instead a 
polyclonal antibody was employed with the capability of detecting several residues. 
These methods, however time-saving, would not be suitable for the quantification of 
several unknown contaminants in foodstuffs. 
 When comparing this lateral-flow assay method to other multi-analyte detection 
methods, such as those reported by Li and collegues in 2006 using LC-MS or by 
Peters et al., (2009) using TOF-MS, the LFIA reported herein appears advantageous 
due to the overall simplicity of the assay. No specially trained personnel, expensive 
laboratory equipment for quantification, or even a laboratory setting are required for 
use of this assay. This means on-site testing can be performed in a matter of minutes. 
Ideally the LFIA would be extended to include a panel of all actively used anti-
protozoan drugs, whereby one assay-strip would be applicable to detect any 
potentially contaminating veterinary residues.  
This assay would be useful for commercialisation if a scanner was incorporated to 
quantify the results and further validate the assay performance. This simple detection 
methodcould potentially revolutionise the field of environmental monitoring. 
Whereby, in the current climate an assay that is relatively inexpensive to use and yet 
highly efficient in multi-analyte detection, appears to have a significant and highly 
applicable niche. 
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6.1 Overall Conclusions 
The aim of the work presented in this thesis was to develop immunoassays for the 
detection of anti-protozoan drug residues. The strategies employed involved the 
construction of a recombinant scFv library for diclazuril, the generation, 
characterisation and subsequent affinity maturation of recombinant antibody 
fragments (scFv) to halofuginone, and the production of polyclonal antibodies for 
toltrazuril. The antibodies generated have been characterised by ELISA, SDS-PAGE, 
Western blotting and Biacore. ELISA, lateral-flow and Biacore-based immunoassays 
were developed for the detection of these anti-protozoan drugs and/or their 
metabolites. 
 
Chapter 3 describes the construction of a halofuginone-specific scFv library. Phage 
display was employed to facilitate the isolation of a halofuginone-specific scFv via 
biopanning.  However, the resulting scFv was not sufficiently sensitive to detect HFG 
below the MRL set by the E.U. To overcome this problem, light-chain shuffling was 
employed to determine the optimal light: heavy chain pairings of the scFv to enhance 
its sensitivity. This led to the isolation of a scFv with 185-times greater sensitivity 
than the original scFv. This scFv was incorporated into an ELISA assay for the 
detection of HFG residues, which was then validated according to E.U. guidelines. 
This work was published in Analytical Biochemistry in March 2011. 
 
A SPR-based detection method for the determination of HFG residues in eggs was 
optimised and validated. Initially a HFG conjugate was immobilised on a CM5 
Biacore chip, and regeneration studies were performed, while using the halofuginone-
specific scFv. Several different extraction procedures for spiked HFG in eggs were 
investigated. This was to determine which procedure gave the highest extraction 
efficiency from the homogenised egg matrix. Once this was optimised, egg samples 
were spiked with varying concentrations of HFG and subsequently extracted. The 
extracted yields were good and recoveries of up to 86.5% were observed. This assay 
was fully validated according to E.U. guidelines. The limits of the assay were 
subsequently determined, whereby, the CCβ or detection capability of the assay, was 
shown to be 2.8 ng/mL. This is the first SPR-based assay described for the detection 
of HFG. 
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The construction of a murine-derived scFv library for diclazuril is described in 
Chapter 4. Initially a chicken was immunised with a carboxy-diclazuril conjugate, but 
after several immunisations no response was observed. Mice were then immunised 
with the same conjugate. A response to diclazuril was observed in the mice and, after 
a full immunisation schedule, the RNA was extracted from the mice spleens and a 
scFv library was constructed. Individual antibody fragments were selected by 
biopanning but none of the selected clones showed binding to diclazuril in solution. 
Further clones were chosen in a bid to isolate any diclazuril-binding scFv. However, 
even after re-construction of the library from the RNA, no diclazuril-specific scFv 
were found. Due to time constraints, no further work could be performed in 
developing a recombinant antibody fragment. The problems encountered during the 
construction of this library were identified as issues which arose from the construction 
of the library from murine-derived cDNA. 
 
The incorporation of an anti-toltrazuril polyclonal antibody into an ELISA is 
described in Chapter 5. The toltrazuril structure proved highly problematic for 
conjugation to another protein carrier (required for immunisation), due to the lack of 
available functional groups.  Previously, a research group had discovered that a 
toltrazuril-mimic (with an identical functional group) could be used to elicit an 
immune response and produce antibodies that would recognise toltrazuril. For this 
reason, rabbits were immunised with both the antigen mimic-conjugate and a 
commercially available toltrazuril conjugate. The sera of the rabbits immunised, were 
screened by ELISA and toltrazuril-specific antibodies purified via Protein G affinity-
chromatography. The purified antibody preparation was characterised by SDS and 
western blotting and was subsequently incorporated into ELISA, Biacore and lateral 
flow-based detection assays using ponazuril (toltrazuril metabolite) residues. The co-
efficients of variation of the ELISA and Biacore assays and the limit of detection were 
determined. These were calculated by extrapolation from a four-parameter calibration 
curve plotted using BIAevaluation TM software.  
 
For the lateral flow assay, the limit of detection was visually determined to be 100 
ng/mL. To experimentally verify the detection capabilities of the Biacore and ELISA 
assays, precision assays were performed for both. These precision assays confirmed a 
limit of detection of 900 pg/mL for both the Biacore and the ELISA assays for 
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toltrazuril detection. The sensitivity of both the Biacore and ELISA assays were 
comparable, with the lateral flow assay  being somewhat less sensitive. However, as 
methods for toltrazuril detection would be required in ‘on-line’ monitoring 
environments with a high throughput of samples, the lateral flow-assay may prove the 
easiest to use in such a lateral-flow application.  
 
Chapter 5 also describes the development of a multi-analyte detection system for the 
simultaneous monitoring of halofuginone, toltrazuril and diclazuril residues. Coloured 
carboxylated microspheres were coated with each of the detection antibodies and used 
in a lateral-flow assay format. Initially problems with chemical coupling of the 
antibody-bead conjugation arose but these were circumvented by using passive 
adsorption methods to couple the antibodies to the beads. Dynamic light scattering 
analysis showed that the beads were the correct size when coupled, and no major 
aggregates were present. Thus the multi-analyte lateral flow assay format was 
feasible. Using this approach, halofuginone was detectable at a limit of 10 ng/mL or 
greater, toltrazuril at 100 ng/mL and, similarly, diclazuril had a detection limit of 100 
ng/mL. This assay approach is highly advantageous in field applications where all 
three of these anti-protozoan drugs are used as prophylactic/preventative methods for 
treating protozoans. This assay could easily be adapted for commercial purposes by 
incorporating a hand-held reader to analyse results, and it could pave the way for 
more efficient monitoring of anti-protozoan drug residues in the future. 
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Please refer to Section 2.6.3 regarding the use of the Pcomb3XSS vector for cloning 
of the scFv libraries. Taken directly from Barbas et al., 2001. 
 
 
Appendix 8.1 Map of pComb3XSS vector used for the construction of anti-
halofuginone and anti-diclazuril antibody libraries. Amber stop codon, 6 x His tag, 
HA-tag, Sfi1 digestion sites and ampicillin resistant cassettes can all be observed. 
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Appendix 8.2 Qiagen gel purification kit protocol taken directly from the 
manufacturers handbook ‘Qiagen Spin Handbook 03/2008’. 
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Appendix 8.3 Qiagen plasmid preparation kit protocol taken directly from the 
manufacturers handbook ‘Qiagen Plasmid preparation handbook, Third Edition, 
Novermber 2005’. 
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Appendix 8.4 Invitrogen protocol taken directly from the manufacturers instructions 
for Superscript III First-Strand synthesis system for RT-PCR. 
 
